Anti-PD-l1 antibodies and uses thereof

Immunoglobulin-related compositions targeting PD-L1 provide a more effective and safer cancer treatment by enhancing antibody binding and neutralization capabilities, addressing the limitations of current therapies with improved response rates and reduced adverse effects.

WO2024238966A1PCT designated stage expired Publication Date: 2024-11-21RNAIMMUNE INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/030039
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current anti-PD-L1 monoclonal antibodies have low response rates and adverse reactions in treating cancer, necessitating the development of alternative therapies that can effectively inhibit PD-L1 activity and cancer cell growth with improved safety profiles.

Method used

Development of immunoglobulin-related compositions, including monoclonal, chimeric, humanized, bispecific, and mRNA-encoded antibodies that specifically bind to PD-L1, designed to inhibit cancer cell growth and immune evasion, either alone or in combination with other therapeutic agents.

Benefits of technology

These antibodies demonstrate strong binding and neutralization activity against PD-L1, potentially increasing treatment efficacy and reducing adverse reactions, thereby offering a more effective and safer approach to cancer therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024030039_21112024_PF_FP_ABST
    Figure US2024030039_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to PD-L1 proteins. The antibodies of the present disclosure are useful in methods for treating cancer in a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

ANTI-PD-L1 ANTIBODIES AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims priority to U.S. Provisional application No. 63 / 503,004, filed May 18, 2023, the content of which is hereby incorporated by reference in its entirety.TECHNICAL FIELD

[0002] The present disclosure relates to the preparation of immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that specifically bind PD-L1 protein and uses of the same. In particular, the present disclosure relates to the preparation of PD-L1 binding antibodies and their use in treating, preventing, and detecting cancer.BACKGROUND

[0003] The following description of the background of the present disclosure is provided simply as an aid in understanding the present disclosure and is not admitted to describe or constitute prior art to the present disclosure.

[0004] Programmed Cell Death Ligand 1 (PD-L1) is an immune inhibitory receptor ligand expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. Programmed Cell Death l igand I (PD-L1) is a transmembrane protein that is considered to be a co-inhibitory factor of the immune response, and it can combine with Programmed Cell Death Protein 1 (PD-1) to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion, and induce apoptosis. In tumor microenvironments, PD-L1 interaction with PD-1 has been shown to attenuate the host immune response to tumor cells and facilitate tumor immune escape. Accordingly, the standard of care for several cancer types currently includes treatment with monoclonal antibodies (mAbs) specific to PD-L1. Monoclonal antibody (mAb)-based therapy for cancer is one of the most successful strategies for treating patients with both hematological and nonhematological malignancies. Three anti-PD-Ll antibodies have been approved by the FDA: atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio). However, due to tumor heterogeneity, the objective response rate for PD-L1 blockade via the currently approved anti-PD-Ll mAbs is approximately 20 % - 30 %. Moreover, different degrees ofside effects and adverse reactions have occurred in subjects treated with such therapies. Accordingly, there exists an urgent need for alternative PD-L1 -targeted therapies that overcome the low PD-L1 blockade response rates and adverse reactions associated with the current standards of care.SUMMARY OF THE DISCLOSURE

[0005] The present disclosure provides immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof), which can bind to PD-L1 polypeptides including the PD-L1 transmembrane receptor. The immunoglobulin-related compositions of the present disclosure are useful in methods for inhibiting the growth of cancer cells in vitro and in vivo and inhibiting the activity of PD-L1 when administered to a subject in need thereof. Accordingly, the various aspects of the present methods relate to the preparation, characterization, and manipulation of anti-PD-Ll antibodies. The immunoglobulin-related compositions of the present disclosure are useful alone or in combination with additional therapeutic agents for treating inhibiting the growth of cancer cells in vitro and in vivo, inhibiting the immune evasion activity of PD-L1, screening for new therapies in vitro and in vivo including combination therapies, and treating cancer in a subject in need thereof. In one aspect, the subject has a PD-L1 positive tumor or cancer, or a PD-L1 -mediated autoimmune disease. In some embodiments, the immunoglobulin-related composition is a monoclonal antibody, chimeric antibody, a humanized antibody, a bispecific antibody, a multi-specific antibody, and / or an mRNA-encoded antibody.

[0006] In one aspect, the present disclosure provides antibodies or antigen binding fragments thereof that bind PD-L1 polypeptides including the PD-L1 transmembrane receptor. In some embodiments, the antibodies or antigen binding fragments thereof comprise a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL). In some embodiments, the VH comprises a VH-CDR1 sequence of SEQ ID NO: 5, a VH- CDR2 sequence of SEQ ID NO: 6, and a VH-CDR3 sequence of SEQ ID NO: 7. In some embodiments, the VH comprises a VH-CDR1 sequence of SEQ ID NO: 15, a VH-CDR2 sequence of SEQ ID NO: 16, and a VH-CDR3 sequence of SEQ ID NO: 17. In some embodiments, the VH comprises a VH-CDR1 sequence of SEQ ID NO: 25, a VH-CDR2 sequence of SEQ ID NO: 26, and a VH-CDR3 sequence of SEQ ID NO: 27. In someembodiments, the VL comprises a VL-CDR1 sequence of SEQ ID NO: 8, a VL-CDR2 sequence of SEQ ID NO: 9, and a VL-CDR3 sequence of SEQ ID NO: 10. In some embodiments, the VL comprises a VL-CDR1 sequence of SEQ ID NO: 18, a VL-CDR2 sequence of SEQ ID NO: 19, and a VL-CDR3 sequence of SEQ ID NO: 20. In some embodiments, the VL comprises a VL-CDR1 sequence of SEQ ID NO: 28, a VL-CDR2 sequence of SEQ ID NO: 29, and a VL-CDR3 sequence of SEQ ID NO: 30.

[0007] In some aspects, the present disclosure provides antibodies or antigen binding fragments thereof, the antibodies or antigen binding fragments thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein: (a) the VH comprises an amino acid sequence selected from any one of SEQ ID NOs: 3, 13, or 23; and / or (b) the VL comprises an amino acid sequence selected from any one of SEQ ID NOs: 4, 14, or 24. In some aspects, the present disclosure provides antibodies or antigen binding fragments thereof, comprising heavy chain immunoglobulin variable domain (VH) and light chain immunoglobulin variable domain (VL) amino acid sequences selected from the group consisting of a VH of SEQ ID NO: 3 and a VL of SEQ ID NO: 4, a VH of SEQ ID NO: 13 and a VL of SEQ ID NO: 14, and a VH of SEQ ID NO: 23 and a VL of SEQ ID NO: 24, respectively.

[0008] In some embodiments, the antibodies or antigen binding fragments provided herein further comprise an Fc domain of an isotype selected from the group consisting of IgGl, IgG2, IgG3, IgG4, IgAl, IgA2, IgM, IgD, and IgE. In some embodiments, the antibody or antigen binding fragment comprises an IgGl constant region. In some embodiments, the antibody or antigen binding fragment comprises one or more amino acid mutations, such as, e.g., an N297A amino acid mutation. In some embodiments, the antigen binding fragment is selected from the group consisting of Fab, F(ab’)2, Fab’, scFv, and Fv. In some embodiments, the antibody comprises variant glycosylation as compared to a parent Fc region.

[0009] In some further aspects, the present disclosure provides a recombinant nucleic acid encoding one or more of the antibodies or antigen binding fragments provided herein. In some embodiments, the recombinant nucleic acid comprises a heavy chain immunoglobulin variable domain (VH) polynucleotide sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 21, SEQ ID NO: 47, SEQ ID NO: 49, and SEQ ID NO: 51. In some embodiments, the recombinant nucleic acid comprises a light chainimmunoglobulin variable domain (VL) polynucleotide sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 22, SEQ ID NO: 48, SEQ ID NO: 50, and SEQ ID NO: 52. In some further embodiments, the recombinant nucleic acid is a recombinant ribonucleic acid (RNA) molecule. In some embodiments, the recombinant nucleic acid further comprises one or more of a 3’ UTR, a 5’ UTR, and / or a polyA tail. In some embodiments, the recombinant RNA molecule comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39. In some embodiments, the recombinant nucleic acid comprises one or more chemical modifications.

[0010] In some embodiments, the present disclosure provides a polynucleotide encoding the recombinant nucleic acid molecules provided herein. In some embodiments, the polynucleotide is, e.g., a deoxyribonucleic acid (DNA), an RNA, a hybrid of DNA and RNA, or an analog of each thereof. In some embodiments, the present disclosure provides vectors comprising the recombinant nucleic acid molecules provided herein. In some embodiments, the vector comprises a regulatory sequence operatively linked to the polynucleotide to direct the transcription thereof. In some embodiments, the vector further comprises a marker, e.g., a detectable marker, a purification marker, or a selection marker. In some embodiments, the vector is a viral vector, e.g., an adenoviral vector, or an adeno-associated viral vector, or a retroviral vector, or a lentiviral vector, or a plant viral vector.

[0011] In some aspects the present disclosure provides a composition comprising the antibodies or antigen binding fragments, recombinant nucleic acids, polynucleotides, or vectors provided herein. In some embodiments, the composition comprises one or more agents selected from, e.g., nanoparticles, isotopes, dyes, chromagens, contrast agents, drugs, toxins, cytokines, enzymes, enzyme inhibitors, hormones, hormone antagonists, growth factors, radionuclides, metals, liposomes, RNA, DNA or any combination thereof.

[0012] In some embodiments, the present disclosure provides, a method for binding PD-L1, comprising contacting a sample suspected of containing PD-L1 with the antibodies, antigen binding fragments, or compositions provided herein, under conditions that favor the binding of the antibody or antigen binding fragment to PD-L1 to form a complex between the antibody or antigen binding fragment and PD-L1. In some further embodiments, the methodcomprises detecting the complex formed between the antibody or antigen binding fragment and PD-L1. In some embodiments, the sample comprises a cell expressing PD-L1, e.g., a cancer cell, that is optionally selected from alveolar soft part sarcoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, small cell lung cancer, biliary tract cancer, merkel cell carcinoma, renal cell carcinoma, urothelial cancer, Hodgkin lymphoma, bladder cancer, kidney cancer, breast cancer, head and neck cancer, cancer of the esophagus, stomach cancer, or cervical cancer.

[0013] The present disclosure also provides a method for treating cancer in a subject in need thereof. In some embodiments, the method comprises administering to the subject an effective amount one or more of the antibodies, antigen binding fragments, or compositions provided herein. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is breast cancer, gastric cancer, osteosarcoma, desmoplastic small round cell cancer, squamous cell carcinoma of head and neck cancer, ovarian cancer, prostate cancer, pancreatic cancer, glioblastoma multiforme, gastric junction adenocarcinoma, gastroesophageal junction adenocarcinoma, cervical cancer, salivary gland cancer, soft tissue sarcoma, leukemia, melanoma, Ewing’s sarcoma, rhabdomyosarcoma, or neuroblastoma. In some embodiments, the antibody or antigen binding fragment or the composition is administered to the subject separately, sequentially or simultaneously with an additional therapeutic agent, e.g., one or more of alkylating agents, platinum agents, taxanes, vinca agents, anti-estrogen drugs, aromatase inhibitors, ovarian suppression agents, VEGF / VEGFR inhibitors, EGF / EGFR inhibitors, PARP inhibitors, cytostatic alkaloids, cytotoxic antibiotics, antimetabolites, endocrine / hormonal agents, T cells, and bisphosphonate therapy agents.

[0014] The present disclosure also provides kits comprising the antibodies, antigen binding fragments, recombinant nucleic acids, and / or compositions provided herein, and instructions for use.BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIG. 1A shows graphical data of enzyme-linked immunosorbent assays (ELISA) for anti-PD-Ll titers in sera collected at day 21 from a mouse immunized with human PD-L1 extracellular domain proteins (Example 1). FIG. IB shows fluorescence activated cellsorting (FACS) graphical data for anti-PD-Ll titers in sera collected at day 21 from a mouse immunized with human PD-L1 extracellular domain proteins.

[0016] FIG. 2A shows a graph depicting titers of mouse hybridoma fusion library culture supernatants in units of mean fluorescence intensity vs. culture supernatant dilution. FIG. 2B shows a graph depicting titers of mouse hybridoma fusion library culture supernatants in units of mean fluorescence intensity vs. antibody concentration.

[0017] FIG. 3 shows representative gel electrophoresis images depicting purification of anti- PD-Ll monoclonal antibodies from single clone culture supernatants. Each lane is labeled according to the single clone culture supernatant identification number.

[0018] FIG. 4A and FIG. 4B show bar graphs with summary FACS screening data of anti- PD-Ll monoclonal antibodies across each of the 36 clones tested. 22 of the 36 clones were selected for their strong binding activity to PD-L1. FIG. 4C and FIG. 4D show bar graphs with summary neutralization activity screening data of anti-PD-Ll monoclonal antibodies across each of the 36 clones tested. 17 out of the 36 clones were selected for their strong neutralization activity against the PD-1, PD-L1 interaction.

[0019] FIG. 5A shows graphs depicting results from epitope binning competitive surface plasmon resonance using a Biacore instrument against the approved PD-L1 monoclonal antibody Atezolizumab. FIG. 5B shows a table containing qualitative summary epitope binning data across each of the anti-PD-Ll antibodies tested.

[0020] FIG. 6A shows representative flow cytometry ICso data for Atezolizumab and the 2M32 anti-PD-Ll antibody. FIG. 6B shows representative ICso curves for Atezolizumab and the 2M32 anti-PD-Ll antibody. FIG. 6C shows a table containing summary ICso data for each of the anti-PD-Ll antibodies tested.

[0021] FIG. 7 shows representative graphical binding kinetics data for the Ml, M10, M15, and M23 PD-L1 antibodies, Atezolizumab, Durvalumab.

[0022] FIG. 8A shows the DNA sequences for heavy chain and light chain regions of anti- PD-Ll antibodies provided herein. FIG. 8B shows the amino acid sequences for heavy chain and light chain regions of anti-PD-Ll antibodies provided herein.

[0023] FIG. 9A shows sequence alignments of the heavy chain and light chain amino acid sequences across the Ml, M10, and M15 anti-PD-Ll antibodies provided herein. FIG. 9B shows a tabulated comparison of the Ml, M10, and M15 heavy chain CDR regions againstthe Atezolizumab, Durvalumab, and Avelumab heavy chain CDR regions (using the Kabat region definition). FIG. 9C shows a tabulated comparison of the Ml, MIO, and M15 light chain CDR regions against the Atezolizumab, Durvalumab, and Avelumab light chain CDR regions (using the Kabat region definition).

[0024] FIG. 10A shows a graph depicting antibody titers of Ml mRNA-transfected Expi293F cell culture supernatants. FIG. 10B shows a graph depicting antibody titers of atezolizumab mRNA-transfected Expi293F cell culture supernatants.

[0025] FIG. 11A shows a graph depicting in vivo expression of lipid nanoparticle (LNP)-Ml mRNA. Serum concentration of Ml in Balb / c mice received single injection of LNP-M1 mRNA at dose (2.0 mg / kg) or Ml antibody proteins at dose (10 mg / kg per mice).Pharmacokinetic test of Ml and mRNA-LNPs encoded Ml in Balb / c mice. FIG. 11B shows a graph depicting in vivo expression of lipid nanoparticle (LNP)-atezolizumab mRNA. Serum concentration of Ml in Balb / c mice received single injection of LNP-atezolizumab mRNA at dose (2.0 mg / kg) or Ml antibody proteins at dose (10 mg / kg per mice). Pharmacokinetic test of atezolizumab and mRNA-LNPs encoded atezolizumab in Balb / c mice.

[0026] FIG. 12 shows the study design and dosing schedule for the pilot experiment for evaluating the antitumor efficacy of atezolizumab mRNA-LNP and proteins in the C57BL6 mouse model.

[0027] FIG. 13 shows the study design and dosing schedule for assessing the dose-dependent antitumor efficacy of atezolizumab mRNA-LNP or proteins in the C57BL6 mouse model.

[0028] FIG. 14A - FIG. 14D show the results of the in vivo anti -tumor efficacy test of LNP - Atezolizumab mRNA in the C57BL6 mouse model with MC38. FIG. 14A shows the tumor growth inhibition (TGI) of MC38 tumors in mice treated with LNP- Atezolizumab mRNA at 2 doses using the Atezolizumab antibodies and PBS as positive control and negative control, respectively. FIG. 14B shows tumor volumes of individual mice in each group injected with LNP -Atezolizumab mRNA or Atezolizumab proteins, respectively. FIG. 14C is a graph showing the effects of LNP- Atezolizumab mRNA or Atezolizumab proteins on body weight changes in the C57BL6 mouse model. FIG. 14D shows the body weight of individual mice in each group injected with LNP-Atezolizumab mRNA or Atezolizumab proteins, respectively. *P<0.05 and **P<0.01 (unpaired Students’ t-test).

[0029] FIG. 15 shows the in vivo expression of LNP-Atezolizumab mRNA at 24 h post injection. The serum concentration of Atezolizumab in C57BL6 mice that received a single injection of LNP-Atezolizumab mRNA and antibody proteins, was assessed by ELISA 24 hours after the initial injection.

[0030] FIG. 16A - FIG. 16C show the dose-dependent anti-tumor efficacy of Atezolizumab mRNA-LNP and proteins. FIG. 16A shows tumor growth inhibition (TGI) of MC38 tumors in mice treated with LNP-Atezolizumab mRNA at three doses using the Atezolizumab antibodies and empty LNP as positive control and negative control, respectively. FIG. 16B shows tumor growth inhibition (TGI) of MC38 tumors in mice treated with Atezolizumab antibody at 2 doses using the Atezolizumab antibodies and PBS as positive control and negative control, respectively. FIG. 16C shows the effects on body weight changes. *P<0.05 and **P<0.01 (unpaired Students’ t-test).

[0031] FIG. 17A - FIG. 17B show the correlation between mRNA-LNP and protein doses and TGI (%). FIG. 17A shows the correlation between mRNA-LNP and protein doses. An injection of 0.6 mg / kg of mRNA-LNP leads to reaching a concentration of 3 mg / kg of protein. FIG. 17B shows Tumor growth inhibition (TGI) was calculated by the following equation: TGI (1 (mean RTV / RTW of control groupmean RTV) / (RTW of treated group ))*100%.

[0032] FIG. 18 shows the dose-dependent in vivo expression of LNP-Atezolizumab mRNA at 24 h post injection.DETAILED DESCRIPTIONDefinitions

[0033] As it would be understood, the section or subsection headings as used herein are for organizational purposes only and are not to be construed as limiting and / or separating the subject matter described.

[0034] It is to be appreciated that certain aspects, modes, embodiments, variations, and features of the present methods are described below in various levels of detail in order to provide a substantial understanding of the present disclosure.

[0035] It is to be understood that this disclosure is not limited to particular embodiments described, as such can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of this disclosure will be limited only by the appended claims.

[0036] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred methods, devices, and materials are now described. All technical and patent publications cited herein are incorporated herein by reference in their entirety. Nothing herein is to be construed as an admission that the disclosure is not entitled to antedate such disclosure by virtue of prior disclosure.

[0037] The present disclosure generally provides immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof), which can specifically bind to PD-L1 polypeptides including the PD-L1 transmembrane receptor. The immunoglobulin-related compositions of the present disclosure are useful in methods for inhibiting the growth of cancer cells in vitro and in vivo and inhibiting the activity of PD-L1 when administered to a subject in need thereof. Accordingly, the various aspects of the present methods relate to the preparation, characterization, and manipulation of anti-PD-Ll antibodies. The immunoglobulin-related compositions of the present disclosure are useful alone or in combination with additional therapeutic agents for treating inhibiting the growth of cancer cells in vitro and in vivo, inhibiting the immune evasion activity of PD-L1, screening for new therapies in vitro and in vivo including combination therapies, and treating cancer in a subject in need thereof. In one aspect, the subject has a PD-L1 positive tumor or cancer, or a PD-L1- mediated autoimmune disease. In some embodiments, the immunoglobulin-related composition is a monoclonal antibody, chimeric antibody, a humanized antibody, a bispecific antibody, a multi-specific antibody, and / or an mRNA-encoded antibody.

[0038] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of tissue culture, immunology, molecular biology, microbiology, cell biology and recombinant DNA, which are within the skill of the art. See, e.g., Sambrook and Russell eds. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition; the series Ausubelet al. eds. (2007) Current Protocols in Molecular Biology; the series Methods in Enzymology (Academic Press, Inc., N.Y.); MacPherson et al. (1991) PCR 1 : A Practical Approach (IRL Press at Oxford University Press); MacPherson et al. (1995) PCR 2: A Practical Approach; Harlow and Lane eds. (1999) Antibodies, A Laboratory Manual; Freshney (2005) Culture of Animal Cells: A Manual of Basic Technique, 5th edition; Gait ed. (1984) Oligonucleotide Synthesis; U.S. Patent No. 4,683,195; Hames and Higgins eds. (1984) Nucleic Acid Hybridization; Anderson (1999) Nucleic Acid Hybridization; Hames and Higgins eds. (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL Press (1986)); Perbal (1984) A Practical Guide to Molecular Cloning; Miller and Calos eds. (1987) Gene Transfer Vectors for Mammalian Cells (Cold Spring Harbor Laboratory); Makrides ed. (2003) Gene Transfer and Expression in Mammalian Cells; Mayer and Walker eds. (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); Herzenberg et al. eds (1996) Weir’s Handbook of Experimental Immunology; Manipulating the Mouse Embryo: A Laboratory Manual, 3rd edition (Cold Spring Harbor Laboratory Press (2002)); Sohail (ed.) (2004) Gene Silencing by RNA Interference: Technology and Application (CRC Press); and Plotkin et al., Plotkin;’ Human Vaccines, 7thedition (Elsevier).

[0039] As used in the specification and claims, the singular form “a,” “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a cell” includes a plurality of cells, including mixtures thereof.

[0040] As used herein, the term “comprising” is intended to mean that the compounds, compositions, and methods include the recited elements, but not exclude others. “Consisting essentially of’ when used to define compounds, compositions, and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants, e.g., from the isolation and purification method and pharmaceutically acceptable carriers, preservatives, and the like. “Consisting of’ shall mean excluding more than trace elements of other ingredients. Embodiments defined by each of these transition terms are within the scope of this disclosure.

[0041] All numerical designations, e.g., pH, temperature, time, concentration, and molecular weight, including ranges, are approximations which are varied (+) or (-) by increments of 1, 5, or 10%. It is to be understood, although not always explicitly stated that all numericaldesignations are preceded by the term “about.” It also is to be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents of such are known in the art.

[0042] The term “about,” as used herein when referring to a measurable value such as an amount or concentration and the like, is meant to encompass variations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1 % of the specified amount.

[0043] As used herein, comparative terms as used herein, such as high, low, increase, decrease, reduce, or any grammatical variation thereof, can refer to certain variation from the reference. In some embodiments, such variation can refer to about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 1 fold, or about 2 folds, or about 3 folds, or about 4 folds, or about 5 folds, or about 6 folds, or about 7 folds, or about 8 folds, or about 9 folds, or about 10 folds, or about 20 folds, or about 30 folds, or about 40 folds, or about 50 folds, or about 60 folds, or about 70 folds, or about 80 folds, or about 90 folds, or about 100 folds or more higher than the reference. In some embodiments, such variation can refer to about 1%, or about 2%, or about 3%, or about 4%, or about 5%, or about 6%, or about 7%, or about 8%, or about 0%, or about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 75%, or about 80%, or about 85%, or about 90%, or about 95%, or about 96%, or about 97%, or about 98%, or about 99% of the reference.

[0044] As will be understood by one skilled in the art, for any and all purposes, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Furthermore, as will be understood by one skilled in the art, a range includes each individual member.

[0045] “Optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.

[0046] As used herein, “and / or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).

[0047] “Substantially” or “essentially” means nearly totally or completely, for instance, 95% or greater of some given quantity. In some embodiments, “substantially” or “essentially” means 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9%.

[0048] The terms or “acceptable,” “effective,” or “sufficient” when used to describe the selection of any components, ranges, dose forms, etc. disclosed herein intend that said component, range, dose form, etc. is suitable for the disclosed purpose.

[0049] In some embodiments, the terms “first” “second” “third” “fourth” or similar in a component name are used to distinguish and identify more than one component sharing certain identity in their names. For example, “first polypeptide” and “second polypeptide” are used to distinguish two polypeptides.

[0050] As used herein, the “administration” of an agent or drug to a subject includes any route of introducing or delivering to a subject a compound to perform its intended function. Administration can be carried out by any suitable route, including but not limited to, orally, intranasally, parenterally (intravenously, intramuscularly, intraperitoneally, or subcutaneously), rectally, intrathecally, intratumorally or topically. Administration includes self-administration and the administration by another.

[0051] As used herein, the term “antibody” collectively refers to immunoglobulins or immunoglobulin-like molecules including by way of example and without limitation, IgA, IgD, IgE, IgG and IgM, combinations thereof, and similar molecules produced during an immune response in any vertebrate, for example, in mammals such as humans, goats, rabbits and mice, as well as non-mammalian species, such as shark immunoglobulins. As used herein, “antibodies” (includes intact immunoglobulins) and “antigen binding fragments” specifically bind to a molecule of interest (or a group of highly similar molecules of interest) to the substantial exclusion of binding to other molecules (for example, antibodies and antibody fragments that have a binding constant for the molecule of interest that is at least 103M'1greater, at least 104M'1greater or at least 105M'1greater than a binding constant for other molecules in a biological sample). The term “antibody” also includes genetically engineered forms such as chimeric antibodies (for example, humanized murine antibodies), heteroconjugate antibodies (such as, bispecific antibodies). See also, Pierce Catalog andHandbook, 1994-1995 (Pierce Chemical Co., Rockford, Ill.); Kuby, J., Immunology, 3rdEd., W.H. Freeman & Co., New York, 1997.

[0052] More particularly, antibody refers to a polypeptide ligand comprising at least a light chain immunoglobulin variable region or heavy chain immunoglobulin variable region which specifically recognizes and binds an epitope of an antigen. Antibodies are composed of a heavy and a light chain, each of which has a variable region, termed the variable heavy (VH) region and the variable light (VL) region. Together, the VH region and the VL region are responsible for binding the antigen recognized by the antibody. Typically, an immunoglobulin has heavy (H) chains and light (L) chains interconnected by disulfide bonds. There are two types of light chain, lambda (X) and kappa (K). There are five main heavy chain classes (or isotypes) which determine the functional activity of an antibody molecule: IgM, IgD, IgG, IgA and IgE. Each heavy and light chain contains a constant region and a variable region, (the regions are also known as “domains”). In combination, the heavy and the light chain variable regions specifically bind the antigen. Light and heavy chain variable regions contain a “framework” region interrupted by three hypervariable regions, also called “complementarity-determining regions” or “CDRs”. The extent of the framework region and CDRs have been defined (see, Kabat el al., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, 1991, which is hereby incorporated by reference). The Kabat database is now maintained online. The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, largely adopt a P-sheet conformation and the CDRs form loops which connect, and in some cases form part of, the P-sheet structure. Thus, framework regions act to form a scaffold that provides for positioning the CDRs in correct orientation by interchain, non-covalent interactions.

[0053] As used herein, the term “antibody heavy chain” refers to the larger of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformations.

[0054] As used herein, the term “antibody light chain” refers to the smaller of the two types of polypeptide chains present in all antibody molecules in their naturally occurringconformations. Kappa (K) and lambda (X) light chains refer to the two major antibody light chain isotypes.

[0055] As used herein, the term “synthetic antibody” means an antibody, which is generated using recombinant DNA technology, such as, for example, an antibody expressed by a bacteriophage. The term should also be construed to mean an antibody, which has been generated by the synthesis of a DNA molecule encoding the antibody and which DNA molecule expresses an antibody protein, or an amino acid sequence specifying the antibody, wherein the DNA or amino acid sequence has been obtained using synthetic DNA or amino acid sequence technology which is available and well known in the art.

[0056] As used herein, the term “antibody variant” includes synthetic and engineered forms of antibodies which are altered such that they are not naturally occurring, e.g., antibodies that comprise at least two heavy chain portions but not two complete heavy chains (such as, domain deleted antibodies or minibodies); multi-specific forms of antibodies (e.g., bispecific, tri-specific, etc.) altered to bind to two or more different antigens or to different epitopes on a single antigen); heavy chain molecules joined to scFv molecules and the like. In addition, the term “antibody variant” includes multivalent forms of antibodies (e.g., trivalent, tetravalent, etc., antibodies that bind to three, four or more copies of the same antigen.

[0057] The CDRs are primarily responsible for binding to an epitope of an antigen. The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus, and are also typically identified by the chain in which the particular CDR is located. Thus, a VH CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found, whereas a VL CDR1 is the CDR1 from the variable domain of the light chain of the antibody in which it is found. An antibody that binds a PD-L1 protein will have a specific VH region and the VL region sequence, and thus specific CDR sequences. Antibodies with different specificities (i.e., different combining sites for different antigens) have different CDRs. Although it is the CDRs that vary from antibody to antibody, only a limited number of amino acid positions within the CDRs are directly involved in antigen binding. These positions within the CDRs are called specificity determining residues (SDRs). “Immunoglobulin-related compositions” as used herein, refers to antibodies (including monoclonal antibodies, polyclonal antibodies, humanized antibodies,chimeric antibodies, recombinant antibodies, multi-specific antibodies, bispecific antibodies, etc.,) as well as antibody fragments. An antibody or antigen binding fragment thereof specifically binds to an antigen.

[0058] As used herein, the term “antibody-related polypeptide” means antigen-binding antibody fragments, including single-chain antibodies, that can comprise the variable region(s) alone, or in combination, with all or part of the following polypeptide elements: hinge region, CHi, CH2, and CH3 domains of an antibody molecule. Also included in the disclosure are any combinations of variable region(s) and hinge region, CHi, CH2, and CH3 domains. Antibody -related molecules useful in the present methods, e.g., but are not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide- linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Examples include: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHi domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHi domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., Nature 341 : 544-546, 1989), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). As such “antibody fragments” or “antigen binding fragments” can comprise a portion of a full length antibody, generally the antigen binding or variable region thereof. Examples of antibody fragments or antigen binding fragments include Fab, Fab1, F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multi-specific antibodies formed from antibody fragments.

[0059] “Bispecific antibody” or “BsAb,” as used herein, refers to an antibody that can bind simultaneously to two targets that have a distinct structure, e.g., two different target antigens, two different epitopes on the same target antigen, or a hapten and a target antigen or epitope on a target antigen. A variety of different bispecific antibody structures are known in the art. In some embodiments, each antigen binding moiety in a bispecific antibody includes VH and / or VL regions; in some such embodiments, the VH and / or VL regions are those found in a particular monoclonal antibody. In some embodiments, the bispecific antibody contains two antigen binding moieties, each including VH and / or VL regions from different monoclonal antibodies. In some embodiments, the bispecific antibody contains two antigen bindingmoieties, wherein one of the two antigen binding moieties includes an immunoglobulin molecule having VH and / or VL regions that contain CDRs from a first monoclonal antibody, and the other antigen binding moiety includes an antibody fragment (e.g., Fab, F(ab'), F(ab')2, Fd, Fv, dAB, scFv, etc.) having VH and / or VL regions that contain CDRs from a second monoclonal antibody.

[0060] As used herein, the term “antibody-dependent cell-mediated cytotoxicity” or “ADCC”, refers to a mechanism of cell-mediated immune defense whereby an effector cell of the immune system actively lyses a target cell, such as a tumor cell, whose membrane-surface antigens have been bound by antibodies, such as anti-PD-Ll antibodies.

[0061] As used herein, an “antigen” refers to a molecule to which an antibody (or antigen binding fragment thereof) can selectively bind. The target antigen can be a protein, carbohydrate, nucleic acid, lipid, hapten, or other naturally occurring or synthetic compound. In some embodiments, the target antigen can be a polypeptide (e.g., a PD-L1 polypeptide). An antigen can also be administered to an animal to generate an immune response in the animal. As used herein, the term “antigen” or “Ag” is also defined as a molecule that provokes an immune response. This immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both. The skilled artisan will understand that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. A skilled artisan will understand that any DNA, which comprises a nucleotide sequence or a partial nucleotide sequence encoding a protein that elicits an immune response therefore encodes an “antigen” as that term is used herein. Furthermore, one skilled in the art will understand that an antigen need not be encoded solely by a full- length nucleotide sequence of a gene. It is readily apparent that the present invention includes, but is not limited to, the use of partial nucleotide sequences of more than one gene and that these nucleotide sequences are arranged in various combinations to elicit a desired immune response. Moreover, the skilled artisan will understand that an antigen need not be encoded by a “gene” at all. It is readily apparent that an antigen can be generated synthesized or can be derived from a biological sample. Such a biological sample can include, but is not limited to a tissue sample, a tumor sample, a cell, or a biological fluid.

[0062] The term “antigen binding fragment” refers to a fragment of the whole immunoglobulin structure which possesses a part of a polypeptide responsible for binding to antigen. Examples of the antigen binding fragment useful in the present disclosure include scFv, (SCFV)2, SCFVFC, Fab, Fab' and F(ab')2, but are not limited thereto. Any of the abovenoted antibody fragments are obtained using conventional techniques known to those of skill in the art, and the fragments are screened for binding specificity and neutralization activity in the same manner as are intact antibodies.

[0063] As used herein, “binding affinity” means the strength of the total noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen or antigenic peptide). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by standard methods known in the art, including those described herein. A low-affinity complex contains an antibody that generally tends to dissociate readily from the antigen, whereas a high-affinity complex contains an antibody that generally tends to remain bound to the antigen for a longer duration.

[0064] As used herein, the term “specifically binds,” with respect to an antibody, means an antibody or binding fragment thereof (e.g., Fv fragment or scFv) which recognizes a specific antigen, but does not substantially recognize or bind other molecules in a sample. For example, an antibody that specifically binds to an antigen from one species may also bind to that antigen from one or more species, but, such cross-species reactivity does not itself alter the classification of an antibody as specific. In another example, an antibody that specifically binds to an antigen may also bind to different allelic forms of the antigen. However, such cross reactivity does not itself alter the classification of an antibody as specific. In some instances, the terms “specific binding” or “specifically binding,” can be used in reference to the interaction of an antibody, a protein, a chimeric antigen receptor, or a peptide with a second chemical species, to mean that the interaction is dependent upon the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species; for example, a chimeric antigen receptor recognizes and binds to a specific protein structure rather than to proteins generally. If an antibody is specific for epitope “A,” the presence of a molecule containing epitope A (or free, unlabeled A), in a reaction containing labeled “A” and the antibody, will reduce the amount of labeled A bound to the antibody.

[0065] As used herein, the term “biological sample” means sample material derived from living cells. Biological samples can include tissues, cells, protein or membrane extracts of cells, and biological fluids (e.g., ascites fluid or cerebrospinal fluid (CSF)) isolated from a subject, as well as tissues, cells and fluids present within a subject. Biological samples of the present disclosure include, but are not limited to, samples taken from breast tissue, renal tissue, the uterine cervix, the endometrium, the head or neck, the gallbladder, parotid tissue, the prostate, the brain, the pituitary gland, kidney tissue, muscle, the esophagus, the stomach, the small intestine, the colon, the liver, the spleen, the pancreas, thyroid tissue, heart tissue, lung tissue, the bladder, adipose tissue, lymph node tissue, the uterus, ovarian tissue, adrenal tissue, testis tissue, the tonsils, thymus, blood, hair, buccal, skin, serum, plasma, CSF, semen, prostate fluid, seminal fluid, urine, feces, sweat, saliva, sputum, mucus, bone marrow, lymph, and tears. Biological samples can also be obtained from biopsies of internal organs or from cancers. Biological samples can be obtained from subjects for diagnosis or research or can be obtained from non-diseased individuals, as controls or for basic research. Samples can be obtained by standard methods including, e.g., venous puncture and surgical biopsy. In certain embodiments, the biological sample is a tissue sample obtained by needle biopsy.

[0066] As used herein, the term “CDR grafting” means replacing at least one CDR of an “acceptor” antibody with a CDR “graft” from a “donor” antibody possessing a desirable antigen specificity.

[0067] As used herein, the term “chimeric antibody” means an antibody in which the Fc constant region of a monoclonal antibody from one species (e.g., a mouse Fc constant region) is replaced, using recombinant DNA techniques, with an Fc constant region from an antibody of another species (e.g., a human Fc constant region). See generally, Robinson et al., PCT / US86 / 02269; Akira et al., European Patent Application 184,187; Taniguchi, European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., WO 86 / 01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 0125,023; Better et al., Science 240: 1041-1043, 1988; Liu et al., Proc. Natl. Acad. Sci. USA 84: 3439-3443, 1987; Liu et al., J. Immunol 139: 3521-3526, 1987; Sun et al., Proc. Natl. Acad. Sci. USA 84: 214-218, 1987; Nishimura et al., Cancer Res 47: 999-1005, 1987; Wood et al., Nature 314: 446-449, 1885; and Shaw et al., J. Natl. Cancer Inst. 80: 1553-1559, 1988.

[0068] As used herein, the term “complement-dependent cytotoxicity” or “CDC” generally refers to an effector function of IgG and IgM antibodies, which trigger classical complement pathway when bound to a surface antigen, inducing formation of a membrane attack complex and target cell lysis.

[0069] As used herein, the term “conjugated” refers to the association of two molecules by any method known to those in the art. Suitable types of associations include chemical bonds and physical bonds. Chemical bonds include, for example, covalent bonds and coordinate bonds. Physical bonds include, for instance, hydrogen bonds, dipolar interactions, van der Waal forces, electrostatic interactions, hydrophobic interactions, and aromatic stacking.

[0070] As used herein, the term “consensus FR” means a framework (FR) antibody region in a consensus immunoglobulin sequence. The FR regions of an antibody do not contact the antigen.

[0071] As used herein, a "control" is an alternative sample used in an experiment for comparison purpose. A control can be "positive" or "negative." For example, where the purpose of the experiment is to determine a correlation of the efficacy of a therapeutic agent for the treatment for a particular type of disease, a positive control (a compound or composition known to exhibit the desired therapeutic effect) and a negative control (a subject or a sample that does not receive the therapy or receives a placebo) are typically employed.

[0072] As used herein, the term “diabodies” refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (VH VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen binding sites. Diabodies are described more fully in, e.g., EP 404,097;WO 93 / 11161; and Hollinger et al., Proc Natl Acad Sci USA, 90: 6444-6448 (1993).

[0073] As used herein, the term “contacting” means direct or indirect binding or interaction between two or more molecules or other entities. A particular example of direct interaction is binding. A particular example of an indirect interaction is where one entity acts upon an intermediary molecule, which in turn acts upon the second referenced entity. Contacting asused herein includes in solution, in solid phase, in vitro, ex vivo, in a cell, and in vivo. Contacting in vivo can be referred to as administering, or administration.

[0074] As used herein, the term “effective amount” refers to a quantity sufficient to achieve a desired therapeutic and / or prophylactic effect, e.g., an amount which results in the prevention of, or a decrease in a disease or condition described herein or one or more signs or symptoms associated with a disease or condition described herein. In the context of therapeutic or prophylactic applications, the amount of a composition administered to the subject will vary depending on the composition, the degree, type, and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. The compositions can also be administered in combination with one or more additional therapeutic compounds. In the methods described herein, the therapeutic compositions can be administered to a subject having one or more signs or symptoms of a disease or condition described herein.

[0075] As used herein, a “therapeutically effective amount” of a composition refers to composition levels in which the physiological effects of a disease or condition are ameliorated or eliminated. A therapeutically effective amount can be given in one or more administrations. In some embodiments, an “effective amount” is an amount sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications, or dosages. Such delivery is dependent on a number of variables including the time period for which the individual dosage unit is to be used, the bioavailability of the therapeutic agent, the route of administration, etc. It is understood, however, that specific dose levels of the therapeutic agents disclosed herein for any particular subject depends upon a variety of factors including the activity of the specific compound employed, bioavailability of the compound, the route of administration, the age of the animal and its body weight, general health, sex, the diet of the animal, the time of administration, the rate of excretion, the drug combination, and the severity of the particular disorder being treated and form of administration. Provided herein in the experimental examples are effective amounts determined in a murine or rat animal model, which can be converted to an effective dose by converting the reported pg of particle per g of the mouse. A typical adult mouse is from about 15g to about 35g for a female mouse and about 20g to about 30g for amale mouse. In general, one will desire to administer an amount of the compound that is effective to achieve a serum level commensurate with the concentrations found to be effective in vivo. These considerations, as well as effective formulations and administration procedures are well known in the art and are described in standard textbooks.

[0076] As used herein, the term “effector cell” means an immune cell which is involved in the effector phase of an immune response, as opposed to the cognitive and activation phases of an immune response. Exemplary immune cells include a cell of a myeloid or lymphoid origin, e.g., lymphocytes (e.g., B cells and T cells including cytolytic T cells (CTLs)), killer cells, natural killer cells, macrophages, monocytes, eosinophils, neutrophils, polymorphonuclear cells, granulocytes, mast cells, and basophils. Effector cells express specific Fc receptors and carry out specific immune functions. An effector cell can induce antibody-dependent cell-mediated cytotoxicity (ADCC), e.g., a neutrophil capable of inducing ADCC. For example, monocytes, macrophages, neutrophils, eosinophils, and lymphocytes which express FcaR are involved in specific killing of target cells and presenting antigens to other components of the immune system, or binding to cells that present antigens.

[0077] As used herein, the term “epitope” means a protein determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents. In some embodiments, an “epitope” of the PD-L1 protein is a region of the protein to which the anti-PD-Ll antibodies of the present disclosure specifically bind. In some embodiments, the epitope is a conformational epitope or a non-conformational epitope. To screen for anti- PD-L1 antibodies which bind to an epitope, a routine cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. This assay can be used to determine if an anti-PD-Ll antibody binds the same site or epitope as an anti-PD-Ll antibody of the present disclosure. Alternatively, or additionally, epitope mapping can be performed by methods known in the art. For example, the antibody sequence can be mutagenized such as by alanine scanning, toidentify contact residues. In a different method, peptides corresponding to different regions of a PD-L1 protein can be used in competition assays with the test antibodies or with a test antibody and an antibody with a characterized or known epitope.

[0078] As used herein, “expression” includes one or more of the following: transcription of the gene into precursor mRNA; splicing and other processing of the precursor mRNA to produce mature mRNA; mRNA stability; translation of the mature mRNA into protein (including codon usage and tRNA availability); and glycosylation and / or other modifications of the translation product, if required for proper expression and function.

[0079] As used herein, the term “gene” means a segment of DNA that contains all the information for the regulated biosynthesis of an RNA product, including promoters, exons, introns, and other untranslated regions that control expression.

[0080] As used herein, “homology” or “identity” or “similarity” refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing a position in each sequence which can be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base or amino acid, then the molecules are homologous at that position. A degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences. A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) has a certain percentage (for example, at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%) of “sequence identity” to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art. In some embodiments, default parameters are used for alignment. One alignment program is BLAST, using default parameters. In particular, programs are BLASTN and BLASTP, using the following default parameters: Genetic code=standard; filter=none; strand=both; cutoff=60; expect=10; Matrix=BLOSUM62; Descriptions=50 sequences; sort by =HIGH SCORE; Databases=non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS translations+SwissProtein+SPupdate+PIR. Details of these programs can be found at the National Center for Biotechnology Information. Biologically equivalent polynucleotides are those having the specified percent homology and encoding a polypeptide having the sameor similar biological activity. Two sequences are deemed “unrelated” or “non-homologous” if they share less than 40% identity, or less than 25% identity, with each other.

[0081] When comparing polynucleotide and polypeptide sequences, two sequences are said to be “identical” if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

[0082] Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, Wis.), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M. O. (1978) A model of evolutionary change in proteins — Matrices for detecting distant relationships; Dayhoff, M. O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington D.C. Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) Unified Approach to Alignment and Phylogeny pp. 626-645 Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, Calif.; Higgins, D. G. and Sharp, P. M. (1989) CABIOS 5: 151-153; Myers, E. W. and Muller W. (1988) CABIOS 4: 11-17; Robinson, E. D. (1971) Comb. Theor 11 : 105; Santou, N. Nes, M. (1987) Mol. Biol. Evol. 4:406-425; Sneath, P. H. A. and Sokal, R. R. (1973) Numerical Taxonomy — the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, Calif.; Wilbur, W. J. and Lipman, D. J. (1983) Proc. Natl. Acad., Sci. USA 80:726-730.

[0083] Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) Add. APL. Math 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity methods of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by inspection.

[0084] One particular example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nucl. Acids Res. 25:3389-3402 and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example, with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the disclosure. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. The rearranged nature of an antibody sequence and the variable length of each gene requires multiple rounds of BLAST searches for a single antibody sequence. Also, manual assembly of different genes is difficult and error-prone. The sequence analysis tool IgBLAST (world- wide-web at ncbi.nlm.nih.gov / igblast / ) identifies matches to the germline V, D and J genes, details at rearrangement junctions, the delineation of Ig V domain framework regions and complementarity determining regions. IgBLAST can analyze nucleotide or protein sequences and can process sequences in batches and allows searches against the germline gene databases and other sequence databases simultaneously to minimize the chance of missing possibly the best matching germline V gene.

[0085] In one illustrative example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89: 10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and a comparison of both strands.

[0086] For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residuealignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.

[0087] In one approach, the “percentage of sequence identity” is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residues occur in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

[0088] In some embodiments, the Fv fragment further comprises a linker domain to generate a single chain variable fragment (scFv). In one embodiment, the linker domain is operably linked to the heavy chain variable domain and the light chain variable domain. In some embodiments, the light and heavy chain variable regions are contiguously linked via a short flexible polypeptide linker, and capable of being expressed as a single chain polypeptide, and the scFv retains the specificity of the intact antibody from which it is derived. In one embodiment, the flexible polypeptide linker includes, but are not limited to, (Gly4 Ser)4 or (Gly4 Ser)3. In another embodiment, the linker includes multiple repeats of (Gly2Ser), (GlySer) or (Gly3Ser).

[0089] As used herein, “humanized” forms of non-human (e.g., murine) antibodies are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit, or nonhuman primate having the desired specificity, affinity, and capacity. In some embodiments, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies can comprise residues which are not found in the recipient antibody or in the donor antibody. Thesemodifications are made to further refine antibody performance such as binding affinity. Generally, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains (e.g., Fab, Fab', F(ab')2, or Fv), in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus FR sequence although the FR regions can include one or more amino acid substitutions that improve binding affinity. The number of these amino acid substitutions in the FR are typically no more than 6 in the H chain, and in the L chain, no more than 3. The humanized antibody optionally can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321 :522-525 (1986); Reichmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). See e.g., Ahmed & Cheung, FEBS Letters 588(2):288- 297 (2014).

[0090] As used herein, the term “hypervariable region” refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region generally comprises amino acid residues from a “complementarity determining region” or “CDR” (e.g., around about residues 24-34 (LI), 50-56 (L2) and 89-97 (L3) in the VL, and around about 31- 35B (Hl), 50-65 (H2) and 95-102 (H3) in the VH (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and / or those residues from a “hypervariable loop” (e.g., residues 26- 32 (LI), 50-52 (L2) and 91-96 (L3) in the VL, and 26-32 (Hl), 52A-55 (H2) and 96-101 (H3) in the VH (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).

[0091] As used herein, the terms “identical” or percent “identity”, when used in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region (e.g., nucleotide sequence encoding an antibody described herein or amino acid sequence of an antibody described herein)), when compared and aligned for maximum correspondence over a comparison window or designated region as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manualalignment and visual inspection (e.g., NCBI web site). Such sequences are then said to be “substantially identical.” This term also refers to, or can be applied to, the complement of a test sequence. The term also includes sequences that have deletions and / or additions, as well as those that have substitutions. In some embodiments, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or 50-100 amino acids or nucleotides in length.

[0092] As used herein, the term “intact antibody” or “intact immunoglobulin” means an antibody that has at least two heavy (H) chain polypeptides and two light (L) chain polypeptides interconnected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CHi, CEE and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FRi, CDRi, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.

[0093] As used herein, the term “linker” refers to a functional group (e.g., chemical or polypeptide) that covalently attaches two or more polypeptides or nucleic acids so that they are connected to one another. As used herein, a “peptide linker” refers to one or more amino acids used to couple two proteins together (e.g., to couple VH and VL domains). In certain embodiments, the linker comprises amino acids sequence of (GGGGS)n, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more. In certain embodiments, the linker comprises amino acids having the sequence of GGGGSGGGGSGGGGS (SEQ ID NO: 45) or GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 46).

[0094] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, ie., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that can be present in minor amounts. For example, a monoclonal antibody can be an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including, e.g., but not limited to, hybridoma, recombinant, and phage display technologies. For example, the monoclonal antibodies to be used in accordance with the present methods can be made by the hybridoma method first described by Kohler et al., Nature 256:495 (1975), or can be made by recombinant DNA methods (See, e.g., U.S. Patent No. 4,816,567). The “monoclonal antibodies” can also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature 352:624-628 (1991) and Marks et al., J. Mol. Biol. 222:581-597 (1991), for example.

[0095] As used herein, the term “nucleic acid” or “polynucleotide” means any RNA or DNA, which can be unmodified or modified RNA or DNA. Polynucleotides include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and doublestranded regions, single- and double-stranded RNA, RNA that is mixture of single- and double-stranded regions, and hybrid molecules comprising DNA and RNA that can be singlestranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.

[0096] A “3’ untranslated region” (3’ UTR) refers to a region of an mRNA that is directly downstream (i.e., 3’) from the stop codon (i.e., the codon of an mRNA transcript that signals a termination of translation) that does not encode a polypeptide. In some embodiments, a 3’ UTR as used herein comprises, or consists essentially of, or yet further consists of SEQ ID NO: 42.

[0097] A “5’ untranslated region” (5’ UTR) refers to a region of an RNA that is directly upstream (i.e., 5') from the start codon (i.e., the first codon of an mRNA transcript translated by a ribosome) that does not encode a polypeptide. In some embodiments, a 5’ UTR as used herein comprises, or consists essentially of, or yet further consists of SEQ ID NO: 40.

[0098] A “polyA tail” is a region of mRNA that is downstream, e.g., directly downstream (i.e., 3’), from the 3’ UTR that contains multiple, consecutive adenosine monophosphates. A polyA tail may contain 10 to 300 adenosine monophosphates. Additionally or alternatively, in a relevant biological setting (e.g., in cells, in vivo) the polyA tail functions to protect mRNA from enzymatic degradation, e.g., in the cytoplasm, and aids in transcription termination, export of the mRNA from the nucleus and translation. In some embodiments, a polyA tail as used herein comprises, or consists essentially of, or yet further consists of: SEQ ID NO: 43.

[0099] The terms “pharmaceutically-acceptable,” “physiologically-tolerable,” and grammatical variations thereof, as they refer to compositions, carriers, diluents, and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a subject without the production of undesirable physiological effects to a degree that would prohibit administration of the composition. For example, “pharmaceutically- acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. Such excipients can be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous.“Pharmaceutically-acceptable salts and esters” means salts and esters that are pharmaceutically-acceptable and have the desired pharmacological properties. Such salts include salts that can be formed where acidic protons present in the composition are capable of reacting with inorganic or organic bases. Suitable inorganic salts include those formed with the alkali metals, e.g., sodium and potassium, magnesium, calcium, and aluminum. Suitable organic salts include those formed with organic bases such as the amine bases, e.g.,ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. Such salts also include acid addition salts formed with inorganic acids (e.g., hydrochloric and hydrobromic acids) and organic acids (e.g., acetic acid, citric acid, maleic acid, and the alkane- and arene-sulfonic acids such as methanesulfonic acid and benzenesulfonic acid). Pharmaceutically acceptable esters include esters formed from carboxy, sulfonyloxy, and phosphonoxy groups present in the anti-PD-Ll antibody, e.g., Ci-6 alkyl esters. When there are two acidic groups present, a pharmaceutically acceptable salt or ester can be a mono-acid-mono-salt or ester or a di-salt or ester; and similarly where there are more than two acidic groups present, some or all of such groups can be salified or esterified. An anti-PD-Ll antibody named in this disclosure can be present in unsalified or unesterified form, or in salified and / or esterified form, and the naming of such anti-PD-Ll antibody is intended to include both the original (unsalified and unesterified) compound and its pharmaceutically acceptable salts and esters. Also, certain embodiments of the present disclosure can be present in more than one stereoisomeric form, and the naming of such anti- PD-Ll antibody is intended to include all single stereoisomers and all mixtures (whether racemic or otherwise) of such stereoisomers. A person of ordinary skill in the art, would have no difficulty determining the appropriate timing, sequence, and dosages of administration for particular drugs and compositions of the present disclosure.

[0100] The term “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal compounds, isotonic and absorption delaying compounds, and the like, compatible with pharmaceutical administration. Pharmaceutically acceptable carriers include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances, such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat. Pharmaceutically acceptable carriers and their formulations are known to one skilled in the art and aredescribed, for example, in Remington's Pharmaceutical Sciences (20thedition, ed. A. Gennaro, 2000, Lippincott, Williams & Wilkins, Philadelphia, Pa.).

[0101] As used herein, the term “polyclonal antibody” means a preparation of antibodies derived from at least two (2) different antibody-producing cell lines. The use of this term includes preparations of at least two (2) antibodies that contain antibodies that specifically bind to different epitopes or regions of an antigen.

[0102] As used herein, the terms “polypeptide,” “peptide”, and “protein” are used interchangeably herein to mean a polymer comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. Polypeptide refers to both short chains, commonly referred to as peptides, glycopeptides, or oligomers, and to longer chains, generally referred to as proteins. Polypeptides can contain amino acids other than the 20 gene-encoded amino acids. Polypeptides include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.

[0103] As used herein, the term “recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein, or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the material is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (nonrecombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.

[0104] As used herein, the term “separate” therapeutic use refers to an administration of at least two active ingredients at the same time or at substantially the same time by different routes.

[0105] As used herein, the term “sequential” therapeutic use refers to administration of at least two active ingredients at different times, the administration route being identical or different. More particularly, sequential use refers to the whole administration of one of the active ingredients before administration of the other or others commences. It is thus possibleto administer one of the active ingredients over several minutes, hours, or days before administering the other active ingredient or ingredients. There is no simultaneous treatment in this case.

[0106] As used herein, the term “simultaneous” therapeutic use refers to the administration of at least two active ingredients by the same route and at the same time or at substantially the same time.

[0107] As used herein, the terms “single-chain antibodies” or “single-chain Fv (scFv)” refer to an antibody fusion molecule of the two domains of the Fv fragment, VL and VH. Single-chain antibody molecules can comprise a polymer with a number of individual molecules, for example, dimer, trimer, or other polymers. Furthermore, although the two domains of the Fvfragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single-chain Fv (scFv)). Bird et al. (1988) Science 242:423-426 and Huston et al. (1988) Proc Natl Acad Sci 85:5879-5883. Such single-chain antibodies can be prepared by recombinant techniques or enzymatic or chemical cleavage of intact antibodies.

[0108] As used herein, “specifically binds” refers to a molecule (e.g., an antibody or antigen binding fragment thereof) which recognizes and binds another molecule (e.g., an antigen), but that does not substantially recognize and bind other molecules. The terms “specific binding,” “specifically binds to,” or is “specific for” a particular molecule (e.g., a polypeptide, or an epitope on a polypeptide), as used herein, can be exhibited, for example, by a molecule having a KD for the molecule to which it binds to of about 104M, I 05M, 106M, 107M, 108M, 109M, 10I OM, 10 " M, or 10l 2M. The term “specifically binds” can also refer to binding where a molecule (e.g., an antibody or antigen binding fragment thereof) binds to a particular polypeptide (e.g., a PD-L1 polypeptide), or an epitope on a particular polypeptide, without substantially binding to any other polypeptide, or polypeptide epitope.

[0109] As used herein, the terms “subject”, “patient”, or “individual” can be an individual organism, a vertebrate, a mammal, or a human. In some embodiments, the subject, patient, or individual is a human. In some aspects, the subject is a mammal selected from a canine, afeline, an equine, a simian, or other. The methods can be used to treat non-human animals or to test for new or combination therapies when in an acceptable animal model.

[0110] As used herein, the term “therapeutic agent” is intended to mean a compound that, when present in an effective amount, produces a desired therapeutic effect on a subject in need thereof.

[0111] “Treating” or “treatment” as used herein covers the treatment of a disease or disorder described herein, in a subject, such as a human, and includes: (i) inhibiting a disease or disorder, z.e., arresting its development; (ii) relieving a disease or disorder, z.e., causing regression of the disorder; (iii) slowing progression of the disorder; and / or (iv) inhibiting, relieving, or slowing progression of one or more symptoms of the disease or disorder. In some embodiments, treatment means that the symptoms associated with the disease are, e.g., alleviated, reduced, cured, or placed in a state of remission. In a further aspect, the term “treatment” excludes prevention or prophylactic use.

[0112] It is also to be appreciated that the various modes of treatment of disorders as described herein are intended to mean “substantial,” which includes total but also less than total treatment, and wherein some biologically or medically relevant result is achieved. The treatment can be a continuous prolonged treatment for a chronic disease or a single, or few time administrations for the treatment of an acute condition.

[0113] Amino acid sequence modification(s) of the anti-PD-Ll antibodies described herein are contemplated. Such modifications can be performed to improve the binding affinity and / or other biological properties of the antibody, for example, to render the encoded amino acid glycosylated, or to destroy the antibody’s ability to bind to Clq, Fc receptor, or to activate the complement system. Amino acid sequence variants of an anti-PD-Ll antibody are prepared by introducing appropriate nucleotide changes into the antibody nucleic acid, by peptide synthesis, or by chemical modifications. Such modifications include, for example, deletions from, and / or insertions into and / or substitutions of, residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution is made to obtain the antibody of interest, as long as the obtained antibody possesses the desired properties. The modification also includes the change of the pattern of glycosylation of the protein. The sites of greatest interest for substitutional mutagenesis include the hypervariableregions, but FR alterations are also contemplated. Alternatively or additionally, it may be useful to combine amino acid modifications with one or more further amino acid modifications that alter Clq binding and / or the complement dependent cytotoxicity (CDC) function of the Fc region of an antigen binding molecule. The binding polypeptide of particular interest may be one that binds to Clq and displays complement dependent cytotoxicity. Polypeptides with pre-existing Clq binding activity, optionally further having the ability to mediate CDC may be modified such that one or both of these activities are enhanced. Amino acid modifications that alter Clq and / or modify its complement dependent cytotoxicity function are described in WO 2000 / 0042072.

[0114] One can design an Fc region of an antibody with altered effector function, e.g., by modifying Clq binding and / or FcyR binding and thereby changing CDC activity and / or ADCC activity. “Effector functions” are responsible for activating or diminishing a biological activity (e.g., in a subject). Examples of effector functions include, but are not limited to: Clq binding; complement dependent cytotoxicity (CDC); Fc receptor binding; antibodydependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor; BCR), etc. Such effector functions may require the Fc region to be combined with a binding domain (e.g., an antibody variable domain) and can be assessed using various assays (e.g., Fc binding assays, ADCC assays, CDC assays, etc.).

[0115] For example, one can generate a variant Fc region of an antibody with improved Clq binding and improved FcyRIII binding (e.g., having both improved ADCC activity and improved CDC activity). Alternatively, if it is desired that effector function be reduced or ablated, a variant Fc region can be engineered with reduced CDC activity and / or reduced ADCC activity. In other embodiments, only one of these activities may be increased, and, optionally, also the other activity reduced (e.g., to generate an Fc region variant with improved ADCC activity, but reduced CDC activity and vice versa).

[0116] Fc mutations can also be introduced and engineered to alter their interaction with the neonatal Fc receptor (FcRn) and improve their pharmacokinetic properties. A collection of human Fc variants with improved binding to the FcRn have been described (Shields et al., (2001). High resolution mapping of the binding site on human IgGl for FcyRI, FcyRII, FcyRIII, and FcRn and design of IgGl variants with improved binding to the FcyR, J. Biol. Chem. 276:6591-6604). A number of methods are known that can result in increased half-life(Kuo and Aveson, (2011), Neonatal Fc receptor and IgG-based therapeutics, MAbs, 3(5):422- 30), including amino acid modifications may be generated through techniques including alanine scanning mutagenesis, random mutagenesis and screening to assess the binding to the neonatal Fc receptor (FcRn) and / or the in vivo behavior. Computational strategies followed by mutagenesis may also be used to select one of amino acid mutations to mutate.

[0117] Conservative amino acid substitutions are amino acid substitutions that change a given amino acid to a different amino acid with similar biochemical properties (e.g., charge, hydrophobicity and size). “Conservative substitutions” are shown in the Table below.

[0118] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody. A convenient way for generating such substitutional variants involves affinity maturation using phage display. Specifically, several hypervariable region sites (e.g., 6-7 sites) are mutated to generate all possible amino acid substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of Ml 3 packaged within each particle. The phage-displayed variants are then screened for their biological activity e.g., binding affinity) as herein disclosed. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or additionally, it can be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points between the antibody and the antigen. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with similar or superior properties in one or more relevant assays can be selected for further development.

[0119] One aspect of the present disclosure provides a “derivative” of an antibody or antigen fragment. The term “derivative” refers to an antibody or antigen-binding fragment thereof that immunospecifically binds to an antigen but which comprises, one, two, three, four, five or more amino acid substitutions, additions, deletions, or modifications relative to a “parental” (or wild-type) molecule. Such amino acid substitutions or additions may introduce naturally occurring (i.e., DNA-encoded) or non-naturally occurring amino acid residues. The term “derivative” encompasses, for example, as variants having altered CHI, hinge, CH2,CH3 or CH4 regions, so as to form, for example, antibodies, etc., having variant Fc regions that exhibit enhanced or impaired effector or binding characteristics. The term “derivative” additionally encompasses non-amino acid modifications, for example, amino acids that may be glycosylated (e.g., have altered mannose, 2-N-acetylglucosamine, galactose, fucose, glucose, sialic acid, 5-N-acetylneuraminic acid, 5-glycolneuraminic acid, etc. content), acetylated, pegylated, phosphorylated, amidated, derivatized by known protecting / blocking groups, proteolytic cleavage, linked to a cellular ligand or other protein, etc.

[0120] In some embodiments, the altered carbohydrate modifications modulate one or more of the following: solubilization of the antibody, facilitation of subcellular transport and secretion of the antibody, promotion of antibody assembly, conformational integrity, and antibody-mediated effector function. In a specific embodiment, the altered carbohydrate modifications enhance antibody mediated effector function relative to the antibody lacking the carbohydrate modification. Carbohydrate modifications that lead to altered antibody mediated effector function are well known in the art. See e.g., Shields et al., J. Biol. Chem. 277(30): 26733-26740 (2002); Davies J. et al., Biotechnology & Bioengineering 74(4): 288- 294 (2001). Methods of altering carbohydrate contents are also known to those skilled in the art. See, e.g., Wallick et al. J. Exp. Med. 168(3): 1099-1109 (1988); Tao et al. J. Immunol. 143(8): 2595-2601 (1989); Routledge et al., Transplantation 60(8):847-53 (1995); Elliott et al., Nature Biotechnol. 21 :414-21 (2003); Shield et al. J. Biol. Chem. 277(30): 26733-26740 (2002).

[0121] A derivative antibody or antibody fragment can be generated with an engineered sequence or glycosylation state to confer preferred levels of activity in antibody dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), antibodydependent neutrophil phagocytosis (ADNP), or antibody-dependent complement deposition (ADCD) functions as measured by bead-based or cell-based assays or in vivo studies in animal models.

[0122] A derivative antibody or antibody fragment may be modified by chemical modifications using techniques known to those of skill in the art, including, but not limited to, specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, etc. In one embodiment, an antibody derivative will possess a similar or identical function as the parental antibody. In another embodiment, an antibody derivative will exhibit an alteredactivity relative to the parental antibody. For example, a derivative antibody (or fragment thereof) can bind to its epitope more tightly or be more resistant to proteolysis than the parental antibody.

[0123] In some embodiments, the antibody or antibody fragment of the present disclosure may be linked to at least one agent to form an antibody conjugate. In order to increase the efficacy of antibody molecules as diagnostic or therapeutic agents, it is conventional to link or covalently bind or complex at least one desired molecule or moiety. Such a molecule or moiety may be, but is not limited to, at least one effector or reporter molecule. Effector molecules comprise molecules having a desired activity, e.g., cytotoxic activity. Non-limiting examples of effector molecules which have been attached to antibodies include toxins, antitumor agents, therapeutic enzymes, radionuclides, antiviral agents, chelating agents, cytokines, growth factors, and oligo- or polynucleotides. By contrast, a reporter molecule is defined as any moiety which may be detected using an assay. Non-limiting examples of reporter molecules, which have been conjugated to antibodies include enzymes, radiolabels, haptens, fluorescent labels, phosphorescent molecules, chemiluminescent molecules, chromophores, photoaffinity molecules, colored particles, or ligands, such as biotin.

[0124] Antibody conjugates are generally preferred for use as diagnostic agents. Antibody diagnostics generally fall within two classes, those for use in in vitro diagnostics, such as in a variety of immunoassays, and those for use in in vivo diagnostic protocols, generally known as “antibody-directed imaging.” Many appropriate imaging agents are known in the art, as are methods for their attachment to antibodies. See e.g., U.S. Pat. Nos. 5,021,236, 4,938,948, and 4,472,509. The imaging moieties used can be paramagnetic ions, radioactive isotopes, fluorochromes, NMR-detectable substances, and X-ray imaging agents. In the case of paramagnetic ions, one might mention by way of example ions such as chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) and / or erbium (III), with gadolinium being particularly preferred. Ions useful in other contexts, such as X-ray imaging, include but are not limited to lanthanum (III), gold (III), lead (II), and especially bismuth (III).

[0125] In the case of radioactive isotopes for therapeutic and / or diagnostic application, one might mention astatine-211, carbon-14, chromium-51, chlorine-36, cobalt-57, cobalt-58,copper-67, europium-152, gallium-67, hydrogen-3, iodine-123, iodine-125, iodine-131, indium-i l l, iron-59, phosphorus-32, rhenium-186, rhenium-188, selenium-75, sulphur-35, technicium-99m and / or yttrium-90. Iodine-125 is often being preferred for use in certain embodiments, and technicium-99m and / or indium- 111 are also often preferred due to their low energy and suitability for long range detection. Radioactively labeled monoclonal antibodies of the present disclosure may be produced according to well-known methods in the art. For instance, monoclonal antibodies can be iodinated by contact with sodium and / or potassium iodide and a chemical oxidizing agent such as sodium hypochlorite, or an enzymatic oxidizing agent, such as lactoperoxidase. Monoclonal antibodies according to the disclosure may be labeled with technetium-99m by ligand exchange process, for example, by reducing pertechnate with stannous solution, chelating the reduced technetium onto a Sephadex column and applying the antibody to this column. Alternatively, direct labeling techniques may be used, e.g., by incubating pertechnate, a reducing agent such as SNC12, a buffer solution such as sodium-potassium phthalate solution, and the antibody. Intermediary functional groups which are often used to bind radioisotopes which exist as metallic ions to antibody are diethylenetriaminepentaacetic acid (DTP A) or ethylene diaminetetracetic acid (EDTA).

[0126] Among the fluorescent labels contemplated for use as conjugates include Alexa 350, Alexa 430, AMCA, BODIPY 630 / 650, BODIPY 650 / 665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy3, Cy5,6-FAM, Fluorescein Isothiocyanate, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, TAMRA, TET, Tetramethylrhodamine, and / or Texas Red.

[0127] Additional types of antibodies contemplated in the present disclosure are those intended primarily for use in vitro, where the antibody is linked to a secondary binding ligand and / or to an enzyme (an enzyme tag) that will generate a colored product upon contact with a chromogenic substrate. Examples of suitable enzymes include urease, alkaline phosphatase, (horseradish) hydrogen peroxidase or glucose oxidase. Preferred secondary binding ligands are biotin and avidin and streptavidin compounds. The use of such labels is well known to those of skill in the art and are described, for example, in U.S. Pat. Nos. 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,277,437, 4,275,149 and 4,366,241.

[0128] Yet another known method of site-specific attachment of molecules to antibodies comprises the reaction of antibodies with hapten-based affinity labels. Essentially, haptenbased affinity labels react with amino acids in the antigen binding site, thereby destroying this site and blocking specific antigen reaction. However, this may not be advantageous since it results in loss of antigen binding by the antibody conjugate.

[0129] Molecules containing azido groups may also be used to form covalent bonds to proteins through reactive nitrene intermediates that are generated by low intensity ultraviolet light (Potter and Haley, 1983, Methods Enzymol., 91 :613-33). In particular, 2- and 8-azido analogues of purine nucleotides have been used as site-directed photoprobes to identify nucleotide binding proteins in crude cell extracts (Owens & Haley, 1987, J. Biol. Chem., vol. 259, pages 14843 - 14848; Atherton et al., 1985, Biol. Reprod., vol. 32, pages 155 - 171). The2- and 8-azido nucleotides have also been used to map nucleotide binding domains of purified proteins (Khatoon et al., 1989, Ann. of Neurology, vol. 26, pages 210 - 219; King et al., 1989, J. Biol. Chem., vol. 269, pages 10210 - 10218; Dholakia et al., 1989, J. Biol. Chem., vol. 264, 1989, pages 20638 - 20642) and may be used as antibody binding agents.

[0130] Several methods are known in the art for the attachment or conjugation of an antibody to its conjugate moiety. Some attachment methods involve the use of a metal chelate complex employing, for example, an organic chelating agent such a diethylenetriaminepentaacetic acid anhydride (DTP A); ethylenetriaminetetraacetic acid; N- chloro-p-toluenesulfonamide; and / or tetrachloro-3a-6a-diphenylglycouril-3 attached to the antibody (U.S. Pat. Nos. 4,472,509 and 4,938,948). Monoclonal antibodies may also be reacted with an enzyme in the presence of a coupling agent such as glutaraldehyde or periodate. Conjugates with fluorescein markers are prepared in the presence of these coupling agents or by reaction with an isothiocyanate. In U.S. Pat. No. 4,938,948, imaging of breast tumors is achieved using monoclonal antibodies and the detectable imaging moieties are bound to the antibody using linkers such as methyl-p-hydroxybenzimidate or N-succinimidyl-3-(4-hydroxyphenyl)propionate.

[0131] In other embodiments, derivatization of immunoglobulins by selectively introducing sulfhydryl groups in the Fc region of an immunoglobulin, using reaction conditions that do not alter the antibody combining site are contemplated. Antibody conjugates produced according to this methodology are disclosed to exhibit improvedlongevity, specificity, and sensitivity (U.S. Pat. No. 5,196,066, incorporated herein by reference). Site-specific attachment of effector or reporter molecules, wherein the reporter or effector molecule is conjugated to a carbohydrate residue in the Fc region have also been disclosed in the literature (O'Shannessy et al., 1987, J IMMUN. METH., vol. 99, pages 153 - 161). This approach has been reported to produce diagnostically and therapeutically promising antibodies which are currently in clinical evaluation.PD-L1

[0132] PD-L1 is an immune inhibitory receptor ligand expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. PD-L1 is a type I transmembrane protein with immunoglobulin V-like and C-like domains. There are three main splice variant isoforms of PD-L1 including PD-L1 isoform a (NCBI Reference Sequence: NP 054862.1; SEQ ID NO: 64), PD-L1, isoform b (NCBI Reference Sequence: NP_001254635.1; SEQ ID NO: 65; lacking an alternative in-frame exon in the 5’ coding region, thereby producing a shorter protein relative to isoform a), PD-L1 isoform c (NCBI Reference Sequence: NP 001300958.1; SEQ ID NO: 66; with a different 3’ UTR and coding region resulting in a shorter protein with a distinct C-terminus compared to isoform a). PD- L1 -receptor interactions prevent autoimmunity and maintain immune response homeostasis by inhibiting T-cell activation and cytokine release during infection or inflammation in normal tissue. The amino acid sequence is well conserved between the human and the mouse PD-L1 (NCBI Reference Sequence: NP 068693.1; SEQ ID NO: 67). In tumor microenvironments, PD-L1 is known to facilitate tumor immune escape by anergizing tumor- reactive T cells via PD-1 binding, rendering tumor cells resistant to CD8+ T cells and Fas ligand-mediated lysis, and tolerizing T cells by reverse signaling through T cell-expressed CD80 (Qu, S., et al., Genome Biol. 2021; 22: 104; Han, Y., et al., Am J Cancer Res. 2020; 10(3): 727-742). The standard of care for several cancer types currently includes treatment with monoclonal antibodies (mAbs) specific to PD-L1. Three anti-PD-Ll antibodies have been approved by the FDA: atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio) (Twomey, JD., and Zhang, B., AAPS J. 2021 Mar; 23(2): 39.). Atezolizumab is a humanized anti-PD-Ll mAb for treating subjects with alveolar soft part sarcoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, and small cell lung cancer. Durvalumab is an IgGlK anti-PD-Ll mAb for treating subjects with biliary tract cancer,hepatocellular carcinoma, non-small cell lung cancer, and small cell lung cancer. Avelumab is a fully human IgGl anti-PD-Ll mAh for treating merkel cell carcinoma, renal cell carcinoma, and urothelial cancer.Immunoglobulin-related Compositions

[0133] The present disclosure describes methods and compositions for the generation and use of anti-PD-Ll immunoglobulin-related compositions (e.g., anti-PD-Ll antibodies or antigen binding fragments thereof). The antibodies and antigen binding fragments of the present disclosure selectively bind to PD-L1 polypeptides. The anti-PD-Ll immunoglobulin- related compositions of the present disclosure can be useful in the diagnosis, or treatment of PD-L1 -associated cancers and in drug discovery and the development of personalized therapies. Anti-PD-Ll immunoglobulin-related compositions within the scope of the present disclosure include, e.g., but are not limited to, monoclonal, chimeric, humanized, bispecific antibodies and diabodies that specifically bind the target polypeptide, a homolog, derivative or a fragment of PD-L1. In one aspect, the anti-PD-Ll immunoglobulin-related compositions bind to human PD-L1 polypeptides and other mammalian species, e.g., murine PD-L1. The present disclosure also provides antigen binding fragments of any of the anti-PD-Ll antibodies disclosed herein, wherein in one embodiment, the antigen binding fragment is selected from the group consisting of Fab, F(ab)'2, Fab’, scFv, and Fv. The amino acid sequences of the anti-PD-Ll immunoglobulin-related compositions of the present disclosure are described in TABLE 2.

[0134] In one aspect, the present disclosure provides an antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein (a) (i) the VH comprises a VH-CDR1 sequence of SEQ ID NO: 5, a VH-CDR2 sequence of SEQ ID NO: 6, and a VH-CDR3 sequence of SEQ ID NO: 7; (ii) the VH comprises a VH-CDR1 sequence of SEQ ID NO: 15, a VH-CDR2 sequence of SEQ ID NO: 16, and a VH-CDR3 sequence of SEQ ID NO: 17; or (iii) the VH comprises a VH-CDR1 sequence of SEQ ID NO: 25, a VH-CDR2 sequence of SEQ ID NO: 26, and a VH-CDR3 sequence of SEQ ID NO: 27; and / or (b) (i) the VL comprises a VL-CDR1 sequence of SEQ ID NO: 8, a VL-CDR2 sequence of SEQ ID NO: 9, and a VL-CDR3 sequence of SEQ ID NO: 10; or (ii) the VL comprises a VL-CDR1 sequence of SEQ ID NO: 18, a VL-CDR2 sequence of SEQ ID NO: 19, and a VL-CDR3 sequence ofSEQ ID NO: 20; or (iii) the VL comprises a VL-CDR1 sequence of SEQ ID NO: 28, a VL- CDR2 sequence of SEQ ID NO: 29, and a VL-CDR3 sequence of SEQ ID NO: 30

[0135] In one aspect, the present disclosure provides an antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), (a) the VH comprises an amino acid sequence selected from any one of SEQ ID NOs: 3, 13, or 23; and / or (b) the VL comprises an amino acid sequence selected from any one of SEQ ID NOs: 4, 14, or 24. In some embodiments, the antibody or antigen binding fragment thereof comprises a VH and a VL selected from the group consisting of a VH of SEQ ID NO: 3 and a VL of SEQ ID NO: 4, a VH of SEQ ID NO: 13 and a VL of SEQ ID NO: 14, and a VH of SEQ ID NO: 23 and a VL of SEQ ID NO: 24, respectively.

[0136] In one aspect, the present disclosure provides a recombinant nucleic acid encoding an antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable region, and / or a light chain immunoglobulin variable region. In some embodiments, the recombinant nucleic acid comprises a heavy chain immunoglobulin variable domain (VH) polynucleotide sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 21, SEQ ID NO: 47, SEQ ID NO: 49, and SEQ ID NO: 51. In some embodiments, the recombinant nucleic acid comprises a light chain immunoglobulin variable domain (VL) polynucleotide sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 22, SEQ ID NO: 48, SEQ ID NO: 50, and SEQ ID NO: 52. In some further embodiments, the recombinant nucleic acid is a ribonucleic acid (RNA) molecule. In some further embodiments, the RNA molecule comprises, consists essentially of, or yet further consists of a 3’ UTR, a 5’ UTR, and / or a polyA tail. In some embodiments, the 3’ UTR comprises, consists essentially of, or yet further consists of SEQ ID NO: 42. In some embodiments, the 5’ UTR comprises, consists essentially of, or yet further consists of SEQ ID NO: 40. In some embodiments, the polyA tail comprises, consists essentially of, or yet further consists of SEQ ID NO: 43. In some embodiments, the RNA comprises, consists essentially of, or yet further consists of a polynucleotide sequence selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39.

[0137] In any of the above embodiments, the antibody further comprises a Fc domain of any isotype, e.g., but are not limited to, IgG (including IgGl, IgG2, IgG3, and IgG4), IgA (including IgAi and IgA?), IgD, IgE, or IgM, and IgY. Non-limiting examples of constant region sequences include:

[0138] Human IgD constant region, Uniprot: P01880 (SEQ ID NO: 55)APTKAPDVFPIISGCRHPKDNSPVVLACLITGYHPTSVTVTWYMGTQSQPQRTFPEIQ RRDSYYMTSSQLSTPLQQWRQGEYKCVVQHTASKSKKEIFRWPESPKAQASSVPTA QPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECPSHTQPLGVY LLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTGGVEEGLLERHSNG SQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMALREPAAQAPVKLSLNLLASS DPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPPQPGSTTFWAWSVL RVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYVTDHGPMK

[0139] Human IgGl constant region, Uniprot: P01857 (SEQ ID NO: 56)ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0140] Human IgG2 constant region, Uniprot: P01859 (SEQ ID NO: 57)ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVA GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPRE EQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYS KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0141] Human IgG3 constant region, Uniprot: P01860 (SEQ ID NO: 58)ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCP EPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKS RWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK

[0142] Human IgM constant region, Uniprot: P01871 (SEQ ID NO: 59)GSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITLSWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVPPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLGQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPS FASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEAS ICEDDWNSGERFTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESA TITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEE WNTGETYTCVAHEALPNRVTERTVDKSTGKPTLYNVSLVMSDTAGTCY

[0143] Human IgG4 constant region, Uniprot: P01861 (SEQ ID NO: 60)ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPRE EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYT LPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS RLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

[0144] Human IgAl constant region, Uniprot: P01876 (SEQ ID NO: 61)ASPTSPKVFPLSLCSTQPDGNVVIACLVQGFFPQEPLSVTWSESGQGVTARNFPPSQD ASGDLYTTSSQLTLPATQCLAGKSVTCHVKHYTNPSQDVTVPCPVPSTPPTPSPSTPPT PSPSCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGVTFTWTPSSGKSAVQGPP ERDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHL LPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGT TTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVM AEVDGTCY

[0145] Human IgA2 constant region, Uniprot: P01877 (SEQ ID NO: 62)ASPTSPKVFPLSLDSTPQDGNVVVACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQD ASGDLYTTSSQLTLPATQCPDGKSVTCHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSL HRPALEDLLLGSEANLTCTLTGLRDASGATFTWTPSSGKSAVQGPPERDLCGCYSVS SVLPGCAQPWNHGETFTCTAAHPELKTPLTANITKSGNTFRPEVHLLPPPSEELALNE LVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVA AEDWKKGDTFSCMVGHEALPLAFTQKTIDRMAGKPTHVNVSVVMAEVDGTCY

[0146] Human Ig kappa constant region, Uniprot: P01834 (SEQ ID NO: 63)TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0147] In some embodiments, the immunoglobulin-related compositions of the present disclosure comprise a heavy chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or is 100% identical to SEQ ID NOs: 55-62. Additionally or alternatively, in some embodiments, the immunoglobulin-related compositions of the present disclosure comprise a light chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or is 100% identical to SEQ ID NO: 63.

[0148] Additionally or alternatively, in some embodiments, the antibody or antigen binding fragment binds to the extracellular region of a PD-L1 polypeptide. In certain embodiments, the epitope is a conformational epitope or non-conformational epitope. In some embodiments, the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof that binds to the extracellular region of a PD-L1 polypeptide. In some embodiments, the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof that binds to the extracellular region of a PD-L1 polypeptide. In some embodiments, the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof that binds to the extracellular region of a PD-L1 polypeptide. In some embodiments, the antibody or antigen binding fragment is a bispecific antibody or antigen binding fragment thereof that binds to the extracellular region of a PD-L1 polypeptide. In some embodiments, the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof that binds to the extracellular region of a PD-L1 polypeptide. In some embodiments, the antibody or antigen binding fragment is a diabody or antigen binding fragment thereof that binds to the extracellular region of a PD-L1 polypeptide.

[0149] In some embodiments, the heavy chain (HC) and light chain (LC) immunoglobulin variable domain sequences are components of the same polypeptide chain. In other embodiments, the HC and LC immunoglobulin variable domain sequences are components of different polypeptide chains. In certain embodiments, the antibody is a full- length antibody.

[0150] In some embodiments, the immunoglobulin-related compositions of the present disclosure bind specifically to at least one PD-L1 polypeptide. In some embodiments, the immunoglobulin-related compositions of the present disclosure bind at least one PD-L1 polypeptide with a dissociation constant (KD) of about I O3M, 104M, I 05M, 106M, 107M, 108M, 109M, 1010M, 101 1M, or 1012M. In certain embodiments, the immunoglobulin-related compositions are monoclonal antibodies, chimeric antibodies, humanized antibodies, bispecific antibodies, or multi-specific antibodies. In some embodiments, the antibodies comprise a human antibody framework region.

[0151] In certain embodiments, the immunoglobulin-related compositions contain an IgGl constant region comprising one or more amino acid substitutions selected from thegroup consisting of N297A, K322A, L234A and L235A. Additionally or alternatively, in some embodiments, the immunoglobulin-related compositions contain an IgG4 constant region comprising a S228P mutation.

[0152] In one aspect, the present disclosure provides a multi-specific (e.g., bispecific) antibody comprising a first polypeptide chain, a second polypeptide chain, a third polypeptide chain and a fourth polypeptide chain, wherein the first and second polypeptide chains are covalently bonded to one another, the second and third polypeptide chains are covalently bonded to one another, and the third and fourth polypeptide chain are covalently bonded to one another, and wherein: (a) each of the first polypeptide chain and the fourth polypeptide chain comprises in the N-terminal to C-terminal direction: (i) a light chain variable domain of a first immunoglobulin that is capable of specifically binding to a first epitope; (ii) a light chain constant domain of the first immunoglobulin; (iii) a flexible peptide linker comprising the amino acid sequence (GGGGS)3; and (iv) a light chain variable domain of a second immunoglobulin that is linked to a complementary heavy chain variable domain of the second immunoglobulin, or a heavy chain variable domain of a second immunoglobulin that is linked to a complementary light chain variable domain of the second immunoglobulin, wherein the light chain and heavy chain variable domains of the second immunoglobulin are capable of specifically binding to a second epitope, and are linked together via a flexible peptide linker comprising the amino acid sequence (GGGGS)e to form a single-chain variable fragment; and (b) each of the second polypeptide chain and the third polypeptide chain comprises in the N-terminal to C-terminal direction: (i) a heavy chain variable domain of the first immunoglobulin that is capable of specifically binding to the first epitope; and (ii) a heavy chain constant domain of the first immunoglobulin; and wherein the heavy chain variable domain of the first immunoglobulin or the heavy chain variable domain of the second immunoglobulin comprises any one of SEQ ID NOs: 3, 13, or 23, and / or the light chain variable domain of the first immunoglobulin or the light chain variable domain of the second immunoglobulin comprises any one of SEQ ID NOs: 4, 14, or 24.

[0153] In one aspect, the immunoglobulin-related compositions of the present disclosure are encoded by a polynucleotide comprising, from 5’ to 3’, a 5’ UTR, a signal sequence, a coding region encoding a light chain or a heavy chain, a human IgGl constant region sequence or a human kappa light chain sequence, a 3’ UTR, and a poly A tail. In someembodiments, the 5’UTR comprises, consists of, or yet further consists essentially of a polynucleotide sequence of SEQ ID NO: 40. In some embodiments, the signal sequence comprises, consists of, or yet further consists essentially of a polynucleotide sequence of SEQ ID NO: 41. In some embodiments, the coding region encoding a light chain or a heavy chain comprises, consists of, or yet further consists essentially of a polynucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, or SEQ ID NO: 52. In some embodiments, the human IgGl constant region sequence comprises, consists of, or yet further consists essentially of a polynucleotide sequence of SEQ ID NO: 53. In some embodiments, the human kappa light chain sequence comprises, consists of, or yet further consists essentially of a polynucleotide sequence of SEQ ID NO: 54. In some embodiments, the 3’ UTR sequence comprises, consists of, or yet further consists essentially of a polynucleotide sequence of SEQ ID NO: 42. In some embodiments, the polyA sequence comprises, consists of, or yet further consists essentially of a polynucleotide sequence of SEQ ID NO: 43.

[0154] In some aspects, the anti-PD-Ll immunoglobulin-related compositions described herein contain structural modifications to facilitate rapid binding and cell uptake and / or slow release. In some aspects, the anti-PD-Ll immunoglobulin-related composition of the present disclosure (e.g., an antibody) can contain a deletion in the CH2 constant heavy chain region to facilitate rapid binding and cell uptake and / or slow release. In some aspects, a Fab fragment is used to facilitate rapid binding and cell uptake and / or slow release. In some aspects, a F(ab)'2 fragment is used to facilitate rapid binding and cell uptake and / or slow release.

[0155] In one aspect, the present disclosure provides a nucleic acid sequence encoding any of the immunoglobulin-related compositions described herein. Also disclosed herein are recombinant nucleic acid sequences encoding any of the antibodies described herein.

[0156] In another aspect, the present disclosure provides a host cell expressing any nucleic acid sequence encoding any of the immunoglobulin-related compositions described herein.

[0157] The immunoglobulin-related compositions of the present disclosure e.g., an anti- PD-L1 antibody) can be monospecific, bispecific, trispecific or of greater multi-specificity. Multi-specific antibodies can be specific for different epitopes of one or more PD-L1 polypeptides as well as for heterologous compositions such as a heterologous polypeptide or solid support material. In certain embodiments, the immunoglobulin-related compositions are humanized.

[0158] In some embodiments, the immunoglobulin-related compositions are chimeric. In some further embodiments, the chimeric immunoglobulin-related composition is encoded by a recombinant nucleic acid. In some further embodiments, the recombinant nucleic acid is an RNA molecule. In some embodiments, the RNA molecule comprises a heavy chain immunoglobulin variable domain (VH) polynucleotide sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 21, SEQ ID NO: 47, SEQ ID NO: 49, and SEQ ID NO: 51. In some embodiments, the RNA molecule comprises a light chain immunoglobulin variable domain (VL) polynucleotide sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 22, SEQ ID NO: 48, SEQ ID NO: 50, and SEQ ID NO: 52. In some embodiments, the RNA molecule comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39.

[0159] The immunoglobulin-related compositions of the present disclosure can further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, the immunoglobulin-related compositions of the present disclosure can be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, or toxins. See, e.g., WO 92 / 08495; WO 91 / 14438; WO 89 / 12624; U.S. Pat. No. 5,314,995; and EP 0 396 387.

[0160] In any of the above embodiments of the immunoglobulin-related compositions of the present disclosure, the antibody or antigen binding fragment can be optionally conjugated to an agent selected from the group consisting of isotopes, dyes, chromagens, contrast agents, drugs, toxins, cytokines, enzymes, enzyme inhibitors, hormones, hormone antagonists,growth factors, radionuclides, metals, liposomes, nanoparticles, RNA, DNA, or any combination thereof. For a chemical bond or physical bond, a functional group on the immunoglobulin-related composition typically associates with a functional group on the agent. Alternatively, a functional group on the agent associates with a functional group on the immunoglobulin-related composition.

[0161] The functional groups on the agent and immunoglobulin-related composition can associate directly. For example, a functional group (e.g., a sulfhydryl group) on an agent can associate with a functional group (e.g., sulfhydryl group) on an immunoglobulin-related composition to form a disulfide. Alternatively, the functional groups can associate through a cross-linking agent (z.e., linker). Some examples of cross-linking agents are described below. The cross-linker can be attached to either the agent or the immunoglobulin-related composition. The number of agents or immunoglobulin-related compositions in a conjugate is also limited by the number of functional groups present on the other. For example, the maximum number of agents associated with a conjugate depends on the number of functional groups present on the immunoglobulin-related composition. Alternatively, the maximum number of immunoglobulin-related compositions associated with an agent depends on the number of functional groups present on the agent.

[0162] In yet another embodiment, the conjugate comprises one immunoglobulin-related composition associated to one agent. In one embodiment, a conjugate comprises at least one agent chemically bonded (e.g., conjugated) to at least one immunoglobulin-related composition. The agent can be chemically bonded to an immunoglobulin-related composition by any method known to those in the art. For example, a functional group on the agent can be directly attached to a functional group on the immunoglobulin-related composition. Some examples of suitable functional groups include, for example, amino, carboxyl, sulfhydryl, maleimide, isocyanate, isothiocyanate and hydroxyl.

[0163] The agent can also be chemically bonded to the immunoglobulin-related composition by means of cross-linking agents, such as dialdehydes, carbodiimides, dimaleimides, and the like. Cross-linking agents can, for example, be obtained from Pierce Biotechnology, Inc., Rockford, Ill. The Pierce Biotechnology, Inc. web-site can provide assistance. Additional cross-linking agents include the platinum cross-linking agentsdescribed in U.S. Pat. Nos. 5,580,990; 5,985,566; and 6,133,038 of Kreatech Biotechnology, B.V., Amsterdam, The Netherlands.

[0164] Alternatively, the functional group on the agent and immunoglobulin-related composition can be the same. Homobifunctional cross-linkers are typically used to cross-link identical functional groups. Examples of homobifunctional cross-linkers include EGS (z.e., ethylene glycol bisfsuccinimidylsuccinate]), DSS (z.e., disuccinimidyl suberate), DMA (z.e., dimethyl adipimidate.2HCl), DTSSP (z.e., 3,3’-dithiobis[sulfosuccinimidylpropionate])), DPDPB (z.e., l,4-di-[3’-(2’-pyridyldithio)-propionamido]butane), and BMH (z.e., bis- maleimidohexane). Such homobifunctional cross-linkers are also available from Pierce Biotechnology, Inc.

[0165] In other instances, it can be beneficial to cleave the agent from the immunoglobulin-related composition. The web-site of Pierce Biotechnology, Inc. described above can also provide assistance to one skilled in the art in choosing suitable cross-linkers which can be cleaved by, for example, enzymes in the cell. Thus, the agent can be separated from the immunoglobulin-related composition. Examples of cleavable linkers include SMPT (z.e., 4-succinimidyloxycarbonyl-methyl-a-[2-pyridyldithio]toluene), Sulfo-LC-SPDP (z.e., sulfosuccinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate), LC-SPDP (z.e., succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate), Sulfo-LC-SPDP (z.e., sulfosuccinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate), SPDP (z.e., N- succinimidyl 3-[2-pyridyldithio]-propionamidohexanoate), and AEDP (z.e., 3-[(2- aminoethyl)dithio]propionic acid HC1).

[0166] In another embodiment, a conjugate comprises at least one agent physically bonded with at least one immunoglobulin-related composition. Any method known to those in the art can be employed to physically bond the agents with the immunoglobulin-related compositions. For example, the immunoglobulin-related compositions and agents can be mixed together by any method known to those in the art. The order of mixing is not important. For instance, agents can be physically mixed with immunoglobulin-related compositions by any method known to those in the art. For example, the immunoglobulin- related compositions and agents can be placed in a container and agitated, by for example, shaking the container, to mix the immunoglobulin-related compositions and agents.

[0167] The immunoglobulin-related compositions can be modified by any method known to those in the art. For instance, the immunoglobulin-related composition can be modified by means of cross-linking agents or functional groups, as described above.Methods of Preparing Anti-PD-Ll Antibodies

[0168] Initially, a target polypeptide is chosen to which an antibody of the present disclosure can be raised. For example, an antibody can be raised against the full-length PD- L1 protein, or to a portion of the extracellular domain of the PD-L1 protein. Techniques for generating antibodies directed to such target polypeptides are well known to those skilled in the art. Examples of such techniques include, for example, but are not limited to, those involving display libraries, xeno or human mice, hybridomas, and the like. Target polypeptides within the scope of the present disclosure include any polypeptide derived from PD-L1 protein containing the extracellular domain which is capable of eliciting an immune response.

[0169] It should be understood that recombinantly engineered antibodies and antibody fragments, e.g., antibody-related polypeptides, which are directed to PD-L1 proteins and fragments thereof are suitable for use in accordance with the present disclosure.

[0170] Anti-PD-Ll antibodies that can be subjected to the techniques set forth herein include monoclonal and polyclonal antibodies, and antibody fragments such as Fab, Fab', F(ab')2, Fd, scFv, diabodies, antibody light chains, antibody heavy chains and / or antibody fragments. Methods useful for the high yield production of antibody Fv-containing polypeptides, e.g., Fab' and F(ab')2 antibody fragments have been described. See U.S. Pat. No. 5,648,237.

[0171] Generally, an antibody is obtained from an originating species. More particularly, the nucleic acid or amino acid sequence of the variable portion of the light chain, heavy chain or both, of an originating species antibody having specificity for a target polypeptide antigen is obtained. An originating species is any species which was useful to generate the antibody of the present disclosure or library of antibodies, e.g., rat, mouse, rabbit, chicken, monkey, human, and the like.

[0172] Phage or phagemid display technologies are useful techniques to derive the antibodies of the present disclosure. Techniques for generating and cloning monoclonalantibodies are well known to those skilled in the art. Expression of sequences encoding antibodies of the present disclosure, can be carried out in E. coli.

[0173] Due to the degeneracy of nucleic acid coding sequences, other sequences which encode substantially the same amino acid sequences as those of the naturally occurring proteins can be used in the practice of the present disclosure These include, but are not limited to, nucleic acid sequences including all or portions of the nucleic acid sequences encoding the above polypeptides, which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change. It is appreciated that the nucleotide sequence of an immunoglobulin according to the present disclosure tolerates sequence homology variations of up to 25% as calculated by standard methods (“Current Methods in Sequence Comparison and Analysis,” Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pp. 127-149, 1998, Alan R. Liss, Inc.) so long as such a variant forms an operative antibody which recognizes PD-L1 proteins. For example, one or more amino acid residues within a polypeptide sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence can be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine, and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Also included within the scope of the present disclosure are proteins or fragments or derivatives thereof which are differentially modified during or after translation, e.g., by glycosylation, proteolytic cleavage, linkage to an antibody molecule or other cellular ligands, etc.Additionally, an immunoglobulin encoding nucleic acid sequence can be mutated in vitro or in vivo to create and / or destroy translation, initiation, and / or termination sequences or to create variations in coding regions and / or form new restriction endonuclease sites or destroy pre-existing ones, to facilitate further in vitro modification. Any technique for mutagenesis known in the art can be used, including but not limited to in vitro site directed mutagenesis, J. Biol. Chem. 253:6551, use of Tab linkers (Pharmacia), and the like.

[0174] In some embodiments, an antibody is a protein, or polypeptide sequence derived from an immunoglobulin molecule which specifically binds with an antigen. Antibodies can be polyclonal or monoclonal, multiple, or single chain, or intact immunoglobulins, and may be derived from natural sources or from recombinant sources. Antibodies can be tetramers of immunoglobulin molecules. In one embodiment, the antibody or antibody molecule comprises, e.g., consists of, an antibody fragment.

[0175] Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv fragments, scFv antibody fragments, linear antibodies, single domain antibodies such as sdAb (either VL or VH), camelid VHH domains, and multi-specific antibodies formed from antibody fragments such as a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region, and an isolated CDR or other epitope binding fragments of an antibody. An antigen binding fragment can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NAR and bis-scFv (see, e.g., Hollinger and Hudson, Nature Biotechnology 23 : 1126-1136, 2005). Antigen binding fragments can also be grafted into scaffolds based on polypeptides such as a fibronectin type III (Fn3)(see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide minibodies). “Fab” means a monovalent antigen-binding fragment of an immunoglobulin that is composed of the light chain and part of the heavy chain. F(ab')2 means a bivalent antigen-binding fragment of an immunoglobulin that contains both light chains and part of both heavy chains.

[0176] As used herein, the term “Fv fragment” or “variable domain fragment” refers to a VH domain and a VL domain of an antibody specifically binding to an antigen, both domains forming together a Fv fragment. In some embodiment, Fv fragments means an antibody fragment comprising the Vnand VL domains of an antibody, wherein these domains are present in a single polypeptide chain as disclosed in Table 4 herein. Generally, die Fv fragment polypeptide further compri es a polypeptide linker between the VH and VL domains polypeptide that enables the scFv to form.

[0177] The term “scFv” refers to a fusion protein comprising at least one antibody fragment comprising a variable region of a light chain and at least one antibody fragment comprising a variable region of a heavy chain, wherein the light and heavy chain variable regions are contiguously linked via a short flexible polypeptide linker, and capable of beingexpressed as a single chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless specified, as used herein an scFv may have the VL and VH variable regions in either order, e.g., with respect to the N-terminal and C- terminal ends of the polypeptide, the scFv may comprise Vr-linker-Vu or may comprise VH- linker-VL. As used herein, the term “single chain antibodies” refer to antibodies formed by recombinant DNA techniques in which immunoglobulin heavy and light chain fragments are linked to the Fv region via an engineered span of amino acids. Various methods of generating single chain antibodies are known, including those described in U.S. Pat. No. 4,694,778; Bird, Science 242:423-442 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879- 5883 (1988); Ward et al., Nature 334:54454 (1989); Skerra et al., Science 242: 1038-1041 (1988).

[0178] Preparation of Polyclonal Antisera and Immunogens. Methods of generating antibodies or antibody fragments of the present disclosure typically include immunizing a subject (generally a non-human subject such as a mouse or rabbit) with a purified PD-L1 protein or fragment thereof, or with a cell expressing the PD-L1 protein or fragment thereof. An appropriate immunogenic preparation can contain, e.g., a recombinantly-expressed PD-L1 protein or a chemically-synthesized PD-L1 peptide. The extracellular domain of the PD-L1 protein, or a portion or fragment thereof, can be used as an immunogen to generate an anti- extracellular domain of the PD-L1 antibody that binds to the PD-L1 protein, or a portion or fragment thereof using standard techniques for polyclonal and monoclonal antibody preparation.

[0179] In some embodiments, the antigenic PD-L1 peptide comprises at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 amino acid residues. Longer antigenic peptides are sometimes desirable over shorter antigenic peptides, depending on use and according to methods well known to those skilled in the art. Multimers of a given epitope are sometimes more effective than a monomer.

[0180] If needed, the immunogenicity of the PD-L1 protein (or fragment thereof) can be increased by fusion or conjugation to a carrier protein such as keyhole limpet hemocyanin (KLH) or ovalbumin (OVA). Many such carrier proteins are known in the art. One can also combine the PD-L1 protein with a conventional adjuvant such as Freund’s complete or incomplete adjuvant to increase the subject’s immune reaction to the polypeptide. Various adjuvants used to increase the immunological response include, but are not limited to,Freund's (complete and incomplete), mineral gels e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), human adjuvants such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory compounds. These techniques are standard in the art.

[0181] The isolation of sufficient purified protein or polypeptide to which an antibody is to be raised can be time consuming and sometimes technically challenging. Additional challenges associated with conventional protein-based immunization include concerns over safety, stability, scalability, and consistency of the protein antigen. Nucleic acid (DNA and RNA) based immunizations have emerged as promising alternatives. DNA vaccines are usually based on bacterial plasmids that encode the polypeptide sequence of candidate antigen, e.g., PD-L1. With a robust eukaryotic promoter, the encoded antigen can be expressed to yield enough levels of transgene expression once the host is inoculated with the plasmids (Galvin T.A., et al., Vaccine 2000, 18:2566-2583). Modem DNA vaccine generation relies on DNA synthesis, possibly one-step cloning into the plasmid vector and subsequent isolation of the plasmid, which takes significantly less time and cost to manufacture. The resulting plasmid DNA is also highly stable at room temperature, avoiding cold transportation and leading to substantially extended shelf-life. These techniques are standard in the art.

[0182] Alternatively, nucleic acid sequences encoding the antigen of interest, e.g., PD- Ll, can be synthetically introduced into an mRNA molecule. The mRNA is then delivered into a host animal, whose cells would recognize and translate the mRNA sequence to the polypeptide sequence of the candidate antigen, e.g., PD-L1, thus triggering the immune response to the foreign antigen. An attractive feature of mRNA antigen or mRNA vaccine is that mRNA is a non-infectious, non-integrating platform. There is no potential risk of infection or insertional mutagenesis associated with DNA vaccines. In addition, mRNA is degraded by normal cellular processes and has a controllable in vivo half-life through modification of design and delivery methods (Kariko, K., el ' al.. Mol Ther 16: 1833-1840 (2008); Kauffman, K. J., et al., J Control Release 240, 227-234 (2016); Guan, S. & Rosenecker, J., Gene Ther 24, 133-143 (2017); Thess, A., et al, Mol Ther 23, 1456-1464 (2015)).

[0183] In describing the present disclosure, immune responses can be described as either “primary” or “secondary” immune responses. A primary immune response, which is also described as a “protective” immune response, refers to an immune response produced in an individual as a result of some initial exposure (e.g., the initial “immunization” or “priming”) to a particular antigen, e.g., PD-L1 protein. In some embodiments, the immunization can occur as a result of vaccinating the individual with a vaccine containing the antigen. For example, the vaccine can be a PD-Llvaccine comprising one or more PD-L1 protein-derived antigens. A primary immune response can become weakened or attenuated over time and can even disappear or at least become so attenuated that it cannot be detected. Accordingly, the present disclosure also relates to a “secondary” immune response, which is also described here as a “memory immune response.” The term secondary immune response refers to an immune response elicited in an individual after a primary immune response has already been produced.

[0184] Thus, a secondary immune response can be elicited, e.g., to enhance an existing immune response that has become weakened or attenuated (e.g., boosting), or to recreate a previous immune response that has either disappeared or can no longer be detected. The secondary or memory immune response can be either a humoral (antibody) response or a cellular response. A secondary or memory humoral response occurs upon stimulation of memory B cells that were generated at the first presentation of the antigen. Delayed type hypersensitivity (DTH) reactions are a type of cellular secondary or memory immune response that are mediated by CD4+T cells. A first exposure to an antigen primes the immune system and additional exposure(s) results in a DTH.

[0185] Following appropriate immunization, the anti-PD-Ll antibody can be prepared from the subject’s serum. If desired, the antibody molecules directed against the PD-L1 protein can be isolated from the mammal (e.g, from the blood) and further purified by well- known techniques, such as polypeptide A chromatography to obtain the IgG fraction.

[0186] Monoclonal Antibody. In one embodiment of the present disclosure, the antibody is an anti-PD-Ll monoclonal antibody. For example, in some embodiments, the anti-PD-Ll monoclonal antibody can be a human or a mouse anti-PD-Ll monoclonal antibody. For preparation of monoclonal antibodies directed towards the PD-L1 protein, or derivatives, fragments, analogs or homologs thereof, any technique that provides for the production ofantibody molecules by continuous cell line culture can be utilized. Such techniques include, but are not limited to, the hybridoma technique (See, e.g., Kohler & Milstein, 1975. Nature 256: 495-497); the trioma technique; the human B-cell hybridoma technique (See, e.g., Kozbor, et al., 1983. Immunol. Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (See, e.g., Cole, et al., 1985. In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies can be utilized in the practice of the present disclosure and can be produced by using human hybridomas (See, e.g., Cote, et al, 1983. Proc. Natl. Acad. Sci. USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (See, e.g., Cole, et al., 1985. In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). For example, a population of nucleic acids that encode regions of antibodies can be isolated. PCR utilizing primers derived from sequences encoding conserved regions of antibodies is used to amplify sequences encoding portions of antibodies from the population and then DNAs encoding antibodies or fragments thereof, such as variable domains, are reconstructed from the amplified sequences. Such amplified sequences also can be fused to DNAs encoding other proteins - e.g., a bacteriophage coat, or a bacterial cell surface protein - for expression and display of the fusion polypeptides on phage or bacteria. Amplified sequences can then be expressed and further selected or isolated based, e.g., on the affinity of the expressed antibody or fragment thereof for an antigen or epitope present on the PD-L1 protein. Alternatively, hybridomas expressing anti- PD-L1 monoclonal antibodies can be prepared by immunizing a subject and then isolating hybridomas from the subject’s spleen using routine methods. See, e.g., Milstein et al., (Galfre and Milstein, Methods Enzymol (1981) 73: 3-46). Screening the hybridomas using standard methods will produce monoclonal antibodies of varying specificity (i.e., for different epitopes) and affinity. A selected monoclonal antibody with the desired properties, e.g., PD-L1 binding, can be used as expressed by the hybridoma, it can be bound to a molecule such as polyethylene glycol (PEG) to alter its properties, or a cDNA encoding it can be isolated, sequenced and manipulated in various ways. Synthetic dendromeric trees can be added to reactive amino acid side chains, e.g., lysine, to enhance the immunogenic properties of PD-L1 protein. Also, CPG-dinucleotide techniques can be used to enhance the immunogenic properties of the PD- L1 protein. Other manipulations include substituting or deleting particular amino acylresidues that contribute to instability of the antibody during storage or after administration to a subject, and affinity maturation techniques to improve affinity of the antibody of the PD-L1 protein.

[0187] Hybridoma Technique. In some embodiments, the antibody of the present disclosure is an anti-PD-Ll monoclonal antibody produced by a hybridoma which includes a B cell obtained from a transgenic non-human animal, e.g., a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell. Hybridoma techniques include those known in the art and taught in Harlow el al.. Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 349 (1988); Hammerling et al. , Monoclonal Antibodies And T-Cell Hybridomas, 563-681 (1981). Other methods for producing hybridomas and monoclonal antibodies are well known to those of skill in the art.

[0188] Phage Display Technique. As noted above, the antibodies of the present disclosure can be produced through the application of recombinant DNA and phage display technology. For example, anti-PD-Ll antibodies, can be prepared using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of a phage particle which carries polynucleotide sequences encoding them. Phages with a desired binding property are selected from a repertoire or combinatorial antibody library (e.g., human or murine) by selecting directly with an antigen, typically an antigen bound or captured to a solid surface or bead. Phages used in these methods are typically filamentous phage including fd and M13 with Fab, Fv or disulfide stabilized Fv antibody domains that are recombinantly fused to either the phage gene III or gene VIII protein. In addition, methods can be adapted for the construction of Fab expression libraries (See, e.g., Huse, et al., Science 246: 1275-1281, 1989) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a PD-L1 polypeptide, e.g., a polypeptide or derivatives, fragments, analogs, or homologs thereof. Other examples of phage display methods that can be used to make the antibodies of the present disclosure include those disclosed in Huston et al, Proc. Natl. Acad. Sci U.S.A., 85: 5879-5883, 1988; Chaudhary et al., Proc. Natl. Acad. Sci U.S.A., 87: 1066-1070, 1990; Brinkman et al., J. Immunol. Methods 182: 41-50, 1995; Ames et al., J. Immunol. Methods 184: 177-186, 1995; Kettleborough et al., Eur. J. Immunol. 24: 952-958, 1994; Persic et al.,Gene 187: 9-18, 1997; Burton c / al., Advances in Immunology 57 : 191-280, 1994; PCT / GB91 / 01134; WO 90 / 02809; WO 91 / 10737; WO 92 / 01047; WO 92 / 18619; WO 93 / 11236; WO 95 / 15982; WO 95 / 20401; WO 96 / 06213; WO 92 / 01047 (Medical Research Council etal.f WO 97 / 08320 (Morphosys); WO 92 / 01047 (CAT / MRC);WO 91 / 17271 (Affymax); and U.S. Pat. Nos. 5,698,426, 5,223,409, 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047, 5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727 and 5,733,743. Methods useful for displaying polypeptides on the surface of bacteriophage particles by attaching the polypeptides via disulfide bonds have been described by Lohning, U.S. Pat. No. 6,753,136. As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host including mammalian cells, insect cells, plant cells, yeast, and bacteria. For example, techniques to recombinantly produce Fab, Fab' and F(ab')2 fragments can also be employed using methods known in the art such as those disclosed inWO 92 / 22324; Mullinax et al., BioTechniques 12: 864-869, 1992; and Sawai et al., AJRI 34: 26-34, 1995; and Better et aL, Science 240: 1041-1043, 1988.

[0189] Generally, hybrid antibodies or hybrid antibody fragments that are cloned into a display vector can be selected against the appropriate antigen in order to identify variants that maintain good binding activity, because the antibody or antibody fragment will be present on the surface of the phage or phagemid particle. See, e.g., Barbas III et al., Phage Display, A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001). However, other vector formats could be used for this process, such as cloning the antibody fragment library into a lytic phage vector (modified T7 or Lambda Zap systems) for selection and / or screening.

[0190] Expression of Recombinant Anti-PD-Ll Antibodies. As noted above, the antibodies of the present disclosure can be produced through the application of recombinant DNA technology. Recombinant polynucleotide constructs encoding an anti-PD-Ll antibody of the present disclosure typically include an expression control sequence operably-linked to the coding sequences of anti-PD-Ll antibody chains, including naturally-associated or heterologous promoter regions. As such, another aspect of the disclosure includes vectors containing one or more nucleic acid sequences encoding an anti-PD-Ll antibody of thepresent disclosure. For recombinant expression of one or more of the polypeptides of the present disclosure, the nucleic acid containing all or a portion of the nucleotide sequence encoding the anti-PD-Ll antibody is inserted into an appropriate cloning vector, or an expression vector (z.e., a vector that contains the necessary elements for the transcription and translation of the inserted polypeptide coding sequence) by recombinant DNA techniques well known in the art and as detailed below. Methods for producing diverse populations of vectors have been described by Lerner et al., U.S. Pat. Nos. 6,291,160 and 6,680,192.

[0191] In general, expression vectors useful in recombinant DNA techniques are often in the form of plasmids. In the present disclosure, “plasmid” and “vector” can be used interchangeably as the plasmid is the most commonly used form of vector. However, the present disclosure is intended to include such other forms of expression vectors that are not technically plasmids, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions. Such viral vectors permit infection of a subject and expression of a construct in that subject. In some embodiments, the expression control sequences are eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences encoding the anti-PD-Ll antibody, and the collection and purification of the anti-PD-Ll antibody, e.g., cross-reacting anti-PD-Ll antibodies. See generally, U.S. 2002 / 0199213. These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA. Commonly, expression vectors contain selection markers, c.g, ampicillin-resistance or hygromycin-resi stance, to permit detection of those cells transformed with the desired DNA sequences. Vectors can also encode signal peptide, e.g., pectate lyase, useful to direct the secretion of extracellular antibody fragments. See U.S. Pat. No. 5,576,195.

[0192] As used herein, the term “expression vector” refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, such ascosmids, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., Sendai viruses, lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.

[0193] As used herein, the term “ex vivo," refers to cells that have been removed from a living organism, (e.g., a human) and propagated outside the organism (e.g., in a culture dish, test tube, or bioreactor).

[0194] The recombinant expression vectors of the present disclosure comprise a nucleic acid encoding a protein with PD-L1 binding properties in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression that is operably-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably-linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcript! on / translati on system or in a host cell when the vector is introduced into the host cell). The term “regulatory sequence” is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, e.g., in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of polypeptide desired, etc. Typical regulatory sequences useful as promoters of recombinant polypeptide expression (e.g., anti-PD-Ll antibody), include, e.g., but are not limited to, promoters of 3 -phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast promoters include, among others, promoters from alcohol dehydrogenase, isocytochrome C, and enzymes responsible for maltose and galactose utilization. In one embodiment, a polynucleotide encoding an anti-PD-Ll antibody of the present disclosure is operably-linked to an araB promoter and expressible in a host cell. See U.S. Pat. 5,028,530. The expression vectors of the present disclosure can be introduced into host cells to therebyproduce polypeptides or peptides, including fusion polypeptides, encoded by nucleic acids as described herein (e.g., anti-PD-Ll antibody, etc.).

[0195] Another aspect of the present disclosure pertains to anti-PD-Ll antibodyexpressing host cells, which contain a nucleic acid encoding one or more anti-PD-Ll antibodies. The recombinant expression vectors of the present disclosure can be designed for expression of an anti-PD-Ll antibody in prokaryotic or eukaryotic cells. For example, an anti-PD-Ll antibody can be expressed in bacterial cells such as Escherichia coh, insect cells (using baculovirus expression vectors), fungal cells, e.g., yeast, yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, e.g., using T7 promoter regulatory sequences and T7 polymerase. Methods useful for the preparation and screening of polypeptides having a predetermined property, e.g., anti-PD- Ll antibody, via expression of stochastically generated polynucleotide sequences has been previously described. See U.S. Pat. Nos. 5,763,192; 5,723,323; 5,814,476; 5,817,483; 5,824,514; 5,976,862; 6,492,107; 6,569,641.

[0196] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding the antibody or fragment thereof or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

[0197] Expression of polypeptides in prokaryotes is most often carried out in E. coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion polypeptides. Fusion vectors add a number of amino acids to a polypeptide encoded therein, usually to the amino terminus of the recombinant polypeptide. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinantpolypeptide; (ii) to increase the solubility of the recombinant polypeptide; and (iii) to aid in the purification of the recombinant polypeptide by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant polypeptide to enable separation of the recombinant polypeptide from the fusion moiety subsequent to purification of the fusion polypeptide. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding polypeptide, or polypeptide A, respectively, to the target recombinant polypeptide.

[0198] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69: 301-315) and pET l id (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89). Methods for targeted assembly of distinct active peptide or protein domains to yield multifunctional polypeptides via polypeptide fusion has been described by Pack et al., U.S. Pat. Nos. 6,294,353; 6,692,935. One strategy to maximize recombinant polypeptide expression, e.g., an anti-PD-Ll antibody, in A. coli is to express the polypeptide in host bacteria with an impaired capacity to proteolytically cleave the recombinant polypeptide.See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in the expression host, e.g., E. coli (See, e.g., Wada, et al., 1992. NucL Acids Res. 20: 2111- 2118). Such alteration of nucleic acid sequences of the present disclosure can be carried out by standard DNA synthesis techniques.

[0199] In another embodiment, the anti-PD-Ll antibody expression vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerevisiae include pYepSecl (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kurjan and Herskowitz, Cell G. 933-943, 1982), pJRY88 (Schultz et al., Gene 54: 113-123, 1987), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (Invitrogen Corp, San Diego, Calif.). Alternatively, an anti-PD-Ll antibody can be expressed in insect cells usingbaculovirus expression vectors. Baculovirus vectors available for expression of polypeptides, e.g., anti-PD-Ll antibody, in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, etal., Mol. Cell. Biol. 3: 2156-2165, 1983) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

[0200] In yet another embodiment, a nucleic acid encoding an anti-PD-Ll antibody of the present disclosure is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include, e.g., but are not limited to, pCDM8 (Seed, Nature 329: 840, 1987) and pMT2PC (Kaufman, et al., EMBO J. 6: 187-195, 1987). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells that are useful for expression of the anti- PD-Ll antibody of the present disclosure, see, e.g., Chapters 16 and 17 of Sambrook, etal., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

[0201] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid in a particular cell type (e.g., tissue-specific regulatory elements). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., Genes Dev. 1 : 268-277, 1987), lymphoid-specific promoters (Calame and Eaton, Adv. Immunol. 43: 235-275, 1988), promoters of T cell receptors (Winoto and Baltimore, EMBO J. 8: 729-733, 1989) and immunoglobulins (Banerji, et al., 1983. Cell 33: 729-740; Queen and Baltimore, Cell 33: 741-748, 1983.), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, Proc. Natl. Acad. Sci. USA 86: 5473-5477,1989), pancreas-specific promoters (Edlund, et al., 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, Science 249: 374-379,1990) and the a-fetoprotein promoter (Campes and Tilghman, Genes Dev. 3: 537-546, 1989).

[0202] Another aspect of the present methods pertains to host cells into which a recombinant expression vector of the present disclosure has been introduced. The terms“host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications can occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. As used herein, the term “recombinant host cell,” “recombinant cell,” “engineered host cell,” or “engineered cell,” also means a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell” or “cell” as used herein. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation and / or change. A host cell includes a cell transfected or infected in vivo or in vitro with a recombinant vector, an expression vector, or a nucleic acid encoding an antibody of the present disclosure. A host cell, which comprises a recombinant vector, expression vector, or a nucleic acid encoding an antibody disclosed herein, may also be referred to as a “recombinant host cell,” “engineered host cell,” or “engineered cell”. The term “host cell” also refers to a cell, which may be used in a process for purifying an immunogenic protein or recombinant antibody in accordance with the present disclosure. Such host cell expresses the protein of interest (the antibody disclosed herein). A host cell may also be referred to as a protein-expressing cell. “Host cell” refers not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

[0203] A host cell can be any prokaryotic or eukaryotic cell. For example, an anti-PD-Ll antibody can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells. Mammalian cells are a suitable host for expressing nucleotide segments encoding immunoglobulins or fragments thereof. See Winnacker, From Genes To Clones, (VCHPublishers, NY, 1987). A number of suitable host cell lines capable of secreting intact heterologous proteins have been developed in the art, and include Chinese hamster ovary (CHO) cell lines, various COS cell lines, HeLa cells, L cells and myeloma cell lines. In some embodiments, the cells are non-human. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer, and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. Queen et cd.. Immunol. Rev. 89: 49, 1986. Illustrative expression control sequences are promoters derived from endogenous genes, cytomegalovirus, SV40, adenovirus, bovine papillomavirus, and the like. Co et al., J Immunol. 148: 1149, 1992. Other suitable host cells are known to those skilled in the art.

[0204] “Eukaryotic cells” comprise all of the life kingdoms except Monera. They can be easily distinguished through a membrane-bound nucleus. Animals, plants, fungi, and protists are eukaryotes or organisms whose cells are organized into complex structures by internal membranes and a cytoskeleton. The most characteristic membrane-bound structure is the nucleus. Unless specifically recited, the term “host” includes a eukaryotic host, including, for example, yeast, higher plant, insect, and mammalian cells. Non-limiting examples of eukaryotic cells or hosts include simian, bovine, porcine, murine, rat, avian, reptilian and human.

[0205] “Prokaryotic cells” that usually lack a nucleus or any other membrane-bound organelles and are divided into two domains, bacteria, and archaea. In addition to chromosomal DNA, these cells can also contain genetic information in a circular loop called an episome. Bacterial cells are very small, roughly the size of an animal mitochondrion (about 1-2 pm in diameter and 10 pm long). Prokaryotic cells feature three major shapes: rod shaped, spherical, and spiral. Instead of going through elaborate replication processes like eukaryotes, bacterial cells divide by binary fission. Examples include but are not limited to Bacillus bacteria, E. coli bacterium, and Salmonella bacterium.

[0206] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calciumphosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, biolistics or viral-based transfection. Other methods used to transform mammalian cells include the use of polybrene, protoplast fusion, liposomes, electroporation, and microinjection (See generally, Sambrook et al. , Molecular Cloning). Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals. The vectors containing the DNA segments of interest can be transferred into the host cell by well-known methods, depending on the type of cellular host.

[0207] Non-limiting examples of suitable vectors include those designed for propagation and expansion, or for expression or both. For example, a cloning vector can be selected from the group consisting of the pUC series, the pBluescript series (Stratagene, LaJolla, Calif.), the pET series (Novagen, Madison, Wis.), the pGEX series (Pharmacia Biotech, Uppsala, Sweden), and the pEX series (Clontech, Palo Alto, Calif.). Bacteriophage vectors, such as lamda-GTIO, lamda-GTl l, lamda-ZapII (Stratagene), lamda-EMBL4, and lamda-NM1149, can also be used. Non-limiting examples of plant expression vectors include pBH 10, pBH01.2, pBH01.3, pBH21 and pBIN19 (Clontech). Non-limiting examples of animal expression vectors include pEUK-Cl, pMAM and pMAMneo (Clontech). The TOPO cloning system (Invitrogen, Carlsbad, CA) can also be used in accordance with the manufacturer’s recommendations.

[0208] In certain embodiments, the vector is a mammalian vector. In certain embodiments, the mammalian vector contains at least one promoter element, which mediates the initiation of transcription of mRNA, the antibody-coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. In certain embodiments, the mammalian vector contains additional elements, such as, for example, enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. In certain embodiments, highly efficient transcription can be achieved with, for example, the early and late promoters from SV40, the long terminal repeats (LTRS) from retroviruses, for example, RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). Cellular elements can also be used (e.g., the human actin promoter). Non-limiting examples of mammalian expression vectors include, vectors such aspIRESlneo, pRetro-Off, pRetro-On, PLXSN, or pLNCX (Clonetech Labs, Palo Alto, Calif.), pcDNA3.1 (+ / -), pcDNA / Zeo (+ / -) or pcDNA3.1 / Hygro (+ / -) (Invitrogen, Carlsbad, CA), PSVL and PMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146) and pBC12MI (ATCC 67109). Non-limiting examples of mammalian host cells that can be used in combination with such mammalian vectors include human Hela 293, HEK 293, H9 and Jurkat cells, mouse 3T3, NIH3T3 and C127 cells, Cos 1, Cos 7 and CV 1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

[0209] In certain embodiments, the vector is a viral vector, for example, retroviral vectors, parvovirus-based vectors, e.g., adeno-associated virus (AAV)-based vectors, AAV- adenoviral chimeric vectors, and adenovirus-based vectors, and lentiviral vectors, such as Herpes simplex (HSV)-based vectors. In certain embodiments, the viral vector is manipulated to render the virus replication deficient. In certain embodiments, the viral vector is manipulated to eliminate toxicity to the host. These viral vectors can be prepared using standard recombinant DNA techniques described in, for example, Sambrook et al., Molecular Cloning, a Laboratory Manual, 2d edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989); and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, New York, N.Y. (1994).

[0210] In certain embodiments, a vector or polynucleotide described herein can be transferred to a cell (e.g., an ex vivo cell) by conventional techniques and the resulting cell can be cultured by conventional techniques to produce an anti-PD-Ll antibody or antigen binding fragment described herein. Accordingly, provided herein are cells comprising a polynucleotide encoding an anti-PD-Ll antibody or antigen binding fragment thereof operably linked to a regulatory expression element (e.g., promoter) for expression of such sequences in the host cell. In certain embodiments, a vector encoding the heavy chain operably linked to a promoter and a vector encoding the light chain operably linked to a promoter can be co-expressed in the cell for expression of the entire anti-PD-Ll antibody or antigen binding fragment. In certain embodiments, a cell comprises a vector comprising a polynucleotide encoding both the heavy chain and the light chain of an anti-PD-Ll antibody or antigen binding fragment described herein that are operably linked to a promoter. In certain embodiments, a cell comprises two different vectors, a first vector comprising a polynucleotide encoding a heavy chain operably linked to a promoter, and a second vectorcomprising a polynucleotide encoding a light chain operably linked to a promoter. In certain embodiments, a first cell comprises a first vector comprising a polynucleotide encoding a heavy chain of an anti-PD-Ll antibody or antigen binding fragment described herein, and a second cell comprises a second vector comprising a polynucleotide encoding a light chain of an anti-PD-Ll antibody or antigen binding fragment described herein. In certain embodiments, provided herein is a mixture of cells comprising said first cell and said second cell. Examples of cells include, but are not limited to, a human cell, a human cell line, E. coli (e.g., E. coli TB-1, TG-2, DH5a, XL-Blue MRF’ (Stratagene), SA2821 and Y1090), B. subtilis, P. aerugenosa, S. cerevisiae, N. crassa. insect cells (e.g., Sf9, Ea4) and the like.

[0211] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding the anti-PD-Ll antibody or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

[0212] A host cell that includes an anti-PD-Ll antibody of the present disclosure, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) recombinant anti-PD-Ll antibody. In one embodiment, the method comprises culturing the host cell (into which a recombinant expression vector encoding the anti-PD-Ll antibody has been introduced) in a suitable medium such that the anti-PD-Ll antibody is produced. In another embodiment, the method further comprises the step of isolating the anti-PD-Ll antibody from the medium or the host cell. Once expressed, collections of the anti-PD-Ll antibody, e.g., the anti-PD-Ll antibodies or the anti-PD-Ll antibody-related polypeptides are purified from culture media and host cells. The anti-PD-Ll antibody can be purified according to standard procedures of the art, including HPLC purification, column chromatography, gel electrophoresis and the like. In one embodiment, the anti-PD-Ll antibody is produced in a host organism by the method of Boss et al., U.S. Pat. No.4,816,397. Usually, anti-PD-Ll antibody chains are expressed with signal sequences and are thus released to the culture media. However, if the anti-PD-Ll antibody chains are not naturally secreted by host cells, the anti-PD-Ll antibody chains can be released by treatment with mild detergent. Purification of recombinant polypeptides is well known in the art and includes ammonium sulfate precipitation, affinity chromatography purification technique, column chromatography, ion exchange purification technique, gel electrophoresis and the like (See generally Scopes, Protein Purification (Springer-Verlag, N.Y., 1982).

[0213] Polynucleotides encoding anti-PD-Ll antibodies, e.g., the anti-PD-Ll antibody coding sequences, can be incorporated in transgenes for introduction into the genome of a transgenic animal and subsequent expression in the milk of the transgenic animal. See, e.g., U.S. Pat. Nos. 5,741,957, 5,304,489, and 5,849,992. Suitable transgenes include coding sequences for light and / or heavy chains in operable linkage with a promoter and enhancer from a mammary gland specific gene, such as casein or P-lactoglobulin. For production of transgenic animals, transgenes can be microinjected into fertilized oocytes, or can be incorporated into the genome of embryonic stem cells, and the nuclei of such cells transferred into enucleated oocytes.

[0214] Single-Chain Antibodies. In one embodiment, the anti-PD-Ll antibody of the present disclosure is a single-chain anti-PD-Ll antibody. According to the present disclosure, techniques can be adapted for the production of single-chain antibodies specific to a PD-L1 protein (See, e.g., U.S. Pat. No. 4,946,778). Examples of techniques which can be used to produce single-chain Fvs and antibodies of the present disclosure include those described in U.S. Pat. Nos. 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology, 203: 46-88, 1991; Shu, L. et al, Proc. Natl. Acad. Sci. USA, 90: 7995-7999, 1993; and Skerra et al., Science 240: 1038-1040, 1988.

[0215] Chimeric and Humanized Antibodies. In one embodiment, the anti-PD-Ll antibody of the present disclosure is a chimeric anti-PD-Ll antibody. In one embodiment, the anti-PD-Ll antibody of the present disclosure is a humanized anti-PD-Ll antibody.

[0216] Recombinant anti-PD-Ll antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, can be made using standard recombinant DNA techniques, and are within the scope of the present disclosure. For someuses, including in vivo use of the anti-PD-Ll antibody of the present disclosure in humans as well as use of these agents in in vitro detection assays, it is possible to use chimeric or humanized anti-PD-Ll antibodies. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art. Such useful methods include, e.g., but are not limited to, methods described in International Application No. PCT / US86 / 02269; U.S. Pat. No. 5,225,539; European Patent No. 184187; European Patent No. 171496; European Patent No. 173494; PCT International Publication No. WO 86 / 01533; U.S. Pat. Nos. 4,816,567; 5,225,539; European Patent No. 125023; Better, et al., 1988. Science 240: 1041-1043; Liu, et al., 1987. Proc. Natl. Acad. Sci. USA 84: 3439-3443; Liu, et al., 1987. J. Immunol. 139: 3521-3526; Sun, et al., 1987. Proc. Natl. Acad. Sci. USA 84: 214- 218; Nishimura, et al., 1987. Cancer Res. 47: 999-1005; Wood, et al., 1985. Nature 314: 446- 449; Shaw, et al., 1988. J. Natl. Cancer Inst. 80: 1553-1559; Morrison (1985) Science 229: 1202-1207; Oi, et al. (1986) BioTechniques 4: 214; Jones, et al., 1986. Nature 321 : 552-525; Verhoeyan, et al., 1988. Science 239: 1534; Morrison, Science 229: 1202, 1985; Oi et al., BioTechniques 4: 214, 1986; Gillies etal., J. Immunol. Methods, 125: 191-202, 1989; U.S. Pat. No. 5,807,715; and Beidler, et al., 1988. J. Immunol. 141 : 4053-4060. For example, antibodies can be humanized using a variety of techniques including CDR-grafting (EP 0 239 400; WO 91 / 09967; U.S. Pat. No. 5,530,101; 5,585,089; 5,859,205; 6,248,516; EP460167), veneering or resurfacing (EP 0 592 106; EP 0 519 596; Padlan E. A., Molecular Immunology, 28: 489-498, 1991; Studnicka et al., Protein Engineering 7: 805-814, 1994; Roguska et al. , PNAS 91 : 969-973, 1994), and chain shuffling (U.S. Pat. No. 5,565,332). In one embodiment, a cDNA encoding a murine anti-PD-Ll monoclonal antibody is digested with a restriction enzyme selected specifically to remove the sequence encoding the Fc constant region, and the equivalent portion of a cDNA encoding a human Fc constant region is substituted (See Robinson et al., PCT / US86 / 02269; Akira et al., European Patent Application 184,187; Taniguchi, European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., WO 86 / 01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988) Science 240: 1041-1043; Liu et al. (1987) roc. Natl. Acad. Sci. USA 84: 3439-3443; Liu et al. (1987) J Immunol 139: 3521-3526; Sun et al. (1987) Proc. Natl. Acad. Sci. USA 84: 214-218; Nishimura et al. (1987) Cancer Res 47: 999-1005; Wood et al. (1985) Nature 314: 446-449;and Shaw et al. (1988) . / . Natl. Cancer Inst. 80: 1553-1559; U.S. Pat. No. 6,180,370; U.S.Pat. Nos. 6,300,064; 6,696,248; 6,706,484; 6,828,422.

[0217] In one embodiment, the present disclosure provides the construction of humanized anti-PD-Ll antibodies that are unlikely to induce a human anti -mouse antibody (hereinafter referred to as “HAMA”) response, while still having an effective antibody effector function. As used herein, the terms “human” and “humanized”, in relation to antibodies, relate to any antibody which is expected to elicit a therapeutically tolerable weak immunogenic response in a human subject. In one embodiment, the present disclosure provides for a humanized anti-PD-Ll antibodies, heavy and light chain immunoglobulins.

[0218] As used herein, the term “humanized antibodies” refers to human forms of nonhuman (e.g., murine) antibodies, and are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies), which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.

[0219] As used herein, the term “fully human antibody” refers to an immunoglobulin, such as an antibody, where the whole molecule is of human origin or consists of an amino acid sequence identical to a human form of the antibody. In some embodiments, the antibodies disclosed herein are fully human antibodies. In some embodiments, the antibodies are humanized antibodies.

[0220] Furthermore, humanized antibodies can comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non- human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optimally also will comprise at least aportion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321 : 522-525 (1986); Reichmann et al., Nature 332: 323-329 (1988); Presta, Curr. Op. Struct. Biol. 2: 593-596 (1992).

[0221] CDR Antibodies . In some embodiments, the anti-PD-Ll antibody of the present disclosure is an anti-PD-Ll CDR antibody. Generally the donor and acceptor antibodies used to generate the anti-PD-Ll CDR antibody are monoclonal antibodies from different species; typically the acceptor antibody is a human antibody (to minimize its antigenicity in a human), in which case the resulting CDR-grafted antibody is termed a “humanized” antibody. The graft can be of a single CDR (or even a portion of a single CDR) within a single VH or VL of the acceptor antibody, or can be of multiple CDRs (or portions thereof) within one or both of the VH and VL. Frequently, all three CDRs in all variable domains of the acceptor antibody will be replaced with the corresponding donor CDRs, though one needs to replace only as many as necessary to permit adequate binding of the resulting CDR-grafted antibody to a PD- L1 protein. Methods for generating CDR-grafted and humanized antibodies are taught by Queen et al. U.S. Pat. No. 5,585,089; U.S. Pat. No. 5,693,761; U.S. Pat. No. 5,693,762; and Winter U.S. 5,225,539; and EP 0682040. Methods useful to prepare VH and VL polypeptides are taught by Winter etal., U.S. Pat. Nos. 4,816,397; 6,291,158; 6,291,159; 6,291,161;6,545,142; EP 0368684; EP0451216; and EP0120694.

[0222] Generally the donor and acceptor antibodies used to generate the antibody are monoclonal antibodies from different species; typically the acceptor antibody is a non-human antibody (to minimize its antigenicity in a non-human animal). The graft may be of a single CDR (or even a portion of a single CDR) within a single VH or VL of the acceptor antibody, or can be of multiple CDRs (or portions thereof) within one or both of the VH and VL. Frequently, all three CDRs in all variable domains of the acceptor antibody will be replaced with the corresponding donor CDRs, though one needs to replace only as many as necessary to permit adequate binding of the resulting CDR-grafted antibody. Methods for generating CDR-grafted antibodies are taught by Queen et al. U.S. Pat. No. 5,585,089; U.S. Pat. No. 5,693,761; U.S. Pat. No. 5,693,762; and Winter U.S. 5,225,539; and EP 0682040. Methods useful to prepare VH and VL polypeptides are taught by Winter et al., U.S. Pat. Nos.4,816,397; 6,291,158; 6,291,159; 6,291,161; 6,545,142; EP 0368684; EP0451216; andEP0120694.

[0223] After selecting suitable framework region candidates from the same family and / or the same family member, either or both the heavy and light chain variable regions are produced by grafting the CDRs from the originating species into the hybrid framework regions. Assembly of hybrid antibodies or hybrid antibody fragments having hybrid variable chain regions with regard to either of the above aspects can be accomplished using conventional methods known to those skilled in the art. For example, DNA sequences encoding the hybrid variable domains described herein (z.e., frameworks based on the target species and CDRs from the originating species) can be produced by oligonucleotide synthesis and / or PCR. The nucleic acid encoding CDR regions can also be isolated from the originating species antibodies using suitable restriction enzymes and ligated into the target species framework by ligating with suitable ligation enzymes. Alternatively, the framework regions of the variable chains of the originating species antibody can be changed by site- directed mutagenesis.

[0224] Since the hybrids are constructed from choices among multiple candidates corresponding to each framework region, there exist many combinations of sequences which are amenable to construction in accordance with the principles described herein. Accordingly, libraries of hybrids can be assembled having members with different combinations of individual framework regions. Such libraries can be electronic database collections of sequences or physical collections of hybrids.

[0225] This process typically does not alter the acceptor antibody’s FRs flanking the grafted CDRs. However, one skilled in the art can sometimes improve antigen binding affinity of the resulting anti-PD-Ll CDR-grafted antibody by replacing certain residues of a given FR to make the FR more similar to the corresponding FR of the donor antibody. Suitable locations of the substitutions include amino acid residues adjacent to the CDR, or which are capable of interacting with a CDR See, e.g., US 5,585,089, especially columns 12- 16). Or one skilled in the art can start with the donor FR and modify it to be more similar to the acceptor FR or a human consensus FR. Techniques for making these modifications are known in the art. Particularly if the resulting FR fits a human consensus FR for that position, or is at least 90% or more identical to such a consensus FR, doing so may not increase theantigenicity of the resulting modified anti-PD-Ll CDR-grafted antibody significantly compared to the same antibody with a fully human FR.

[0226] Bispecific Antibodies (BsAbs). A bispecific antibody is an antibody that can bind simultaneously to two targets that have a distinct structure, e.g., two different target antigens, two different epitopes on the same target antigen, or a hapten and a target antigen or epitope on a target antigen. BsAbs can be made, for example, by combining heavy chains and / or light chains that recognize different epitopes of the same or different antigen. In some embodiments, by molecular function, a bispecific binding agent binds one antigen (or epitope) on one of its two binding arms (one VH / VL pair), and binds a different antigen (or epitope) on its second arm (a different VH / VL pair). By this definition, a bispecific binding agent has two distinct antigen binding arms (in both specificity and CDR sequences), and is monovalent for each antigen to which it binds.

[0227] Antibody molecules will comprise fragments (such as F(ab'), F(ab')2) that are produced, for example, by the proteolytic cleavage of the monoclonal antibodies, or singlechain immunoglobulins producible, for example, via recombinant means. F(ab') antibody derivatives are monovalent, while F(ab')2 antibody derivatives are bivalent. In one embodiment, such fragments can be combined with one another, or with other antibody fragments or receptor ligands to form “chimeric” binding molecules. Significantly, such chimeric molecules may contain substituents capable of binding to different epitopes of the same molecule.

[0228] In related embodiments, the antibody is a derivative of the disclosed antibodies, e.g., an antibody comprising the CDR sequences identical to those in the disclosed antibodies (e.g., a chimeric, or CDR-grafted antibody). Alternatively, one may wish to make modifications, such as introducing conservative changes into an antibody molecule. In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.

[0229] It also is understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Pat. No. 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein. As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: basic amino acids: arginine (+3.0), lysine (+3.0), and histidine (—0.5); acidic amino acids: aspartate (+3.0+1), glutamate (+3.0+1), asparagine (+0.2), and glutamine (+0.2); hydrophilic, nonionic amino acids: serine (+0.3), asparagine (+0.2), glutamine (+0.2), and threonine (—0.4), sulfur containing amino acids: cysteine (—1.0) and methionine (—1.3); hydrophobic, nonaromatic amino acids: valine (—1.5), leucine (—1.8), isoleucine (—1.8), proline (-0.5+1), alanine (-0.5), and glycine (0); hydrophobic, aromatic amino acids: tryptophan (-3.4), phenylalanine (-2.5), and tyrosine (-2.3).

[0230] It is understood that an amino acid can be substituted for another having a similar hydrophilicity and produce a biologically or immunologically modified protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ±2 is preferred, those that are within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.

[0231] Amino acid substitutions generally are based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take into consideration the various foregoing characteristics are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

[0232] Antibodies according to the present disclosure may be defined, in the first instance, by their binding specificity. Those of skill in the art, by assessing the binding specificity / affinity of a given antibody using techniques well known to those of skill in the art, can determine whether such antibodies fall within the scope of the instant claims. For example, the epitope to which a given antibody bind may consist of a single contiguous sequence of 3 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) amino acids located within the antigen molecule (e.g., a linear epitope in a domain). Alternatively,the epitope may consist of a plurality of non-contiguous amino acids (or amino acid sequences) located within the antigen molecule (e.g., a conformational epitope).

[0233] Various techniques known to persons of ordinary skill in the art can be used to determine whether an antibody “interacts with one or more amino acids” within a polypeptide or protein. Exemplary techniques include, for example, routine cross-blocking assays, such as that described in Antibodies: A Laboratory Manual, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1988). Cross-blocking can be measured in various binding assays such as ELISA, biolayer interferometry, or surface plasmon resonance. Other methods include alanine scanning mutational analysis, peptide blot analysis (Reineke, Methods Mol. Biol. 248: 443-63, 2004), peptide cleavage analysis, high-resolution electron microscopy techniques using single particle reconstruction, cryoEM, or tomography, crystallographic studies and NMR analysis. In addition, methods such as epitope excision, epitope extraction and chemical modification of antigens can be employed (Tomer, Prot. Sci. 9: 487-496, 2000). Another method that can be used to identify the amino acids within a polypeptide with which an antibody interacts is hydrogen / deuterium exchange detected by mass spectrometry. In general terms, the hydrogen / deuterium exchange method involves deuterium-labeling the protein of interest, followed by binding the antibody to the deuterium-labeled protein. Next, the protein / antibody complex is transferred to water and exchangeable protons within amino acids that are protected by the antibody complex undergo deuterium-to-hydrogen back- exchange at a slower rate than exchangeable protons within amino acids that are not part of the interface. As a result, amino acids that form part of the protein / antibody interface may retain deuterium and therefore exhibit relatively higher mass compared to amino acids not included in the interface. After dissociation of the antibody, the target protein is subjected to protease cleavage and mass spectrometry analysis, thereby revealing the deuterium-labeled residues which correspond to the specific amino acids with which the antibody interacts. See, e.g., Ehring, Analytical Biochemistry 267: 252-259 (1999), Engen and Smith, Anal. Chem. 73: 256A-265A (2001).

[0234] Modification-Assisted Profiling (MAP), also known as Antigen Structure-based Antibody Profiling (ASAP) is a method that categorizes large numbers of monoclonal antibodies (mAbs) directed against the same antigen according to the similarities of the binding profile of each antibody to chemically or enzymatically modified antigen surfaces(see U.S. Patent Publication 2004 / 0101920, herein specifically incorporated by reference in its entirety). Each category may reflect a unique epitope either distinctly different from or partially overlapping with epitope represented by another category. This technology allows rapid filtering of genetically identical antibodies, such that characterization can be focused on genetically distinct antibodies. When applied to hybridoma screening, MAP may facilitate identification of rare hybridoma clones that produce mAbs haying the desired characteristics. MAP may be used to sort the antibodies of the disclosure into groups of antibodies binding different epitopes.

[0235] The present disclosure includes antibodies that may bind to the same epitope, or a portion of the epitope. Likewise, the present disclosure also includes antibodies that compete for binding to a target or a fragment thereof with any of the specific exemplary antibodies described herein. One can easily determine whether an antibody binds to the same epitope as, or competes for binding with, a reference antibody by using routine methods known in the art. For example, to determine if a test antibody binds to the same epitope as a reference, the reference antibody is allowed to bind to target under saturating conditions. Next, the ability of a test antibody to bind to the target molecule is assessed. If the test antibody is able to bind to the target molecule following saturation binding with the reference antibody, it can be concluded that the test antibody binds to a different epitope than the reference antibody. On the other hand, if the test antibody is not able to bind to the target molecule following saturation binding with the reference antibody, then the test antibody may bind to the same epitope as the epitope bound by the reference antibody.

[0236] To determine if an antibody competes for binding with a reference anti-PD-Ll antibody, the above-described binding methodology is performed in two orientations: to a first orientation, the reference antibody is allowed to bind to the PD-L1 antigen under saturating conditions followed by assessment of binding of the test antibody to the PD-L1 molecule. In a second orientation, the test antibody is allowed to bind to the PD-L1 antigen molecule under saturating conditions followed by assessment of binding of the reference antibody to the PD-L1 molecule. If, in both orientations, only the first (saturating) antibody is capable of binding to PD-L1, then it is concluded that the test antibody and the reference antibody compete for binding to PD-L1. As will be appreciated by a person of ordinary skill in the art, an antibody that competes for binding with a reference antibody may notnecessarily bind to the identical epitope as the reference antibody but may sterically block binding of the reference antibody by binding an overlapping or adjacent epitope.

[0237] Two antibodies bind to the same or overlapping epitope if each competitively inhibits (blocks) binding of the other to the antigen. That is, a l-, 5-, 10-, 20- or 100-fold excess of one antibody inhibits binding of the other by at least 50% but preferably 75%, 90% or even 99% as measured in a competitive binding assay (see, e.g., Junghans et at., Cancer Res. 1990 50: 1495-1502). Alternatively, two antibodies have the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other. Two antibodies have overlapping epitopes if some amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.

[0238] Additional routine experimentation (e.g., peptide mutation and binding analyses) can then be carried out to confirm whether the observed lack of binding of the test antibody is in fact due to binding to the same epitope as the reference antibody or if steric blocking (or another phenomenon) is responsible for the lack of observed binding. Experiments of this sort can be performed using ELISA, radioimmunoassay (RIA), surface plasmon resonance (SPR), flow cytometry or any other quantitative or qualitative antibody-binding assay available in the art. Structural studies with electron microscopy (EM) or crystallography also can demonstrate whether or not two antibodies that compete for binding recognize the same epitope.

[0239] The rapid availability of antibody produced in the same host cell and cell culture process as the final cGMP manufacturing process has the potential to reduce the duration of process development programs. Lonza has developed a generic method using pooled transfectants grown in CDACF medium, for the rapid production of small quantities (up to 50 g) of antibodies in CHO cells. Although slightly slower than a true transient system, the advantages include a higher product concentration and use of the same host and process as the production cell line. Example of growth and productivity of GS-CHO pools, expressing a model antibody, in a disposable bioreactor: in a disposable bag bioreactor culture (5 L working volume) operated in fed-batch mode, a harvest antibody concentration of 2 g / L was achieved within 9 weeks of transfection.

[0240] Multi-specific antibodies, such as bispecific antibodies (BsAb) and bispecific antibody fragments (BsFab) have at least one arm that specifically binds to, for example, PD- L1 and at least one other arm that specifically binds to a second target antigen. In some embodiments, the second target antigen is an antigen or epitope of a B-cell, a T-cell, a myeloid cell, a plasma cell, or a mast-cell. Additionally or alternatively, in certain embodiments, the second target antigen is selected from the group consisting of CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCR gamma / delta, NKp46 and KIR. In certain embodiments, the BsAbs are capable of binding to tumor cells that express PD-L1 antigens on the cell surface. In some embodiments, the BsAbs have been engineered to facilitate killing of tumor cells by directing (or recruiting) cytotoxic T cells to a tumor site. Other exemplary BsAbs include those with a first antigen binding site specific for PD-L1 and a second antigen binding site specific for a small molecule hapten (e.g., DTP A, IMP288, DOTA, DOTA-Bn, DOTA-desferrioxamine, other DOTA-chelates described herein, Biotin, fluorescein, or those disclosed in Goodwin, D A. et al, 1994, Cancer Res. 54(22):5937-5946).

[0241] A variety of bispecific fusion proteins can be produced using molecular engineering. For example, BsAbs have been constructed that either utilize the full immunoglobulin framework (e.g., IgG), single chain variable fragment (scFv), or combinations thereof. In some embodiments, the bispecific fusion protein is divalent, comprising, for example, a scFv with a single binding site for one antigen and a Fab fragment with a single binding site for a second antigen. In some embodiments, the bispecific fusion protein is divalent, comprising, for example, an scFv with a single binding site for one antigen and another scFv fragment with a single binding site for a second antigen. In other embodiments, the bispecific fusion protein is tetravalent, comprising, for example, an immunoglobulin (e.g., IgG) with two binding sites for one antigen and two identical scFvs for a second antigen. BsAbs composed of two scFv units in tandem have been shown to be a clinically successful bispecific antibody format. In some embodiments, BsAbs comprise two single chain variable fragments (scFvs) in tandem have been designed such that an scFv that binds a tumor antigen (e.g., PD-L1) is linked with an scFv that engages T cells (e.g., by binding CD3). In this way, T cells are recruited to a tumor site such that they can mediate cytotoxic killing of the tumor cells. See e.g., Dreier et al., J. Immunol. 170:4397-4402(2003); Bargou et aL, Science 321 :974- 977 (2008)). In some embodiments, BsAbs of the present disclosure comprise two single chain variable fragments (scFvs) in tandem have been designed such that an scFv that binds a tumor antigen (e.g., PD-L1) is linked with an scFv that engages a small molecule DOTA hapten.

[0242] Recent methods for producing BsAbs include engineered recombinant monoclonal antibodies which have additional cysteine residues so that they crosslink more strongly than the more common immunoglobulin isotypes. See, e.g., FitzGerald et al., Protein Eng.10(10): 1221-1225 (1997). Another approach is to engineer recombinant fusion proteins linking two or more different single-chain antibody or antibody fragment segments with the needed dual specificities. See, e.g., C om et al. , Nature Biotech. 15: 159-163 (1997). A variety of bispecific fusion proteins can be produced using molecular engineering.

[0243] Bispecific fusion proteins linking two or more different single-chain antibodies or antibody fragments are produced in a similar manner. Recombinant methods can be used to produce a variety of fusion proteins. In some certain embodiments, a BsAb according to the present disclosure comprises an immunoglobulin, which immunoglobulin comprises a heavy chain and a light chain, and an scFv. In some certain embodiments, the scFv is linked to the C-terminal end of the heavy chain of any PD-L1 immunoglobulin disclosed herein. In some certain embodiments, scFvs are linked to the C-terminal end of the light chain of any PD-L1 immunoglobulin disclosed herein. In various embodiments, scFvs are linked to heavy or light chains via a linker sequence. Appropriate linker sequences necessary for the in-frame connection of the heavy chain Fd to the scFv are introduced into the VL and Vkappa domains through PCR reactions. The DNA fragment encoding the scFv is then ligated into a staging vector containing a DNA sequence encoding the CHI domain. The resulting scFv-CHl construct is excised and ligated into a vector containing a DNA sequence encoding the VH region of a PD-L1 antibody. The resulting vector can be used to transfect an appropriate host cell, such as a mammalian cell for the expression of the bispecific fusion protein.

[0244] In some embodiments, a linker is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids in length. In some embodiments, a linker is characterized in that it tends not to adopt a rigid three-dimensional structure, but rather provides flexibility to the polypeptide (e.g., first and / or second antigen binding sites).

[0245] In some embodiments, a linker is employed in a BsAb described herein based on specific properties imparted to the BsAb such as, for example, an increase in stability. In some embodiments, a BsAb of the present disclosure comprises a G4S linker. In some certain embodiments, a BsAb of the present disclosure comprises a (G4S)n linker, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15 or more.

[0246] Fc Modifications. In some embodiments, the anti-PD-Ll antibodies of the present disclosure comprise a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region (or the parental Fc region), such that said molecule has an altered affinity for an Fc receptor (e.g., an FcyR), provided that said variant Fc region does not have a substitution at positions that make a direct contact with Fc receptor based on crystallographic and structural analysis of Fc-Fc receptor interactions such as those disclosed by Sondermann et al., Nature, 406:267-273 (2000). Examples of positions within the Fc region that make a direct contact with an Fc receptor such as an FcyR, include amino acids 234-239 (hinge region), amino acids 265-269 (B / C loop), amino acids 297-299 (C7E loop), and amino acids 327-332 (F / G) loop.

[0247] In some embodiments, an anti-PD-Ll antibody of the present disclosure has an altered affinity for activating and / or inhibitory receptors, having a variant Fc region with one or more amino acid modifications, wherein said one or more amino acid modification is a N297 substitution with alanine, or a K322 substitution with alanine. Additionally or alternatively, in some embodiments, the Fc regions of the PD-L1 antibodies disclosed herein comprise two amino acid substitutions, Leu234Ala and Leu235Ala (so called LALA mutations) to eliminate FcyRIIa binding. The LALA mutations are commonly used to alleviate the cytokine induction from T cells, thus reducing toxicity of the antibodies (Wines BD, et al. , J Immunol 164:5313-5318 (2000)).

[0248] In some embodiments, anti-PD-Ll antibodies of the present disclosure have an Fc region with variant glycosylation as compared to a parent Fc region. In some embodiments, variant glycosylation includes the absence of fucose; in some embodiments, variant glycosylation results from expression in GnTl -deficient CHO cells.

[0249] In some embodiments, the antibodies of the present disclosure, can have a modified glycosylation site relative to an appropriate reference antibody that binds to anantigen of interest (e.g., PD-L1), without altering the functionality of the antibody, e.g., binding activity to the antigen. As used herein, "glycosylation sites" include any specific amino acid sequence in an antibody to which an oligosaccharide (z.e., carbohydrates containing two or more simple sugars linked together) will specifically and covalently attach.

[0250] Oligosaccharide side chains are typically linked to the backbone of an antibody via either N-or O-linkages. N-linked glycosylation refers to the attachment of an oligosaccharide moiety to the side chain of an asparagine residue. O-linked glycosylation refers to the attachment of an oligosaccharide moiety to a hydroxyamino acid, e.g., serine, threonine. For example, an Fc-gly coform that lacks certain oligosaccharides including fucose and terminal N- acetylglucosamine can be produced in special CHO cells and exhibit enhanced ADCC effector function.

[0251] In some embodiments, the carbohydrate content of an immunoglobulin-related composition disclosed herein is modified by adding or deleting a glycosylation site. Methods for modifying the carbohydrate content of antibodies are well known in the art and are included within the present disclosure, see, e.g., U.S. Patent No. 6,218,149; EP 0359096B1; U.S. Patent Publication No. US 2002 / 0028486; International Patent Application Publication WO 03 / 035835; U.S. Patent Publication No. 2003 / 0115614; U.S. Patent No. 6,218,149; U.S. Patent No. 6,472,511 ; all of which are incorporated herein by reference in their entirety. In some embodiments, the carbohydrate content of an antibody (or relevant portion or component thereof) is modified by deleting one or more endogenous carbohydrate moieties of the antibody. In some certain embodiments, the present disclosure includes deleting the glycosylation site of the Fc region of an antibody, by modifying position 297 from asparagine to alanine.

[0252] Engineered glycoforms can be useful for a variety of purposes, including but not limited to enhancing or reducing effector function. Engineered glycoforms can be generated by any method known to one skilled in the art, for example by using engineered or variant expression strains, by co-expression with one or more enzymes, for example N- acetylglucosaminyltransf erase III (GnTIII), by expressing a molecule comprising an Fc region in various organisms or cell lines from various organisms, or by modifying carbohydrate(s) after the molecule comprising Fc region has been expressed. Methods for generating engineered glycoforms are known in the art, and include but are not limited tothose described in Umana et aL, 1999, Nat. Biotechnol. 17: 176-180; Davies et aL, 2001, Biotechnol. Bioeng. 74:288-294; Shields et al., 2002, J. Biol. Chem. 277:26733-26740; Shinkawa et al, 2003, J. Biol. Chem. 278:3466-3473; U.S. Patent No. 6,602,684; U.S. Patent Application Serial No. 10 / 277,370; U.S. Patent Application Serial No. 10 / 113,929;International Patent Application Publications WO 00 / 61739A1 ; WO 01 / 292246A1; WO 02 / 311140A1; WO 02 / 30954A1; POTILLEGENT™ technology (Biowa, Inc. Princeton, N.J.); GLYCOMAB™ glycosylation engineering technology (GLYCART biotechnology AG, Zurich, Switzerland); each of which is incorporated herein by reference in its entirety. See, e.g., International Patent Application Publication WO 00 / 061739; U.S. Patent Application Publication No. 2003 / 0115614; Okazaki et al., 2004, JMB, 336: 1239-49.

[0253] Fusion Proteins. In one embodiment, the anti-PD-Ll antibody of the present disclosure is a fusion protein. The anti-PD-Ll antibodies of the present disclosure, when fused to a second protein, can be used as an antigenic tag. Examples of domains that can be fused to polypeptides include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but can occur through linker sequences. Moreover, fusion proteins of the present disclosure can also be engineered to improve characteristics of the anti-PD-Ll antibodies. For instance, a region of additional amino acids, particularly charged amino acids, can be added to the N-terminus of the anti-PD-Ll antibody to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties can be added to an anti- PD-Ll antibody to facilitate purification. Such regions can be removed prior to final preparation of the anti-PD-Ll antibody. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art. The anti-PD-Ll antibody of the present disclosure can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In select embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., Chatsworth, Calif), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86: 821-824, 1989, for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the “HA” tag, corresponds to an epitope derived from the influenza hemagglutinin protein. Wilson et al., Cell 37: 767, 1984.

[0254] Thus, any of these above fusion proteins can be engineered using the polynucleotides or the polypeptides of the present disclosure. Also, in some embodiments, the fusion proteins described herein show an increased half-life in vivo.

[0255] Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can be more efficient in binding and neutralizing other molecules compared to the monomeric secreted protein or protein fragment alone. Fountoulakis et al.. J. Biochem. 270: 3958-3964, 1995.

[0256] In one embodiment, an anti-PD-Ll antibody of the present disclosure is coupled with a label moiety, z.e., detectable group. The particular label or detectable group conjugated to the anti-PD-Ll antibody is not a critical aspect of the disclosure, so long as it does not significantly interfere with the specific binding of the anti-PD-Ll antibody of the present disclosure to the PD-L1 protein. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immunoassays and imaging. In general, almost any label useful in such methods can be applied to the present disclosure. Thus, a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical, or chemical means. Labels useful in the practice of the present disclosure include magnetic beads (e.g., Dynabeads™), fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red, rhodamine, and the like), radiolabels (e.g.,3H,14C,35S,125I,121I,131I,112In, "mTc), other imaging agents such as microbubbles (for ultrasound imaging),18F,nC,150,89Zr (for Positron emission tomography), "mTC,U 1ln (for Single photon emission tomography), enzymes (e.g, horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and calorimetric labels such as colloidal gold or colored glass or plastic (e.g, polystyrene, polypropylene, latex, and the like) beads. Patents that describe the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241, each incorporated herein by reference in their entirety and for all purposes. See also Handbook of Fluorescent Probes and Research Chemicals (6thEd., Molecular Probes, Inc., Eugene OR ).

[0257] The label can be coupled directly or indirectly to the desired component of an assay according to methods well known in the art. As indicated above, a wide variety of labels can be used, with the choice of label depending on factors such as required sensitivity,ease of conjugation with the compound, stability requirements, available instrumentation, and disposal provisions.

[0258] Non-radioactive labels are often attached by indirect means. Generally, a ligand molecule (e.g., biotin) is covalently bound to the molecule. The ligand then binds to an antiligand (e.g., streptavidin) molecule which is either inherently detectable or covalently bound to a signal system, such as a detectable enzyme, a fluorescent compound, or a chemiluminescent compound. A number of ligands and anti-ligands can be used. Where a ligand has a natural anti-ligand, e.g., biotin, thyroxine, and cortisol, it can be used in conjunction with the labeled, naturally-occurring anti-ligands. Alternatively, any haptenic or antigenic compound can be used in combination with an antibody, e.g., an anti-PD-Ll antibody.

[0259] The molecules can also be conjugated directly to signal generating compounds, e.g, by conjugation with an enzyme or fluorophore. Enzymes of interest as labels will primarily be hydrolases, particularly phosphatases, esterases, and glycosidases, or oxidoreductases, particularly peroxidases. Fluorescent compounds useful as labeling moi eties, include, but are not limited to, e.g, fluorescein and its derivatives, rhodamine, and its derivatives, dansyl, umbelliferone, and the like. Chemiluminescent compounds useful as labeling moieties, include, but are not limited to, e.g., luciferin, and 2,3- dihydrophthalazinediones, e.g., luminol. For a review of various labeling or signal-producing systems which can be used, see U.S. Pat. No. 4,391,904.

[0260] Means of detecting labels are well known to those of skill in the art. Thus, for example, where the label is a radioactive label, means for detection include a scintillation counter or photographic film as in autoradiography. Where the label is a fluorescent label, it can be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence can be detected visually, by means of photographic film, by the use of electronic detectors such as charge coupled devices (CCDs) or photomultipliers and the like. Similarly, enzymatic labels can be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Finally, simple colorimetric labels can be detected simply by observing the color associated with the label. Thus, in various dipstick assays, conjugated gold often appears pink, while various conjugated beads appear the color of the bead.

[0261] Some assay formats do not require the use of labeled components. For instance, agglutination assays can be used to detect the presence of the target antibodies, e.g., the anti- PD-L1 antibodies. In this case, antigen-coated particles are agglutinated by samples comprising the target antibodies. In this format, none of the components need be labeled and the presence of the target antibody is detected by simple visual inspection.Identifying and Characterizing the Anti-PD-Ll Antibodies

[0262] Methods useful to identify and screen antibodies against PD-L1 polypeptides for those that possess the desired specificity to PD-L1 protein (e.g., those that bind to the extracellular domain of PD-L1 protein, such as polypeptides comprising the amino acid sequence of SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, or SEQ ID NO: 67, include any immunologically-mediated techniques known within the art. Components of an immune response can be detected in vitro by various methods that are well known to those of ordinary skill in the art. For example, (1) cytotoxic T lymphocytes can be incubated with radioactively labeled target cells and the lysis of these target cells detected by the release of radioactivity; (2) helper T lymphocytes can be incubated with antigens and antigen presenting cells and the synthesis and secretion of cytokines measured by standard methods (Windhagen A et al., Immunity, 2: 373-80, 1995); (3) antigen presenting cells can be incubated with whole protein antigen and the presentation of that antigen on MHC detected by either T lymphocyte activation assays or biophysical methods (Harding et al., Proc. Natl. Acad. Sci., 86: 4230-4, 1989); (4) mast cells can be incubated with reagents that cross-link their Fc-epsilon receptors and histamine release measured by enzyme immunoassay (Siraganian et al., TIPS, 4: 432- 437, 1983); and (5) enzyme-linked immunosorbent assay (ELISA).

[0263] Similarly, products of an immune response in either a model organism (e.g., mouse) or a human subject can also be detected by various methods that are well known to those of ordinary skill in the art. For example, (1) the production of antibodies in response to vaccination can be readily detected by standard methods currently used in clinical laboratories, e.g., an ELISA; (2) the migration of immune cells to sites of inflammation can be detected by scratching the surface of skin and placing a sterile container to capture the migrating cells over scratch site (Peters et al., Blood, 72: 1310-5, 1988); (3) the proliferation of peripheral blood mononuclear cells (PBMCs) in response to mitogens or mixed lymphocyte reaction can be measured using3H-thymidine; (4) the phagocytic capacity ofgranulocytes, macrophages, and other phagocytes in PBMCs can be measured by placing PBMCs in wells together with labeled particles (Peters et al., Blood, 72: 1310-5, 1988); and (5) the differentiation of immune system cells can be measured by labeling PBMCs with antibodies to CD molecules such as CD4 and CD8 and measuring the fraction of the PBMCs expressing these markers.

[0264] In one embodiment, anti-PD-Ll antibodies of the present disclosure are selected using display of PD-L1 peptides on the surface of replicable genetic packages. See, e.g., U.S. Pat. Nos. 5,514,548; 5,837,500; 5,871,907; 5,885,793; 5,969,108; 6,225,447; 6,291,650; 6,492,160; EP 585 287; EP 605522; EP 616640; EP 1024191; EP 589 877; EP 774 511;EP 844 306. Methods useful for producing / selecting a filamentous bacteriophage particle containing a phagemid genome encoding for a binding molecule with a desired specificity has been described. See, e.g., EP 774 511; US 5871907; US 5969108; US 6225447; US 6291650; US 6492160.

[0265] In some embodiments, anti-PD-Ll antibodies of the present disclosure are selected using display of PD-L1 peptides on the surface of a yeast host cell. Methods useful for the isolation of scFv polypeptides by yeast surface display have been described by Kieke et al., Protein Eng. 1997 Nov; 10(11): 1303-10.

[0266] In some embodiments, anti-PD-Ll antibodies of the present disclosure are selected using ribosome display. Methods useful for identifying ligands in peptide libraries using ribosome display have been described by Mattheakis et al., Proc. Natl. Acad. Sci. USA 91 : 9022-26, 1994; and Hanes et al., Proc. Natl. Acad. Sci. USA 94: 4937-42, 1997.

[0267] In certain embodiments, anti-PD-Ll antibodies of the present disclosure are selected using tRNA display of PD-L1 peptides. Methods useful for in vitro selection of ligands using tRNA display have been described by Merryman et al., Chem. BioL, 9: 741-46, 2002.

[0268] In one embodiment, anti-PD-Ll antibodies of the present disclosure are selected using RNA display. Methods useful for selecting peptides and proteins using RNA display libraries have been described by Roberts et al. Proc. Natl. Acad. Sci. USA, 94: 12297-302, 1997; and Nemoto et al., FEBS Lett., 414: 405-8, 1997. Methods useful for selectingpeptides and proteins using unnatural RNA display libraries have been described by Frankel etal., Curr. Opin. Struct. Biol., 13: 506-12, 2003.

[0269] In some embodiments, anti-PD-Ll antibodies of the present disclosure are expressed in the periplasm of gram negative bacteria and mixed with labeled PD-L1 protein. See WO 02 / 34886. In clones expressing recombinant polypeptides with affinity for PD-L1 protein, the concentration of the labeled PD-L1 protein bound to the anti-PD-Ll antibodies is increased and allows the cells to be isolated from the rest of the library as described in Harvey etal., Proc. Natl. Acad. Sci. 22: 9193-98 2004 and U.S. Pat. Publication No. 2004 / 0058403.

[0270] After selection of the desired anti-PD-Ll antibodies, it is contemplated that said antibodies can be produced in large volume by any technique known to those skilled in the art, e.g., prokaryotic or eukaryotic cell expression and the like. The anti-PD-Ll antibodies which are, e.g., but not limited to, anti-PD-Ll hybrid antibodies or fragments can be produced by using conventional techniques to construct an expression vector that encodes an antibody heavy chain in which the CDRs and, if necessary, a minimal portion of the variable region framework, that are required to retain original species antibody binding specificity (as engineered according to the techniques described herein) are derived from the originating species antibody and the remainder of the antibody is derived from a target species immunoglobulin which can be manipulated as described herein, thereby producing a vector for the expression of a hybrid antibody heavy chain.

[0271] Measurement ofPD-Ll Binding. In some embodiments, a PD-L1 binding assay refers to an assay format wherein PD-L1 protein and an anti- PD-L1 antibody are mixed under conditions suitable for binding between the PD-L1 protein and the anti-PD-Ll antibody and assessing the amount of binding between the PD-L1 protein and the anti- PD-L1 antibody. The amount of binding is compared with a suitable control, which can be the amount of binding in the absence of the PD-L1 protein, the amount of the binding in the presence of a non-specific immunoglobulin composition, or both. The amount of binding can be assessed by any suitable method. Binding assay methods include, e.g., ELISA, radioimmunoassays, scintillation proximity assays, fluorescence energy transfer assays, liquid chromatography, membrane filtration assays, and the like. Biophysical assays for the direct measurement of PD-L1 protein binding to anti-PD-Ll antibody are, e.g., nuclearmagnetic resonance, fluorescence, fluorescence polarization, surface plasmon resonance (BIACORE chips) and the like. Specific binding is determined by standard assays known in the art, e.g., radioligand binding assays, ELISA, FRET, immunoprecipitation, SPR, NMR (2D-NMR), mass spectroscopy and the like. If the specific binding of a candidate anti-PD-Ll antibody is at least 1 percent greater than the binding observed in the absence of the candidate anti-PD-Ll antibody, the candidate anti-PD-Ll antibody is useful as an anti-PD-Ll antibody of the present disclosure.Uses of Anti-PD-Ll Antibodies

[0272] The present disclosure generally provides immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof), which can specifically bind to PD-L1 polypeptides including the PD-L1 transmembrane receptor. The immunoglobulin-related compositions of the present disclosure are useful in methods for inhibiting the growth of cancer cells in vitro and in vivo, inhibiting the activity of PD-L1, and inhibiting the activity of PD-1 when administered to a subject in need thereof. The immunoglobulin-related compositions of the present disclosure are useful alone or in combination with additional therapeutic agents for treating inhibiting the growth of cancer cells in vitro and in vivo, inhibiting the immune evasion activity of PD-L1, screening for new therapies in vitro and in vivo including combination therapies, and treating cancer in a subject in need thereof. In one aspect, the subject has a PD-L1 positive tumor or cancer, or a PD-L1 -mediated autoimmune disease .

[0273] In one aspect, the immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) of the present disclosure are useful for the treatment of cancer in a subject in need thereof. Administration can be effected as a first line, a second line, a third line or fourth line therapy. Cancers amenable to the methods and uses comprising the immunoglobulin-related compositions disclosed herein include, but are not limited to, alveolar soft part sarcoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, small cell lung cancer, biliary tract cancer, merkel cell carcinoma, renal cell carcinoma, urothelial cancer, Hodgkin lymphoma, bladder cancer, kidney cancer, breast cancer, head and neck cancer, cancer of the esophagus, stomach cancer, or cervical cancer. Cancers amenable to the methods and uses comprising the immunoglobulin-related compositions disclosed herein also include, but are not limited to breast cancer, gastriccancer, osteosarcoma, desmoplastic small round cell cancer, squamous cell carcinoma of head and neck cancer, ovarian cancer, prostate cancer, pancreatic cancer, glioblastoma multiforme, gastric junction adenocarcinoma, gastroesophageal junction adenocarcinoma, cervical cancer, salivary gland cancer, soft tissue sarcoma, leukemia, melanoma, Ewing’s sarcoma, rhabdomyosarcoma, or neuroblastoma. In some embodiments, the cancer is a solid tumor. Such treatment can be used in patients identified as having pathologically high levels of PD-L1 or PD-1, or in patients diagnosed with a disease known to be associated with such pathological levels. Patients can be identified as having pathologically high levels of PD-L1 or PD-1, via PD-L1 or PD-1 testing according to any method known in the art, such as surgical removal and sampling of a tumor, or biopsy. Published validation metric data for PD-L1 tests are focused on immunohistochemistry (IHC) tests. In routine diagnostics, PD-L1 expression is measured using immunohistochemistry (IHC). Various commercially available assays and antibody clones for PD-L1 detection as well as multiple expression scores and cutoffs exist, each of which has been specifically used to evaluate clinical efficacy in clinical studies. For example, the VENTANA PD-L1 (SP142) assay (Roche / Genentech) and VENTANA PD-L1 (SP263) assay (AstraZeneca) implement an OptiView DAB IHC detection platform to assay PD-L1 levels in clinical contexts (Udall, M., Diagn Pathol. 2018; 13: 12.; Erber, B., and Hartmann, A., Breast Care (Basel). 2020 Oct; 15(5): 481-490). The mAbs and / or fragments thereof can be combined with other mAbs or fragments of this disclosure.

[0274] The compositions of the present disclosure can be employed in conjunction with other therapeutic agents useful in the treatment of cancer. For example, the antibodies or antigen binding fragments of the present disclosure can be separately, sequentially, or simultaneously administered with at least one additional therapeutic agent. In some embodiments, the at least one additional therapeutic agent is a chemotherapeutic agent. Specific chemotherapeutic agents include, but are not limited to, cyclophosphamide, fluorouracil (or 5 -fluorouracil or 5-FU), methotrexate, edatrexate (10-ethyl-10-deaza- aminopterin), thiotepa, carboplatin, cisplatin, taxanes, paclitaxel, protein-bound paclitaxel, docetaxel, vinorelbine, tamoxifen, raloxifene, toremifene, fulvestrant, gemcitabine, irinotecan, ixabepilone, temozolmide, topotecan, vincristine, vinblastine, eribulin, mutamycin, capecitabine, anastrozole, exemestane, letrozole, leuprolide, abarelix, buserlin,goserelin, megestrol acetate, risedronate, pamidronate, ibandronate, alendronate, denosumab, zoledronate, trastuzumab, tykerb, anthracyclines (e.g., daunorubicin and doxorubicin), bevacizumab, oxaliplatin, melphalan, etoposide, mechlorethamine, bleomycin, microtubule poisons, annonaceous acetogenins, or combinations thereof.

[0275] Additionally or alternatively, in some embodiments, the antibodies or antigen binding fragments of the present disclosure can be separately, sequentially or simultaneously administered with at least one additional immuno-modulating / stimulating antibody including but not limited to an anti-PD-L2 antibody, anti-CTLA-4 antibody, anti-TIM3 antibody, anti- 4- IBB antibody, anti-CD73 antibody, anti-GITR antibody, anti-HER2 antibody, and anti- LAG-3 antibody or a chimeric antigen receptor T or B cell specific for the tumor or cancer to be treated.

[0276] In addition, the mAbs or fragments thereof can be combined with surgical resection before or after administration.

[0277] The compositions of the present disclosure can optionally be administered as a single bolus to a subject in need thereof. Alternatively, the dosing regimen can comprise multiple administrations performed at various times after the appearance of tumors.

[0278] Administration can be carried out by any suitable route, including orally, intranasally, parenterally (intravenously, intramuscularly, intraperitoneally, or subcutaneously), rectally, intracranially, intratumorally, intrathecally, or topically. Administration includes self-administration and the administration by another. It is also to be appreciated that the various modes of treatment of medical conditions as described are intended to mean “substantial”, which includes total but also less than total treatment, and wherein some biologically or medically relevant result is achieved.

[0279] In some embodiments, the antibodies of the present disclosure comprise pharmaceutical formulations which can be administered to subjects in need thereof in one or more doses. Dosage regimens can be adjusted to provide the desired response e.g., a therapeutic response).

[0280] Typically, an effective amount of the antibody compositions of the present disclosure, sufficient for achieving a therapeutic effect, ranges from about 0.000001 mg per kilogram body weight per day to about 10,000 mg per kilogram body weight per day.Typically, the dosage ranges are from about 0.0001 mg per kilogram body weight per day to about 100 mg per kilogram body weight per day. For administration of anti-PD-Ll antibodies, the dosage ranges from about 0.0001 to 100 mg / kg, and more usually 0.01 to 5 mg / kg every week, every two weeks, or every three weeks, of the subject body weight. For example, dosages can be 1 mg / kg body weight or 10 mg / kg body weight every week, every two weeks, or every three weeks or within the range of 1-10 mg / kg every week, every two weeks, or every three weeks. In one embodiment, a single dosage of antibody ranges from 0.1-10,000 micrograms per kg body weight. In one embodiment, antibody concentrations in a carrier range from 0.2 to 2000 micrograms per delivered milliliter. In one embodiment, the dosage of the anti-PD-Ll antibodies is about 0.2 mg / kg of body weight. In yet another embodiment, the dosage range is from about 50 pg / human to about 300 pg / human. In one embodiment, the dosage of the anti-PD-Ll antibodies is about 50 pg / human, about 75 pg / human, about 100 pg / human, about 125 pg / human, about 150 pg / human, about 175 pg / human, about 200 pg / human, about 225 pg / human, about 250 pg / human, about 275 pg / human, or about 300 pg / human.

[0281] An exemplary treatment regime entails administration once per every two weeks or once a month or once every 3 to 6 months. Anti-PD-Ll antibodies can be administered on multiple occasions. Intervals between single dosages can be hourly, daily, weekly, monthly, or yearly. Intervals can also be irregular as indicated by measuring blood levels of the antibody in the subject. In some methods, dosage is adjusted to achieve a serum antibody concentration in the subject of from about 75 pg / mL to about 125 pg / mL, 100 pg / mL to about 150 pg / mL, from about 125 pg / mL to about 175 pg / mL, or from about 150 pg / mL to about 200 pg / mL. Alternatively, anti-PD-Ll antibodies can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the antibody in the subject. The dosage and frequency of administration can vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, a relatively low dosage is administered at relatively infrequent intervals over a long period of time. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, or until the subject shows partial or complete amelioration of symptoms of disease. Thereafter, the patient can be administered a prophylactic regime.

[0282] In another aspect, the present disclosure provides a method for detecting cancer in a subject in vivo comprising (a) administering to the subject an effective amount of an antibody (or antigen binding fragment thereof) of the present disclosure, wherein the antibody is configured to localize to a cancer cell expressing PD-L1 and is labeled with a radioisotope; and (b) detecting the presence of a tumor in the subject by detecting radioactive levels emitted by the antibody that are higher than a reference value. In some embodiments, the reference value is expressed as injected dose per gram (%ID / g). The reference value can be calculated by measuring the radioactive levels present in non-tumor (normal) tissues, and computing the average radioactive levels present in non-tumor (normal) tissues ± standard deviation. In some embodiments, the ratio of radioactive levels between a tumor and normal tissue is about 2:l, 3: 1, 4: 1, 5: 1, 6: 1, 7:1, 8: 1, 9: 1, 10: 1, 15: 1, 20: 1, 25: 1, 30: 1, 35: 1, 40:1, 45: 1, 50: 1, 55: 1, 60: 1, 65: 1, 70:1, 75: 1, 80: 1, 85: 1, 90: 1, 95: 1 or 100: 1.

[0283] In some embodiments, the subject is diagnosed with or is suspected of having cancer. Radioactive levels emitted by the antibody can be detected using positron emission tomography or single photon emission computed tomography.

[0284] Additionally or alternatively, in some embodiments, the method further comprises administering to the subject an effective amount of an immunoconjugate comprising an antibody of the present disclosure conjugated to a radionuclide. In some embodiments, the radionuclide is an alpha particle-emitting isotope, a beta particle-emitting isotope, an Augeremitter, or any combination thereof. Examples of beta particle-emitting isotopes include86Y,90Y,89Sr,165Dy,186Re,188Re,177Lu, and67Cu. Examples of alpha particle-emitting isotopes include213Bi,211At,225Ac,152Dy,212Bi,223Ra,219Rn,215Po,211Bi,221Fr,217At, and255Fm. Examples of Auger-emitters includen iIn,67Ga,51Cr,58Co, "mTc,103mRh,195mPt,119Sb,161HO,189mOs,192Ir,2O1T1, and203Pb. In some embodiments of the method, nonspecific FcR- dependent binding in normal tissues is eliminated or reduced (e.g., via N297A mutation in Fc region, which results in aglycosylation). The therapeutic effectiveness of such an immunoconjugate can be determined by computing the area under the curve (AUC) tumor: AUC normal tissue ratio. In some embodiments, the immunoconjugate has a AUC tumor: AUC normal tissue ratio of about 2:1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 15:1, 20: 1, 25: 1, 30: 1, 35: 1, 40: 1, 45: 1, 50: 1, 55:1, 60: 1, 65: 1, 70: 1, 75: 1, 80: 1, 85: 1, 90: 1, 95: 1 or 100: 1.

[0285] Optimally, an effective amount e.g., dose) of an anti-PD-Ll antibody described herein will provide therapeutic benefit without causing substantial toxicity to the subject. Toxicity of the anti-PD-Ll antibody described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LDso (the dose lethal to 50% of the population) or the LD100 (the dose lethal to 100% of the population). The dose ratio between toxic and therapeutic effect is the therapeutic index. The data obtained from these cell culture assays and animal studies can be used in formulating a dosage range that is not toxic for use in human. The dosage of the anti-PD-Ll antibody described herein lies within a range of circulating concentrations that include the effective dose with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the subject’s condition. See, e.g., Fingl el al., In: The Pharmacological Basis of Therapeutics, Ch. 1 (1975).

[0286] Formulations of Pharmaceutical Compositions. According to the methods of the present disclosure, the anti-PD-Ll antibody can be incorporated into pharmaceutical compositions suitable for administration. The pharmaceutical compositions generally comprise recombinant or substantially purified antibody and a pharmaceutically acceptable carrier in a form suitable for administration to a subject. Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions for administering the antibody compositions (See, e.g., Remington’ s Pharmaceutical Sciences, Mack Publishing Co., Easton, PA 18thed., 1990). The pharmaceutical compositions are generally formulated as sterile, substantially isotonic and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration. The pharmaceutical composition can further comprise an agent selected from the group consisting of isotopes, dyes, chromagens, contrast agents, drugs, toxins, cytokines, enzymes, enzyme inhibitors, hormones, hormone antagonists, growth factors, radionuclides, metals, liposomes, nanoparticles, RNA, DNA, or any combination thereof.

[0287] Examples of carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils can also be used. The use of such media and compounds for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or compound is incompatible with the anti-PD-Ll antibody, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0288] A pharmaceutical composition of the present disclosure is formulated to be compatible with its intended route of administration. The anti-PD-Ll antibody compositions of the present disclosure can be administered by parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intradermal, transdermal, rectal, intracranial, intrathecal, intraperitoneal, intranasal, or intramuscular routes, or as inhalants. The anti-PD-Ll antibody can optionally be administered in combination with other agents that are at least partly effective in treating various cancers as described above or as known in the art.

[0289] Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and compounds for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0290] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminatingaction of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, e.g., water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, e.g., by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal compounds, e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be desirable to include isotonic compounds, e.g., sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition a compound which delays absorption, e.g., aluminum monostearate and gelatin.

[0291] Sterile injectable solutions can be prepared by incorporating an anti-PD-Ll antibody of the present disclosure in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the anti-PD-Ll antibody into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The antibodies of the present disclosure can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner as to permit a sustained or pulsatile release of the active ingredient.

[0292] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the anti-PD-Ll antibody can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding compounds, and / or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanthor gelatin; an excipient such as starch or lactose, a disintegrating compound such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening compound such as sucrose or saccharin; or a flavoring compound such as peppermint, methyl salicylate, or orange flavoring.

[0293] For administration by inhalation, the anti-PD-Ll antibody is delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0294] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, e.g., for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the anti-PD-Ll antibody is formulated into ointments, salves, gels, or creams as generally known in the art.

[0295] In one embodiment, the anti-PD-Ll antibody is prepared with carriers that will protect the anti-PD-Ll antibody against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, e.g., as described in U.S. Pat. No. 4,522,811.

[0296] In one embodiment, provided are nanoparticle carrier compositions that are useful to capture and deliver the polynucleotides and / or vectors as described herein.

[0297] In some embodiments, the pharmaceutically acceptable carrier comprises, or consists essentially of, or yet further consists of a nanoparticle. In some embodiments, the nanoparticle is a lipid nanoparticle (LNP).

[0298] In some embodiments, the LNP has a mean diameter of about 50 nm to about 200 nm. In some embodiments, the LNP carriers / formulations comprise a four-component LNP composition comprising a cationic or ionizable lipid, a neutral lipid a steroidal or structural lipid-containing component; and a molecule capable of reducing particle aggregation, for example a PEG or PEG-modified lipid (also referred to herein as PEGylated lipid).

[0299] In some further embodiments, the nanoparticle carrier comprises a three- component LNP composition wherein the three components are: 1) a steroidal or structural lipid-containing component; 2) a PEGylated lipid-containing component; and 3) a cationic or ionizable lipid-containing component.

[0300] Additional exemplary lipid nanoparticle compositions and methods of making same are described, for example, in Semple et al. (2010) Nat. Biotechnol. 28: 172-176; Jayarama et al. (2012), Angew. Chem. Int. Ed., 51 :8529-8533; and Maier et al. (2013) Molecular Therapy 21 : 1570-1578, the contents of each of which are incorporated herein by reference in their entirety.

[0301] In some embodiments, the neutral lipid comprises, or consists essentially of, or yet further consists of one or more of: disteroylphosphatidyl choline (DSPC), Dipalmitoylphosphatidylcholine (DPPC), (2A)-3-(Hexadecanoyloxy)-2-{ [(9Z)-octadec-9- enoyl] oxy} propyl 2-(trimethylazaniumyl)ethyl phosphate (POPC), or dioleoyl phosphatidylethanolamine (DOPE).

[0302] In some embodiments, the cholesterol comprises, or consists essentially of, or yet further consists of a plant cholesterol or an animal cholesterol or both.

[0303] In some embodiments, the PEGylated lipid comprises, or consists essentially of, or yet further consists of one or more of: PEG-c-DOMG (R-3-[(co-methoxy- poly(ethyleneglycol)2000)carbamoyl)]-l,2-dimyristyloxypropyl-3-amine), PEG-DSG (1,2- Distearoyl-sn-glycerol, methoxypolyethylene glycol), PEG-DMG (1,2-Dimyristoyl-sn- glycerol) optionally PEG2000-DMG ((l,2-dimyristoyl-sn-glycero-3-phophoethanolamine-N- [methoxy(polyethylene glycol)-2000)], or PEG-DPG (1,2-Dipalmitoyl-sn-glycerol, methoxypolyethylene glycol).

[0304] In some embodiments, lipid nanoparticle carriers / formulations typically comprise, or alternatively consist essentially of, or yet further consist of a lipid, in particular, anionizable cationic lipid, for example, SM-102, 2,2-dilinoleyl-4-dimethylaminoethyl-[l,3]- di oxolane (DLin-KC2-DMA), dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3- DMA), or di((Z)-non-2-en-l-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319).

[0305] In one aspect, the nanoparticle carrier composition comprises a cationic or ionizable lipid-containing component comprising compounds of Formula IA:or a salt or isomer thereof, wherein m is 0-9; n is 0-9; o is 0-12; p is 0-12;Ri is a linear C1-12 alkyl;R2 is H or a linear C1-12 alkyl;R3 is a linear C1-12 alkyl;R4is H or a linear C1-12 alkyl; andMi and M2 are independently selected from -C(O)N(R)-, -N(R)C(O)-, -C(O)S-, - SC(O)-, -OC(O)O-, -OC(O)N(R)-, or -N(R)C(O)O- groups wherein R is a H or a methyl group.

[0306] Synthesis Scheme 1. General synthesis route for the synthesis of compounds of Formula IA.

[0307] Scheme 2. Fatty acid tail synthesis of Ri and R2, which also applies to synthesis of R3 and R4.

[0308] Scheme 3a. Fatty Acid tail conversion from hydroxy to thiol

[0309] Scheme 4. Fatty acid tail conversion of hydroxy to carboxylic acid.

[0310] Scheme 5. Fatty acid tail conversion of hydroxy to isocyanate.

[0311] In certain aspects, compounds of Formula IA may include, for example, the following compounds:(IAb);(IAC).

[0312] In another aspect, the nanoparticle carrier composition comprises a cationic or ionizable lipid-containing component comprising compounds of Formula IB:or a salt or isomer thereof, wherein m is selected from 0-9; n is selected from 0-9; o is selected from 0-12; p is selected from 0-12;R is the side chain of an independently selected amino acid;Ri is a linear C1-12 alkyl;R2 is H or linear C1-12 alkyl;R3 is a linear C1-12 alkyl;R4is H or a linear C1-12 alkyl;Rs is the side chain of an independently selected amino acid;Xi is -OC(O)N(H)-, -C(O)N(H)-, -N(H)C(O)-, or -OC(O)-;X2is -C(O)N(H)-, -C(O)O-, -N(H)C(O)-, or -N(H)C(O)-;X3is -OC(O)N(H)-, -C(O)N(H)-, -N(H)C(O)-, or -OC(O)-;X4is -C(O)N(H)-, -C(O)O-, -N(H)C(O)-, or -N(H)C(O)-. In some aspects, R or Rs comprises the side chain of the amino acid, wherein the amino acid is Serine (S), Threonine (T), Cysteine (C), Selenocysteine (U), Glycine (G), Alanine (A), Isoleucine (I), Leucine (L), Methionine (M), or Valine (V).

[0313] In some aspects, the carbonyl group in Formula IB is bonded to the amino terminus of the amino acid. For example, a compound of Formula IB may have the following structure:in which Xi and X2 represent independently an amino acid, wherein the amino acid is Serine (S), Threonine (T), Cysteine (C), Selenocysteine (U), Glycine (G), Alanine (A), Isoleucine (I), Leucine (L), Methionine (M), or Valine (V).

[0314] In some aspects, the carbonyl group in Formula IB is bonded to the carboxy terminus of the amino acid.

[0315] Synthesis Scheme 6. General synthetic route for the synthesis of compounds of Formula IB.

[0316] Scheme 6a. General synthesis for the protection of the amino acid and orientation of the amino acid with the carbonyl group on the fatty acid tail side.Step 1R is the selected amino acid side chain;Re is the protected amino acid side chain;X is a compatible functional group with carboxylic acid;Xi is N(H)C(O) or N(H)C(O);X2is C(O)N(H) or C(O)O and;X3 is a compatible functional group with the amine.

[0317] Scheme 6b. General synthesis for the orientation of the amino acid so that the carbonyl is on the ionizable head group side of the lipid.R is the selected amino acid side chain;Re is the protected amino acid side chain;X is a compatible functional group with carboxylic acid;Xi is C(O)N(H) or C(O)O;X2is N(H)C(O) or N(H)C(O) and;X3 is a compatible functional group with the amine.

[0318] Scheme 6c. General synthetic scheme of the lipid with included amino acids.Rs is the side chain of an independently selected amino acid side chain and;R?is the protected side chain of an independently selected amino acid side chain.

[0319] Synthesis of fatty acid tails are shown in Schemes 2 through 5 above.

[0320] In certain aspects, compounds of Formula IB may include, for example, the following compounds:

[0321] In another aspect, the nanoparticle carrier composition comprises a cationic or ionizable lipid-containing component comprising compounds of Formula IC:or a salt or isomer thereof, wherein m is selected from 0-9; n is selected from 0-9; o is selected from 0-12; p is selected from 0-12; q is selected from 0-5;Ri is a linear C1-12 alkyl;R2 is H or linear C1-12 alkyl;R3 is a linear C1-12 alkyl;R4is H or a linear C1-12 alkyl;Rs is H or CH3;MI and M2 are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R)-, - N(R)C(O)-, -C(O)S-, -SC(O)-, -OC(O)O-, -OC(O)N(R)-, or -N(R)C(O)O- groups, wherein R is a H or a methyl group; and X is selected from -CH2-, -O-, -S-, or - P(O)(OR)O-.

[0322] Scheme 7. General synthetic route for the precursor to compounds of Formula IC.

[0323] Scheme 8. Synthetic route of the conversion of the precursor hydroxy to thiol group.

[0324] Scheme 9. Synthetic route of the conversion of the precursor hydroxy to amine group.

[0325] Scheme 10. Synthetic route of the conversion of the precursor hydroxy to phosphine group.

[0326] Scheme 11. General synthetic route of the synthesis of compound IC.

[0327] In another aspect, the nanoparticle carrier composition comprises a cationic or ionizable lipid-containing component comprising compounds of Formula IIA:or a salt or isomer thereof, wherein m is selected from 0-5; n is selected from 0-12; o is selected from 0-12; q is selected from 1-3;Ri is a linear C1-12 alkyl;R2 is H or linear C1-12 alkyl;R3 is a linear C1-12 alkyl;R4is H or a linear C1-12 alkyl; andX is selected from C(R)2, N(R), or O, wherein R is independently selected from a methyl and H.

[0328] Scheme 12. General synthesis route for the synthesis of compounds of FormulaIIA.wherein Xi, X2, and X3 are either carboxylic acid (RC(O)O) functional groups, or they are isocyanate (RNCO) functional groups, and X is as defined above.

[0329] Scheme 13. Fatty acid tail synthesis for Ri and R2. The route is the same for R3 and R4.

[0330] In another aspect, the nanoparticle carrier composition comprises a cationic or ionizable lipid-containing component comprising compounds of Formula IIB:or a salt or isomer thereof, wherein m is selected from 0-9; n is selected from 0-9; o is selected from 0-12; p is selected from 0-12; q is selected from 0-6;Ri is a linear C1-12 alkyl;R2 is H or a linear C1-12 alkyl;R3 is a linear C1-12 alkyl;R4is H or a linear C1-12 alkyl;Rs is a linear Ci-4 alkyl alcohol;Re is a linear Ci-4 alkyl alcohol;Mi and M2 are independently selected from - C(O)N(R)-, -N(R)C(O)-, -C(O)S-, -SC(O)-, -OC(O)O-, -OC(O)N(R)-, or - N(R)C(O)O- groups, wherein R is independently selected from a methyl and H.

[0331] Scheme 14. General route for the synthesis of head groups of compounds of Formula IIB.X is a halide and;PG is a protecting group such as N-Zc / V-butyloxycarbonyl group.

[0332] Scheme 15. General synthesis route for the compound IIB.

[0333] Scheme 16. Fatty Acid tail conversion from hydroxy to thiol

[0334] Scheme 17. Fatty acid tail conversion of hydroxy to amine.

[0335] Scheme 18. Fatty acid tail conversion of hydroxy to carboxylic acid.

[0336] Scheme 19. Fatty acid tail conversion of hydroxy to isocyanate.

[0337] In another aspect, the nanoparticle carrier composition comprises a cationic or ionizable lipid-containing component comprising compounds of Formula IIC:or a salt or isomer thereof, wherein m is selected from 0-9; n is selected from 0-9; o is selected from 0-12; p is selected from 0-12; q is selected from 2-6;Ri is a linear C1-12 alkyl;R2 is H or linear C1-12 alkyl;R3 is a linear C1-12 alkyl;R4is H or a linear C1-12 alkyl;Rs is a linear Ci-4 alkyl alcohol;Re is a linear Ci-4 alkyl alcohol;MI and M2 are independently selected from -C(O)N(R)-, -N(R)C(O)-, -C(O)S-, - SC(O)-, -OC(O)O-, -OC(O)N(R)-, or -N(R)C(O)O- groups, wherein R is independently selected from a methyl and H.

[0338] Scheme 20. General synthesis for compound IIC.

[0339] The side chains are synthesized according to Schemes 16-19.

[0340] In another aspect, the nanoparticle carrier composition comprises a cationic or ionizable lipid-containing component comprising compounds of Formula IID:or a salt or isomer thereof, wherein m is selected from 0-9; n is selected from 1-7; o is selected from 0-12; p is selected from 0-12;Ri is a linear C1-12 alkyl;R2 is H or linear C1-12 alkyl;R3 is a linear C1-12 alkyl;R4is H or a linear C1-12 alkyl; andMi and M2 are independently selected from -C(O)N(R)-, -N(R)C(O)-, -C(O)S-, - SC(O)-, -OC(O)O-, -OC(O)N(R)-, or -N(R)C(O)O- groups, wherein R is independently selected from a methyl and H.

[0341] Scheme 21. General route for the synthesis of the head groups for the synthesis of compounds of Formula IID.Xi is a functional group (such as an amine, carboxylic acid, isocyante, etc) compatible with X2 (an amine, carboxylic acid, isocyanate, etc) to give Mi such that it is - C(O)N(R)-, -N(R)C(O)-, -C(O)S-, -SC(O)-, -OC(O)O-, -OC(O)N(R)-, or - N(R)C(O)O- groups, wherein R is independently selected from a methyl and H.

[0342] In another aspect, the nanoparticle carrier composition comprises a cationic or ionizable lipid-containing component comprising compounds of Formula HE:or a salt or isomer thereof, wherein m is selected from 0-9; n is selected from 0-9; o is selected from 0-12; p is selected from 0-12; q is selected from 2-6;Ri is a linear C1-12 alkyl;R2 is H or linear C1-12 alkyl;R3 is a linear C1-12 alkyl;R4is H or a linear C1-12 alkyl; andMi and M2 are independently selected from -C(O)N(R)-, -N(R)C(O)-, -C(O)S-, - SC(O)-, -OC(O)O-, -OC(O)N(R)-, or -N(R)C(O)O- groups, wherein R is independently selected from a methyl and H.

[0343] Scheme 21. General route for the synthesis of compound HE.

[0344] In another aspect, the nanoparticle carrier composition comprises a cationic or ionizable lipid-containing component comprising compounds of Formula IIF:or a salt or isomer thereof, whereinm is selected from 0-9; n is selected from 0-9; o is selected from 0-12; p is selected from 0-12; q is selected from 2-6;Ri is a linear C1-12 alkyl;R2 is H or linear C1-12 alkyl;R3 is a linear C1-12 alkyl;R4is H or a linear C1-12 alkyl; andMi and M2 are independently selected from -C(O)N(R)-, -N(R)C(O)-, -C(O)S-, - SC(O)-, -OC(O)O-, -OC(O)N(R)-, or -N(R)C(O)O- groups, wherein R is independently selected from a methyl and H.

[0345] Scheme 23. General route for the synthesis of compound IIF.

[0346] In the reaction schemes described herein, multiple stereoisomers may be produced. When no particular stereoisomer is indicated, it is understood to mean all possible stereoisomers that could be produced from the reaction. A person of ordinary skill in the art will recognize that the reactions can be optimized to give one isomer preferentially, or new schemes may be devised to produce a single isomer. If mixtures are produced, techniques such as preparative thin layer chromatography, preparative HPLC, preparative chiral HPLC, or preparative SFC may be used to separate the isomers.

[0347] The present disclosure further provides nanoparticle compositions comprising, consisting essentially of, or yet further consisting of a lipid component including at least one compound according to Formulae IA, IB, IC, IIA, IIB, IIC, IID, HE, HF, including lAa-IAc, IBa-Ibe, ICa-ICc, IIAa-IIAb, IIBa, IlCa, HDa, HEa-HEb, and IIFa-IIFb, and any combination thereof. Nanoparticle compositions can also include a variety of other components. For example, the lipid component of a nanoparticle composition can include one or more other lipids in addition to a lipid according to Formula IA, IB, IC, IIA, IIB, IIC, IID, HE, HF, including lAa-IAc, IBa-Ibe, ICa-ICc, IIAa-IIAb, IIBa, IlCa, HDa, HEa-HEb, and IIFa-IIFb.

[0348] In some embodiments, the mass ratio of LNP and the RNA in the composition is about 10: 1 to about 1: 10, including any range or ratio there between, for example, about 5:1 to 1:5, about 5:1 to 1:1, about 10:1, about 9.5:1, about 9:1, about 8.5:1, about 8:1, about 7.5:1, about 7:1, about 6.5:1, about 6:1, about 5.5:1, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2:5 :1, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, about 1:5.5, about 1:6, about 1:6.5, about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, or about 1:10. In one embodiment, the mass ratio of LNP and the RNA in the composition is about 2.5:1. In another embodiment, the mass ratio of LNP and the RNA in the composition is about 4: 1.

[0349] In some embodiments, the mass ratio of the cationic lipid and the helper lipid is about 10: 1 to about 1: 10, including any range or ratio there between, for example, about 5:1 to 1:5, about 5:1 to 1:1, about 10:1, about 9.5:1, about 9:1, about 8.5:1, about 8:1, about 7.5:1, about 7:1, about 6.5:1, about 6:1, about 5.5:1, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2:5 :1, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, about 1:5.5, about 1:6, about 1:6.5,about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, or about 1:10. In one embodiment, the mass ratio of the cationic lipid and the helper lipid is about 1:1.

[0350] In some embodiments, the mass ratio of the cationic lipid and cholesterol is about 10: 1 to about 1 : 10, including any range or ratio there between, for example, about 5:1 to 1:5, about 5:1 to 1:1, about 10:1, about 9.5:1, about 9:1, about 8.5:1, about 8:1, about 7.5:1, about 7:1, about 6.5:1, about 6:1, about 5.5:1, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2:5 :1, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, about 1:5.5, about 1:6, about 1:6.5, about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, or about 1:10. In one embodiment, the mass ratio of the cationic lipid and cholesterol is about 1:1.

[0351] In some embodiments, the mass ratio of the cationic lipid and PEGylated lipid is about 10: 1 to about 1: 10, including any range or ratio there between, for example, about 5:1 to 1:5, about 5:1 to 1:1, about 10:1, about 9.5:1, about 9:1, about 8.5:1, about 8:1, about 7.5:1, about 7:1, about 6.5:1, about 6:1, about 5.5:1, about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2:5 :1, about 2:1, about 1.5:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, about 1:5, about 1:5.5, about 1:6, about 1:6.5, about 1:7, about 1:7.5, about 1:8, about 1:8.5, about 1:9, about 1:9.5, or about 1:10. In one embodiment, the mass ratio of the cationic lipid and PEGylated lipid is about 1:1.

[0352] The mass ratio of the cationic lipid, helper lipid, cholesterol and PEGylated lipid can be calculated by one of skill in the art based on the ratios of the cationic lipid and the helper lipid, the cationic lipid and the cholesterol and the cationic lipid and the PEGylated lipid as disclosed herein.

[0353] In some embodiments, the LNP comprises, or consists essentially of, or yet further consists of SM-102, DSPC, cholesterol and PEG2000-DMG. In some embodiments, the mass ratio of the SM-102, DSPC, cholesterol and PEG200-DMG is about 1 : 1 : 1 : 1. In some embodiments, the molar ratio of the SM-102, DSPC, cholesterol and PEG2000-DMG is about 50:10:38.5:1.5.

[0354] In some embodiments, the liposomal nanoparticle carrier comprises, or consists essentially of, or yet further consists of a Spermine-Lipid Cholesterol (SLiC). In some embodiments, the SLiC is selected from any one of TM1-TM5 as illustrated below.

[0355] In some embodiments, a mass ratio as provided here can be substituted with another parameter, such as a molar ratio, a weight percentage over the total weight, a component’s weight over the total volume, or a molar percentage over the total molar amount. Knowing the component and its molecular weight, one of skill in the art would have no difficulty in converting a mass ratio to a molar ratio or other equivalent parameters.

[0356] In yet a further aspect, provided is a method of producing a composition as disclosed herein. The method comprises, or consists essentially of, or yet further consists of contacting an RNA as disclosed herein with a lipid, thereby the RNA and the lipid are selfassembled into lipid nanoparticles (LNPs).

[0357] In some embodiments, the contacting step is performed in a microfluidic mixer. In further embodiments, the microfluidic mixer is a slit interdigitial micromixer, or a staggered herringbone micromixer (SHM).

[0358] Any numerical value within the recited ranges and any combination of ranges and specific numerical values within the claimed ranges are contemplated and supported by the foregoing disclosures, i.e., 5 to 60 mole % of a steroidal or structural lipid-containing component includes any numerical value and range within the range of 5 to 60, e.g., 5, 5.01, 5.02, ...59.97, 59.98, 59.99, 60, 5-10, 5-20, 10-30, 15-25, etc. Similarly, 0.5 to 20 mole % of a PEGylated lipid-containing component includes any numerical value and range within the range of 0.5 to 20, e.g., 0.5, 0.501, 0.502, . . . 19.97, 19.98, 19.99, 20, 0.5-10, 0.52-15, 1-12, 5- 13, etc. Similarly, 30 to 70 mole % of a cationic or ionizable lipid-containing component includes any numerical value and range within the range of 30 to 70, e.g., 30, 30.01, 30.02, ...69.97, 69.98, 69.99, 70, 30.5-68, 35-51, 40-52, 45-63, etc.

[0359] In some embodiments, the present disclosure provides methods of delivering a therapeutic and / or prophylactic to a mammalian cell, specifically delivering a therapeutic and / or prophylactic to a mammalian organ, producing a polypeptide of interest in a mammalian cell, and treating a disease or disorder in a mammal in need thereof. For example, a method of producing a polypeptide of interest in a cell involves contacting a nanoparticle carrier composition comprising a four-component LNP composition comprising an mRNA with a mammalian cell, whereby the mRNA is introduced into the cell and translated to produce the polypeptide of interest. As another example, a method of producing a polypeptide of interest in a cell involves contacting a nanoparticle carrier composition comprising an LNP composition comprising an mRNA with a mammalian cell, whereby the mRNA is introduced into the cell and translated to produce the polypeptide of interest. The contacting can be in vitro or in vivo. When performed in vivo, provided herein is a method of delivering a therapeutic and / or prophylactic to a mammalian cell or organ by administration of a four-component LNP carrier composition including the therapeutic and / or prophylactic to a subject, whereby the therapeutic and / or prophylactic is delivered to the cell or organ.

[0360] Nanoparticle compositions can be formulated in whole or in part as pharmaceutical compositions. Pharmaceutical compositions can include one or more nanoparticle compositions. For example, a pharmaceutical composition can include one or more nanoparticle compositions including one or more different therapeutic and / or prophylactics. Pharmaceutical compositions can further include one or more pharmaceutically acceptable excipients or accessory ingredients such as those described herein. General guidelines for the formulation and manufacture of pharmaceutical compositions and agents are available, for example, in Remington's The Science and Practice of Pharmacy, 21stEdition, A. R. Gennaro; Lippincott, Williams & Wilkins, Baltimore, Md., 2006. Conventional excipients and accessory ingredients can be used in any pharmaceutical composition, except insofar as any conventional excipient or accessory ingredient can be incompatible with one or more components of a nanoparticle composition. An excipient or accessory ingredient can be incompatible with a component of a nanoparticle composition if its combination with the component may result in any undesirable biological effect or otherwise deleterious effect.

[0361] In some embodiments, one or more excipients or accessory ingredients can make up greater than 50% of the total mass or volume of a pharmaceutical composition including a nanoparticle composition. For example, the one or more excipients or accessory ingredients can make up 50%, 60%, 70%, 80%, 90%, or more of a pharmaceutical convention. In some embodiments, a pharmaceutically acceptable excipient is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, an excipient is approved for use in humans and for veterinary use. In some embodiments, an excipient is approved by United States Food and Drug Administration. In some embodiments, an excipient is pharmaceutical grade. In some embodiments, an excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and / or the International Pharmacopoeia.

[0362] Relative amounts of the one or more nanoparticle compositions, the one or more pharmaceutically acceptable excipients, and / or any additional ingredients in a pharmaceutical composition in accordance with the present disclosure will vary, depending upon the identity, size, and / or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, a pharmaceutical composition may comprise between 0.1% and 100% (wt / wt) of one or more nanoparticle compositions.

[0363] In certain embodiments, the LNP is cryo-protected with 8% v / v sucrose. However, any cryo-protectant will suffice (e.g. trehalose). The concentration of the cryo-protectant can be from 4%-32% v / v.

[0364] In certain embodiments, the nanoparticle compositions and / or pharmaceutical compositions of the disclosure are refrigerated or frozen for storage and / or shipment (e.g., being stored at a temperature of 4° C or lower, such as a temperature between about -150° C and about 0° C or between about -80° C and about -20° C (e.g., about -5° C, -10° C, -15° C, -20° C, -25° C, -30° C, -40° C, -50° C, -60° C, -70° C, -80° C, -90° C, -130° C or -150° C). In certain embodiments, the disclosure also relates to a method of increasing stability of the LNP compositions and / or pharmaceutical compositions by storing the nanoparticle compositions and / or pharmaceutical compositions at a temperature of 4° C or lower, such as a temperature between about -150° C and about 0° C or between about -80° C and about -20° C., e.g., about -5° C, -10° C, -15° C, -20° C, -25° C, -30° C, -40° C, -50° C, -60° C, -70° C, -80° C, -90° C, -130° C or -150° C). For example, the LNPcompositions and / or pharmaceutical compositions disclosed herein are stable for about at least 1 week (z.e., 7 days), at least 2 weeks (z.e., 14 days), at least 3 weeks (z.e., 21 days), at least 4 weeks (z.e., 28 days), at least 5 weeks, at least 6 weeks, at least 1 month, at least 2 months, at least 4 months, at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 14 months, at least 16 months, at least 18 months, at least 20 months, at least 22 months, or at least 24 months, e.g., at a temperature of 4° C. or lower (e.g., between about 4° C and -20° C). In one embodiment, the formulation is stabilized for at least 4 weeks at about 4° C. In certain embodiments, the pharmaceutical composition of the disclosure comprises a nanoparticle composition disclosed herein and a pharmaceutically acceptable carrier selected from one or more of Tris, an acetate (e.g., sodium acetate), a citrate (e.g., sodium citrate), saline, PBS, and sucrose. In certain embodiments, the carrier can be at a concentration of 1-100 mM (e.g., including but not limited to any numerical value or range within the range of 1-lOOmM such as 1, 2, 3, 4, .. .97, 98, 99, 100, 10-90 mM, 20-80 mM, 30- 70 mM and so on).

[0365] In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions of the disclosure have an encapsulation efficiency of at least 50% when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have an encapsulation efficiency of at least 60% when stored at 25°C, 4°C, - 20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have an encapsulation efficiency of at least 70% when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have an encapsulation efficiency of at least 80% when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have an encapsulation efficiency of at least 85% when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have an encapsulation efficiency of at least 90% when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have an encapsulation efficiency of at least 95% when stored at 25°C, 4°C, - 20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have an encapsulation efficiency of at least 96% when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have an encapsulation efficiency of at least 97% when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have an encapsulation efficiency of at least 98% when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have an encapsulation efficiency of at least 99% when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days.

[0366] Zeta potential is a measure of colloidal stability. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions of the disclosure have a zeta potential of 1-25 mV when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a zeta potential of 5-20 mV when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a zeta potential of 5-15 mV when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days.

[0367] Poly dispersity Index (PDI) is a measure of sample heterogeneity based on particle size. PDI value may vary from 0 to 1, where the colloidal particles with a PDI of less than 0.1 implies monodisperse particle size distributions, and the values greater than 0.1 imply polydisperse particle size distributions. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a PDI of 0.1 when stored at 25°C, 4°C, -20°C, or - 80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a PDIof 0.2 when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a PDI of 0.3 when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a PDI of 0.4 when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a PDI of 0.5 when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a PDI of 0.6 when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a PDI of 0.7 when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a PDI of 0.8 when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a PDI of 0.9 when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a PDI of 1.0 when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days.

[0368] Nanoparticles range from 1 nm to 999 nm in diameter. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions of the disclosure have a nanoparticle size of less than 300 nm when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a nanoparticle size of less than 200 nm when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a nanoparticle size of less than 150 nm when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a nanoparticle size of less than 140 nm when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a nanoparticle size of less than 125 nm when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days. In some embodiments, the nanoparticle compositions and / or pharmaceutical compositions have a nanoparticle size of less than 100 nm when stored at 25°C, 4°C, -20°C, or -80°C for at least 7 days, at least 14 days, at least 21 days, or at least 28 days.

[0369] LNP buffer exchange can be performed by dialysis, tangential flow filtration, or any other method that effectively removes and replaces buffer.

[0370] A pharmaceutical composition including the LNP compositions can be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include bringing the active ingredient into association with an excipient and / or one or more other accessory ingredients, and then, if desirable or necessary, dividing, shaping, and / or packaging the product into a desired single- or multi-dose unit.

[0371] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing agents, wetting agents, and / or suspending agents. Sterile injectable preparations can be sterile injectable solutions, suspensions, and / or emulsions in nontoxic parenterally acceptable diluents and / or solvents, for example, as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, U.S.P., and isotonic sodium chloride solution. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. Fatty acids such as oleic acid can be used in the preparation of injectables.

[0372] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, and / or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.Kits

[0373] The present disclosure provides kits for the treatment of cancers, comprising at least one immunoglobulin-related composition of the present disclosure (e.g., any antibody or antigen binding fragment described herein), or a functional variant (e.g., substitutional variant) thereof. Optionally, the above described components of the kits of the present disclosure are packed in suitable containers and labeled for diagnosis and / or treatment of cancer. The above-mentioned components can be stored in unit or multi-dose containers, for example, sealed ampoules, vials, bottles, syringes, and test tubes, as an aqueous, preferably sterile, solution or as a lyophilized, preferably sterile, formulation for reconstitution. The kit can further comprise a second container which holds a diluent suitable for diluting the pharmaceutical composition towards a higher volume. Suitable diluents include, but are not limited to, the pharmaceutically acceptable excipient of the pharmaceutical composition and a saline solution. Furthermore, the kit can comprise instructions for diluting the pharmaceutical composition and / or instructions for administering the pharmaceutical composition, whether diluted or not. The containers can be formed from a variety of materials such as glass or plastic and can have a sterile access port (for example, the container can be an intravenous solution bag or a vial having a stopper which can be pierced by a hypodermic injection needle). The kit can further comprise more containers comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It can further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, culture medium for one or more of the suitable hosts. The kits can optionally include instructions customarily included in commercial packages of therapeutic or diagnostic products, that contain information about, for example, the indications, usage, dosage, manufacture, administration, contraindications and / or warnings concerning the use of such therapeutic or diagnostic products.

[0374] For antibody -based kits, the kit can comprise, e.g., 1) a first antibody, e.g. a humanized, chimeric, bispecific, or multi-specific PD-L1 antibody of the present disclosure (or an antigen binding fragment thereof), attached to a solid support, which binds to a PD-L1 protein; and, optionally; 2) a second, different antibody which binds to either the PD-L1 protein or to the first antibody, and is conjugated to a detectable label.

[0375] The kit can also comprise, e.g., a buffering agent, a preservative or a proteinstabilizing agent. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for using the kit. The kits of the present disclosure can contain a written product on or in the kit container. The written product describes how to use the reagents contained in the kit, e.g., for treatment of cancer in a subject in need thereof. In certain embodiments, the use of the reagents can be according to the methods of the present disclosure.

[0376] The following examples are included to demonstrate some embodiments of the disclosure. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.EXAMPLESExample 1: Generating and testing mouse hybridoma fusion libraries for anti-PD-Ll antibodies

[0377] Method for generating / collecting mouse hybridoma fusion libraries for anti-PD- Ll antibodies:

[0378] Hybridomas producing monoclonal antibodies generated against glycosylated human PD-L1 were obtained by the fusion of SP2 / 0 murine myeloma cells with spleen cells isolated from human PD-L1 -immunized BALB / c mice (n=6) (Antibody Solutions, Inc., Sunnyvale, CA, USA) according to standardized protocol. Before fusion, sera from the immunized mice were validated for binding to the PD-L1 immunogen using FACS analysis. Monoclonal antibody (MAb)-producing hybridomas were generated. The hybridomas that produced antibodies were again tested for specificity. To this end, over 80 candidate MAb- producing hybridomas were selected, grown in ADCF medium, and their monoclonal antibody-containing supernatant was concentrated and purified. The purified MAbs were tested for their ability to neutralize or inhibit the interaction between PD-L1 and PD-1 (PD- Ll / PD-1 binding interaction) using a FACS analysis.

[0379] Method and Results for Enzyme-linked immunosorbent assays (ELISA) for anti- PD-L1 titers in sera from an immunized mouse or collected at day 21 from a mouse hybridoma fusion library:

[0380] For ELISA, MaxiSorp plates (Biolegend) were coated with 100 pl of recombinant PD-Ll-ECD-His (1 pg / ml) in sodium carbonate buffer overnight at 4°C. The wells were washed 3 times with PBS-T and incubated the plates with 200 pl of blocking buffer for 2 hours at RT. After washing 3 times with PBS-T, the plate was incubated with 100 pl of diluted sera / hybridoma culture supernatants for 2 hours at RT. And the plate washed 5 times with PBS-T and incubated with HRP-conjugated secondary antibody for 1 hour at RT. Finally, the plate was washed 5 times with PBS-T and incubated the plates with 100 pl of lx TMB substrate for 10 minutes. The reaction was stopped by adding 100 pl of 1N-HC1 and read at 450 nm using the Cytation7 or SpectraMax microplate reader.

[0381] Method and results for Fluorescence activated cell sorting (FACS) for anti-PD-Ll titers in sera collected at day 21 from a mouse hybridoma fusion library:

[0382] Cells overexpressing PD-L1 WT were isolated by trypsinization and collected in Cell Staining Buffer (CSB) (BioLegend, San Diego, CA, US) at 2 x 106cells / mL. 50 pL of cells were aliquoted to a 96 well round-bottom plate, to which 50 pL of 20 pg / mL primary antibody (diluted sera or hybridoma culture supernatant) was added, followed by gentle mixing and Ih incubation at 4°C in the dark. Cells were washed with CSB, incubated with fluorescence labeled secondary anti-mouse IgG antibody (10 pg / mL) with DAPI (1 : 100) 30 seconds at 21 °C in the dark. Cells were washed and data acquired using FACS Celesta (Becton Dickinson, Franklin Lakes, NJ, US) flow cytometer.

[0383] Purification and confirmation of anti-PD-Ll antibodies from single clone culture supernatants:

[0384] Samples were centrifuged at 10,000 RPM for 10 min and filtered through a 0.45 pm filter. The filtrates were diluted 4-fold with lx PBS and injected to the column (HiTrap Mabselect SURE, 1 ml) installed in Cytiva AKTA purifier. After washing out the column with 3 to 5 column volumes of lx PBS, the bound antibody was eluted with elution buffer (0.1M Glycine-HCl, pH 2.7) using a one-step gradient. Collection tubes were used by adding100 pL of 1 M Tris-HCl, pH 9.0 per milliliter of fraction to be collected. The purified antibodies were subjected to buffer change to lx PBS by using a 30-kDa cut-off centrifugal filter (Millipore). Purity of the antibodies were confirmed by a SDS-PAGE analysis.Example 2: FACS and neutralization screening of anti-PD-Ll antibodies

[0385] To measure the interaction of PD-1 protein and PD-L1 protein, PD-L1 expressing cells were fixed in 4% paraformaldehyde at room temperature for 5 minutes and then were incubated with serially diluted antibody solution for 1 hour. Recombinant human PD-l-Fc chimera protein (R&D Systems) conjugated with Alexa Fluor 488 dye (Life Technologies)(FIG. 4A-4D). The fluorescence intensity of Alexa Fluor 488 dye was then monitored using FACS Celesta (BD Biosciences). Binding of PD-1 to cell surface PD-L1 was calculated by mean fluorescence intensity (MFI) according to the antibody concentration and ICso was calculated from antibody concentration vs. MFI using a GraphPad software. 17 out of the 36 clones were selected for their strong neutralization activity against the PD-1, PD-L1 interactionExample 3: Epitope binning competitive assays

[0386] In a typical epitope binning assay, the antigen, PD-Ll-His (10 nM), was preincubated with a second antibody (10 nM) for 1 hour at room temperature. Control antibody (20 nM) was immobilized onto a CM-5 chip (Cytiva). The chip was exposed to preincubated antigen-second antibody mixture. Raw data was processed using a Biacore X-100 (Cytiva) Analysis Software and the antibody pairs were assessed for competitive binding (FIG. 5A- 5B) Additional binding by the second control antibody indicates an unoccupied epitope (noncompetitor) by the second antibody, while no binding indicates epitope blocking (competitor).Example 4: Binding kinetics of anti-PD-Ll antibodies

[0387] A Biacore XI 00 instrument (GE Healthcare) was used for KD determination via surface plasmon resonance (SPR). Protein A-immobilized CM5 chip was used for capturing antibody. 6 concentrations of PD-Ll-His, each a 2-fold dilution (from 64 nM to 2 nM), were then passed over the chip in HBS-EP buffer (Cytiva). Sensorgram data was analyzed by Biacore X100 evaluation software version 2.0.1 with 1 : 1 binding kinetics (FIG. 6A-7).Example 5: Sequencing of anti-PD-Ll antibodies and alignment of CDRs

[0388] Hybridoma cell pellets were frozen at -80°C and total RNA isolated with RNeasy Plus Mini Kit (Qiagen, Hilden, DE) and quantitated by Nanodrop 2000 (Fisher Scientific, Waltham, MA, US). cDNA synthesis was performed using SuperScript™ IV First-Strand Synthesis System (ThermoFisher Scientific) according to the manufacturer’s instructions. PCR primers were from Novagen Mouse Ig-Primer (Merck KGaA, Darmstadt, DE). Heavy chain primer sets: A-F, light (kappa) chain primer sets: A-G. Template: RNA 0.5 pL / 25pL reaction volume. After gel separation, PCR product is ligated into pCR 2.1 vector (Topo reaction), transformed into ToplO competent cells, selected on 100 pg / mL ampicillin with 50pL X-gal / IPTG agar plates, and white colonies were picked after 24h. After culture, plasmid DNA was prepared, and Sanger sequencing was performed using Ml 3 fwd forward and reverse primer. CDRs were identified by a web-based antibody search / annotation software AbYsis (http: / / abysis.org). The sequences were aligned with a multiple sequence alignment tool (Clustal Omega) (FIG.8A-9C).Example 6: Antibody Binding Assay

[0389] PD-L1 expressing cell lines are cultured according to manufacturer’s recommendations. PD-L1 expressing cell lines are known in the art, and include Primary CD4+ T cells, Jurkat E61, TALL-104, MOLT-3, HM2, Caco-2, SW620, SW480, Colo-205, HT-29, OV-17, OVCAR-3, ES-2, SKOV-3, MDA-MB-231, MCF-7, ZR-75, H441, H1703, H460, LnCap, PC-3, CFPAC-1 and ASPC-1 cells (Grenga I., et al., Journal for ImmunoTherapy of Cancer 2014; 2:P102). In vitro assays and in vivo animal models are also known in the art. In particular, mouse models have been established for evaluating the effects of anti-PD-1 antibodies on tumor growth (Katano, I., etal., Scientific Reports volume 11, Article number: 21087 (2021); Monjazeb, AM., et al., Cancers (Basel). 2021 Feb; 13(4): 729). All cells are cultured at 37°C with 5% CO2. Normal counterpart cells and counterpart cancer cells that do not express or overexpress PD-L1 can be cultured as controls. Cells are analyzed by flow-cytometry for PD-L1 expression. Varying amounts of the compositions of the disclosure are contacted with the cells and binding of the compositions to the cells can be moni...

Claims

WHAT IS CLAIMED IS:

1. An antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein(a) (i) the VH comprises a VH-CDR1 sequence of SEQ ID NO: 5, a VH-CDR2 sequence of SEQ ID NO: 6, and a VH-CDR3 sequence of SEQ ID NO: 7;(ii) the VH comprises a VH-CDR1 sequence of SEQ ID NO: 15, a VH-CDR2 sequence of SEQ ID NO: 16, and a VH-CDR3 sequence of SEQ ID NO: 17; or(iii) the VH comprises a VH-CDR1 sequence of SEQ ID NO: 25, a VH-CDR2 sequence of SEQ ID NO: 26, and a VH-CDR3 sequence of SEQ ID NO: 27; and / or(b) (i) the VL comprises a VL-CDR1 sequence of SEQ ID NO: 8, a VL-CDR2 sequence of SEQ ID NO: 9, and a VL-CDR3 sequence of SEQ ID NO: 10; or(ii) the VL comprises a VL-CDR1 sequence of SEQ ID NO: 18, a VL-CDR2 sequence of SEQ ID NO: 19, and a VL-CDR3 sequence of SEQ ID NO: 20; or(iii) the VL comprises a VL-CDR1 sequence of SEQ ID NO: 28, a VL-CDR2 sequence of SEQ ID NO: 29, and a VL-CDR3 sequence of SEQ ID NO: 30.

2. An antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein: (a) the VH comprises an amino acid sequence selected from any one of SEQ ID NOs: 3, 13, or 23; and / or (b) the VL comprises an amino acid sequence selected from any one of SEQ ID NOs: 4, 14, or 24.

3. An antibody or antigen binding fragment thereof comprising heavy chain immunoglobulin variable domain (VH) and light chain immunoglobulin variable domain (VL) amino acid sequences selected from the group consisting of: a VH of SEQ ID NO: 3 and a VL of SEQ ID NO: 4, a VH of SEQ ID NO: 13 and a VL of SEQ ID NO: 14, and a VH of SEQ ID NO: 23 and a VL of SEQ ID NO: 24, respectively.

4. The antibody or antigen binding fragment of any one of claims 1-4, further comprising a Fc domain of an isotype selected from the group consisting of IgGl, IgG2, IgG3, IgG4, IgAl, IgA2, IgM, IgD, and IgE.

5. The antibody of claim 4, comprising an IgGl constant region.

6. The antibody of claim 5, comprising an IgGl constant region comprising an N297A amino acid mutation.

7. The antigen binding fragment of any one of claims 1-4, wherein the antigen binding fragment is selected from the group consisting of Fab, F(ab’)2, Fab’, scFv, and Fv.

8. The antibody of any one of claims 1-7, wherein the antibody comprises variant glycosylation as compared to a parent Fc region.

9. A recombinant nucleic acid encoding the antibody or antigen binding fragment of any one of claims 1-8.

10. The recombinant nucleic acid of claim 9, comprising a heavy chain immunoglobulin variable domain (VH) polynucleotide sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 21, SEQ ID NO: 47, SEQ ID NO: 49, and SEQ ID NO: 51.

11. The recombinant nucleic acid of claim 9 or claim 10, comprising a light chain immunoglobulin variable domain (VL) polynucleotide sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 22, SEQ ID NO: 48, SEQ ID NO: 50, and SEQ ID NO: 52.

12. The recombinant nucleic acid of claim 11, wherein the recombinant nucleic acid is a recombinant ribonucleic acid (RNA) molecule.

13. The recombinant nucleic acid of claim 12, further comprising a 3’ UTR.

14. The recombinant nucleic acid of claim 13, wherein the 3’ UTR comprises SEQ ID NO: 42.

15. The recombinant nucleic acid of any one of claims 12-14, further comprising a 5’UTR.

16. The recombinant nucleic acid of claim 15, wherein the 5’ UTR comprises SEQ ID NO: 40.

17. The recombinant nucleic acid of any one of claims 12-16, further comprising a polyA tail.

18. The recombinant nucleic acid of claim 17, wherein the polyA tail comprises SEQ ID NO: 43.

19. The recombinant nucleic acid of any one of claims 12-18, wherein the recombinant RNA molecule comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39.

20. The recombinant nucleic acid of any one of claims 13-19, wherein the recombinant RNA molecule comprises one or more chemical modifications.

21. A polynucleotide encoding the recombinant RNA molecule of any one of claims 12- 20, wherein the polynucleotide is selected from a deoxyribonucleic acid (DNA), an RNA, a hybrid of DNA and RNA, or an analog of each thereof.

22. A vector comprising the recombinant nucleic acid of any one of claims 12-20 or the polynucleotide of claim 21.

23. The vector of claim 22, further comprising a regulatory sequence operatively linked to the polynucleotide to direct the transcription thereof.

24. The vector of claim 23, wherein the regulatory sequence comprises a promoter.

25. The vector of claim 24, wherein the promoter comprises: a bacteriophage RNA polymerase promoter, optionally a T7 promoter, or a SP6 promoter, or a T3 promoter.

26. The vector of any one of claims 22-25, further comprising a marker selected from a detectable marker, a purification marker, or a selection marker.

27. The vector of any one of claims 22-26, wherein the vector is a non-viral vector, optionally a plasmid, or a liposome, or a micelle.

28. The vector of any one of claims 22-27, wherein the vector is a viral vector, optionally an adenoviral vector, or an adeno-associated viral vector, or a retroviral vector, or a lentiviral vector, or a plant viral vector.

29. A composition comprising the antibody or antigen binding fragment of any one of claims 1-11, the recombinant nucleic acid of any one of claims 12-20, the polynucleotide of claim 21, or the vector of any one of claims 22-28, and a pharmaceutically-acceptable carrier.

30. The composition of claim 29, wherein the composition further comprises an agent selected from the group consisting of nanoparticles, isotopes, dyes, chromagens, contrast agents, drugs, toxins, cytokines, enzymes, enzyme inhibitors, hormones, hormone antagonists, growth factors, radionuclides, metals, liposomes, RNA, DNA or any combination thereof.

31. A method for binding PD-L1, comprising contacting a sample suspected of containing PD-L1 with an effective amount of the antibody or antigen binding fragment of any one of claims 1-11, or the composition of claim 29 or 30, under conditions that favor the binding of the antibody or antigen binding fragment to PD-L1 to form a complex between the antibody or antigen binding fragment and PD-L1.

32. The method of claim 31, further comprising detecting the complex formed between the antibody or antigen binding fragment and PD-L1.

33. The method of claim 31 or 32, wherein the sample comprises a cell expressing PD- Ll, optionally a cancer cell, that is further optionally selected from alveolar soft part sarcoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, small cell lung cancer, biliary tract cancer, merkel cell carcinoma, renal cell carcinoma, urothelial cancer,Hodgkin lymphoma, bladder cancer, kidney cancer, breast cancer, head and neck cancer, cancer of the esophagus, stomach cancer, or cervical cancer.

34. A method for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of the antibody or antigen binding fragment of any one of claims 1-11, or the composition of claim 29 or 30, wherein the antibody or antigen binding fragment specifically binds to PD-L1.

35. The method of claim 34, wherein the cancer is a solid tumor.

36. The method of claim 34 or 35, wherein the cancer is breast cancer, gastric cancer, osteosarcoma, desmoplastic small round cell cancer, squamous cell carcinoma of head and neck cancer, ovarian cancer, prostate cancer, pancreatic cancer, glioblastoma multiforme, gastric junction adenocarcinoma, gastroesophageal junction adenocarcinoma, cervical cancer, salivary gland cancer, soft tissue sarcoma, leukemia, melanoma, Ewing’s sarcoma, rhabdomyosarcoma, or neuroblastoma.

37. The method of any one of claims 31-36, wherein the antibody or antigen binding fragment or the composition is administered to the subject separately, sequentially or simultaneously with an additional therapeutic agent.

38. The method of claim 37, wherein the additional therapeutic agent is one or more of alkylating agents, platinum agents, taxanes, vinca agents, anti-estrogen drugs, aromatase inhibitors, ovarian suppression agents, VEGF / VEGFR inhibitors, EGFZEGFR inhibitors, PARP inhibitors, cytostatic alkaloids, cytotoxic antibiotics, antimetabolites, endocrine / hormonal agents, T cells, and bisphosphonate therapy agents.

39. The method of claim 38, wherein the additional therapeutic agent is an immunomodulating / stimulating antibody.

40. A kit comprising the antibody or antigen binding fragment of any one of claims 1-11, or the composition of claim 29 or 30 and instructions for use.

Citation Information

Patent Citations

  • Chimeric antigen receptors targeting cancer

    US20190112380A1

  • Anti-PDL1 antibodies, activatable Anti-PDL1 antibodies, and methods of use thereof

    US20200231677A1

  • MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF

    US20220010018A1